TWI840311B - Rip1k抑制劑 - Google Patents
Rip1k抑制劑 Download PDFInfo
- Publication number
- TWI840311B TWI840311B TW112142937A TW112142937A TWI840311B TW I840311 B TWI840311 B TW I840311B TW 112142937 A TW112142937 A TW 112142937A TW 112142937 A TW112142937 A TW 112142937A TW I840311 B TWI840311 B TW I840311B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- compounds
- carboxamide
- disease
- nmr
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 168
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- -1 I-24 Chemical compound 0.000 claims description 64
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 58
- 201000010099 disease Diseases 0.000 abstract description 43
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract description 27
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 13
- 102000020233 phosphotransferase Human genes 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract description 5
- 229940043355 kinase inhibitor Drugs 0.000 abstract description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract description 4
- 125000003118 aryl group Chemical group 0.000 description 40
- 125000001786 isothiazolyl group Chemical group 0.000 description 39
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 38
- 229910052757 nitrogen Inorganic materials 0.000 description 38
- 238000000034 method Methods 0.000 description 34
- 125000001424 substituent group Chemical group 0.000 description 34
- 239000000203 mixture Substances 0.000 description 32
- 125000001931 aliphatic group Chemical group 0.000 description 31
- 125000000217 alkyl group Chemical group 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 208000006673 asthma Diseases 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 25
- 125000001072 heteroaryl group Chemical group 0.000 description 24
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 22
- 125000000623 heterocyclic group Chemical group 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 21
- 229910052799 carbon Inorganic materials 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 208000011580 syndromic disease Diseases 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 125000005842 heteroatom Chemical group 0.000 description 18
- 229910052760 oxygen Inorganic materials 0.000 description 18
- 229910052736 halogen Inorganic materials 0.000 description 17
- 125000005647 linker group Chemical group 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 17
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 description 16
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 description 16
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 150000002500 ions Chemical class 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- 229910020008 S(O) Inorganic materials 0.000 description 14
- 125000002619 bicyclic group Chemical group 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 102000015696 Interleukins Human genes 0.000 description 12
- 108010063738 Interleukins Proteins 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 125000002947 alkylene group Chemical group 0.000 description 10
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 229960001866 silicon dioxide Drugs 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 206010063837 Reperfusion injury Diseases 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 229940047122 interleukins Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 description 7
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 206010052015 cytokine release syndrome Diseases 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010061323 Optic neuropathy Diseases 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- 108700012920 TNF Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 5
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003124 biologic agent Substances 0.000 description 5
- 229910052805 deuterium Inorganic materials 0.000 description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960001507 ibrutinib Drugs 0.000 description 5
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 208000020911 optic nerve disease Diseases 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000020084 Bone disease Diseases 0.000 description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 108010044091 Globulins Proteins 0.000 description 4
- 102000006395 Globulins Human genes 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 206010038910 Retinitis Diseases 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 230000006931 brain damage Effects 0.000 description 4
- 231100000874 brain damage Toxicity 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 201000010659 intrinsic asthma Diseases 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 229960001940 sulfasalazine Drugs 0.000 description 4
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- CDCABXRWMLXBQS-KRWDZBQOSA-N 5-benzyl-N-[(4S)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound C(C1=CC=CC=C1)C=1NC(=NN=1)C(=O)N[C@@H]1C=2N(C3=C(CC1)C=CC=C3)C=CN=2 CDCABXRWMLXBQS-KRWDZBQOSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 3
- 101710090077 NF-kappa-B essential modulator Proteins 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229910001413 alkali metal ion Inorganic materials 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229960002170 azathioprine Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 description 3
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 125000005561 phenanthryl group Chemical group 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- JNQCNNCAVCIURE-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]-N-(2-methyl-1-oxo-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl)-1,2,4-triazole-3-carboxamide Chemical compound CN(C1=O)N=C(C(CC2)NC(C3=NN(CC(C(Cl)=CC=C4)=C4Cl)C=N3)=O)N1C1=C2C=CC=C1 JNQCNNCAVCIURE-UHFFFAOYSA-N 0.000 description 2
- ZGFSSODFPHSORY-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]-N-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC(C(Cl)=CC=C2)=C2Cl)C=N1)NC(CC1)C2=NC=CN2C2=C1C=CC=C2 ZGFSSODFPHSORY-UHFFFAOYSA-N 0.000 description 2
- ZGFSSODFPHSORY-SFHVURJKSA-N 1-[(2,6-dichlorophenyl)methyl]-N-[(4S)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC(C(Cl)=CC=C2)=C2Cl)C=N1)N[C@@H](CC1)C2=NC=CN2C2=C1C=CC=C2 ZGFSSODFPHSORY-SFHVURJKSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- CRIZPXKICGBNKG-UHFFFAOYSA-N 3,7-dihydropurin-2-one Chemical group OC1=NC=C2NC=NC2=N1 CRIZPXKICGBNKG-UHFFFAOYSA-N 0.000 description 2
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
- BNQBLHBBVSCXJZ-UHFFFAOYSA-N 5-benzyl-N-(1-oxo-5,6-dihydro-4H-[1,2,4]oxadiazolo[4,3-a][1]benzazepin-4-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC(CCC(C=CC=C1)=C1N12)C1=NOC2=O BNQBLHBBVSCXJZ-UHFFFAOYSA-N 0.000 description 2
- CDCABXRWMLXBQS-UHFFFAOYSA-N 5-benzyl-N-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(NC1CCc2ccccc2-n2ccnc12)c1n[nH]c(Cc2ccccc2)n1 CDCABXRWMLXBQS-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 229940124291 BTK inhibitor Drugs 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000016615 Central areolar choroidal dystrophy Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000033810 Choroidal dystrophy Diseases 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 108010053317 Hexosaminidase A Proteins 0.000 description 2
- 102000016871 Hexosaminidase A Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 206010021113 Hypothermia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010072927 Mucolipidosis type I Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000034247 Pattern dystrophy Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 206010039094 Rhinitis perennial Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 150000007824 aliphatic compounds Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229960004238 anakinra Drugs 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000781 anti-lymphocytic effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000001494 anti-thymocyte effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 108010044481 calcineurin phosphatase Proteins 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002085 enols Chemical group 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- 229960001419 fenoprofen Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229950005309 fostamatinib Drugs 0.000 description 2
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 208000024557 hepatobiliary disease Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 description 2
- 108010024409 linaclotide Proteins 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 150000004866 oxadiazoles Chemical class 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 description 2
- 208000025487 periodic fever syndrome Diseases 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 208000019629 polyneuritis Diseases 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 229940117820 purinethol Drugs 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960000953 salsalate Drugs 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 108010078373 tisagenlecleucel Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229950005972 urelumab Drugs 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 description 1
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- MVNAQKWFVRRGPD-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]-N-(1-methyl-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1,2,4-triazole-3-carboxamide Chemical compound CC1=CN=C(C(CC2)NC(C3=NN(CC(C(Cl)=CC=C4)=C4Cl)C=N3)=O)N1C1=C2C=CC=C1 MVNAQKWFVRRGPD-UHFFFAOYSA-N 0.000 description 1
- RFFHWHLDMDGTSH-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]-N-(1-oxo-2,4,5,6-tetrahydro-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl)-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC(C(Cl)=CC=C2)=C2Cl)C=N1)NC(CCC(C=CC=C1)=C1N12)C1=NNC2=O RFFHWHLDMDGTSH-UHFFFAOYSA-N 0.000 description 1
- JHGHIWAZFOILBB-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]-N-(2-methyl-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1,2,4-triazole-3-carboxamide Chemical compound CC(N=C1C(CC2)NC(C3=NN(CC(C(Cl)=CC=C4)=C4Cl)C=N3)=O)=CN1C1=C2C=CC=C1 JHGHIWAZFOILBB-UHFFFAOYSA-N 0.000 description 1
- VNAWWONYAFOJKC-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]-N-(5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl)-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC(C(Cl)=CC=C2)=C2Cl)C=N1)NC(CC1)C2=NN=CN2C2=C1C=CC=C2 VNAWWONYAFOJKC-UHFFFAOYSA-N 0.000 description 1
- XCEQGQQSVJFIDF-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]-N-(9-thia-1,2,5-triazatricyclo[8.3.0.02,6]trideca-3,5,10,12-tetraen-7-yl)-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC(C(Cl)=CC=C2)=C2Cl)C=N1)NC(CS1)C2=NC=CN2N2C1=CC=C2 XCEQGQQSVJFIDF-UHFFFAOYSA-N 0.000 description 1
- SWBMQZNRGNONPE-UHFFFAOYSA-N 1-[(2,6-dichlorophenyl)methyl]-N-[9-(3-oxa-9-azaspiro[5.5]undecan-9-yl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC(C(Cl)=CC=C2)=C2Cl)C=N1)NC(CC1)C2=NC=CN2C2=C1C=CC(N(CC1)CCC11CCOCC1)=C2 SWBMQZNRGNONPE-UHFFFAOYSA-N 0.000 description 1
- VASLSHBJTDAJHB-AWEZNQCLSA-N 1-[(4-fluorophenyl)methyl]-N-[(4R)-1-oxo-4,5-dihydro-[1,2,4]oxadiazolo[3,4-d][1,5]benzothiazepin-4-yl]-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC(C=C2)=CC=C2F)C=N1)N[C@@H](CSC(C=CC=C1)=C1N12)C1=NOC2=O VASLSHBJTDAJHB-AWEZNQCLSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- FDNNSQHNOOCLLD-UHFFFAOYSA-N 1-benzyl-N-(5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl)-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC2=CC=CC=C2)C=N1)NC(CC1)C2=NN=CN2C2=C1C=CC=C2 FDNNSQHNOOCLLD-UHFFFAOYSA-N 0.000 description 1
- IBWGOERHYKDNSL-UHFFFAOYSA-N 1-benzyl-N-[9-(3-oxa-9-azaspiro[5.5]undecan-9-yl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]pyrazole-3-carboxamide Chemical compound O=C(C1=NN(CC2=CC=CC=C2)C=C1)NC(CC1)C2=NC=CN2C2=C1C=CC(N(CC1)CCC11CCOCC1)=C2 IBWGOERHYKDNSL-UHFFFAOYSA-N 0.000 description 1
- QOICGHLCFYEFGI-UHFFFAOYSA-N 1-benzyl-N-[9-(7-oxa-2-azaspiro[3.5]nonan-2-yl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]pyrazole-3-carboxamide Chemical compound O=C(C1=NN(CC2=CC=CC=C2)C=C1)NC(CC1)C2=NC=CN2C2=C1C=CC(N(C1)CC11CCOCC1)=C2 QOICGHLCFYEFGI-UHFFFAOYSA-N 0.000 description 1
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PLDDTNKKLOTJCZ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CNC2CNNC2=C1 PLDDTNKKLOTJCZ-UHFFFAOYSA-N 0.000 description 1
- IBLQRMNMEWSJHT-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-triazolo[4,5-b]pyridine Chemical compound N1C=CC=C2NNNC21 IBLQRMNMEWSJHT-UHFFFAOYSA-N 0.000 description 1
- PHXGAJLBHUUAKB-UHFFFAOYSA-N 2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound O1CCC2OCCC21 PHXGAJLBHUUAKB-UHFFFAOYSA-N 0.000 description 1
- PNJUXCNBOXMPEY-UHFFFAOYSA-N 2,4-dihydropyrrolo[2,3-d]triazole Chemical compound N1N=NC2=C1C=CN2 PNJUXCNBOXMPEY-UHFFFAOYSA-N 0.000 description 1
- PXMMMDWDQWVSDV-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methyl]-N-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NC=NN1CC(C(Cl)=CC=C1)=C1Cl)NC(CC1)C2=NC=CN2C2=C1C=CC=C2 PXMMMDWDQWVSDV-UHFFFAOYSA-N 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KBIYXIRTJIUCNL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-N-[9-(3-hydroxy-3-methylbut-1-ynyl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]pyrazole-1-carboxamide Chemical compound CC(C)(C#CC1=CC(N2C(C(CC3)NC(N4N=CC(CC(C=C5)=CC=C5F)=C4)=O)=NC=C2)=C3C=C1)O KBIYXIRTJIUCNL-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical group NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- GCQLEAOQHTUGNU-UHFFFAOYSA-N 5-[(2,6-dichlorophenyl)methyl]-N-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC(C(Cl)=CC=C2)=C2Cl)=N1)NC(CC1)C2=NC=CN2C2=C1C=CC=C2 GCQLEAOQHTUGNU-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- BEVFRFDLVAINOX-UHFFFAOYSA-N 5-benzyl-N-(1,2-dichloro-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC(CCC(C=CC=C1)=C1N12)C1=NC(Cl)=C2Cl BEVFRFDLVAINOX-UHFFFAOYSA-N 0.000 description 1
- XVOAXHBJZFGMEY-UHFFFAOYSA-N 5-benzyl-N-(1-chloro-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1,2-oxazole-3-carboxamide Chemical compound O=C(C1=NOC(CC2=CC=CC=C2)=C1)NC(CCC(C=CC=C1)=C1N12)C1=NC=C2Cl XVOAXHBJZFGMEY-UHFFFAOYSA-N 0.000 description 1
- KODDQWVYDHDSTP-UHFFFAOYSA-N 5-benzyl-N-(1-chloro-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC(CCC(C=CC=C1)=C1N12)C1=NC=C2Cl KODDQWVYDHDSTP-UHFFFAOYSA-N 0.000 description 1
- ZHIMQTANLNKUAF-UHFFFAOYSA-N 5-benzyl-N-(1-methyl-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound CC1=CN=C(C(CC2)NC(C3=NNC(CC4=CC=CC=C4)=N3)=O)N1C1=C2C=CC=C1 ZHIMQTANLNKUAF-UHFFFAOYSA-N 0.000 description 1
- VTZHNDSGCYVODF-UHFFFAOYSA-N 5-benzyl-N-(4,5-dihydroimidazo[1,2-a]quinolin-4-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC1C2=NC=CN2C2=CC=CC=C2C1 VTZHNDSGCYVODF-UHFFFAOYSA-N 0.000 description 1
- CHPJWDWTCMTQOD-UHFFFAOYSA-N 5-benzyl-N-(5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC(CC1)C2=NN=CN2C2=C1C=CC=C2 CHPJWDWTCMTQOD-UHFFFAOYSA-N 0.000 description 1
- HFOPVNLMWBHIFT-UHFFFAOYSA-N 5-benzyl-N-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1,2-oxazole-3-carboxamide Chemical compound O=C(C1=NOC(CC2=CC=CC=C2)=C1)NC(CC1)C2=NC=CN2C2=C1C=CC=C2 HFOPVNLMWBHIFT-UHFFFAOYSA-N 0.000 description 1
- SHVFJHMSTGXYBK-UHFFFAOYSA-N 5-benzyl-N-(9-thia-1,2,5-triazatricyclo[8.3.0.02,6]trideca-3,5,10,12-tetraen-7-yl)-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC(CS1)C2=NC=CN2N2C1=CC=C2 SHVFJHMSTGXYBK-UHFFFAOYSA-N 0.000 description 1
- NZSDFIMCMHPEQT-NRFANRHFSA-N 5-benzyl-N-[(4S)-9-(3-hydroxy-3-methylbut-1-ynyl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound CC(C)(C#CC1=CC(N2C([C@H](CC3)NC(C4=NNC(CC5=CC=CC=C5)=N4)=O)=NC=C2)=C3C=C1)O NZSDFIMCMHPEQT-NRFANRHFSA-N 0.000 description 1
- VXLAWGSLADMRSU-VWLOTQADSA-N 5-benzyl-N-[(4S)-9-(3-oxa-9-azaspiro[5.5]undecan-9-yl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)N[C@@H](CC1)C2=NC=CN2C2=C1C=CC(N(CC1)CCC11CCOCC1)=C2 VXLAWGSLADMRSU-VWLOTQADSA-N 0.000 description 1
- WKRLIMXAUYJRGV-UHFFFAOYSA-N 5-benzyl-N-[9-(3-hydroxy-3-methylbut-1-ynyl)-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound CC(C)(C#CC1=CC(N2C(C(CC3)NC(C4=NNC(CC5=CC=CC=C5)=N4)=O)=NN=C2)=C3C=C1)O WKRLIMXAUYJRGV-UHFFFAOYSA-N 0.000 description 1
- NZSDFIMCMHPEQT-UHFFFAOYSA-N 5-benzyl-N-[9-(3-hydroxy-3-methylbut-1-ynyl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound CC(C)(C#CC1=CC(N2C(C(CC3)NC(C4=NNC(CC5=CC=CC=C5)=N4)=O)=NC=C2)=C3C=C1)O NZSDFIMCMHPEQT-UHFFFAOYSA-N 0.000 description 1
- ZQIVANSRBPRCRG-UHFFFAOYSA-N 5-benzyl-N-[9-(3-hydroxy-3-methylbutyl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound CC(C)(CCC1=CC(N2C(C(CC3)NC(C4=NNC(CC5=CC=CC=C5)=N4)=O)=NC=C2)=C3C=C1)O ZQIVANSRBPRCRG-UHFFFAOYSA-N 0.000 description 1
- QFRQIZSMPYCWPK-UHFFFAOYSA-N 5-benzyl-N-[9-(3-oxa-9-azaspiro[5.5]undecan-9-yl)-1-oxo-5,6-dihydro-4H-[1,2,4]oxadiazolo[4,3-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC(CCC(C=CC(N(CC1)CCC11CCOCC1)=C1)=C1N12)C1=NOC2=O QFRQIZSMPYCWPK-UHFFFAOYSA-N 0.000 description 1
- VXLAWGSLADMRSU-UHFFFAOYSA-N 5-benzyl-N-[9-(3-oxa-9-azaspiro[5.5]undecan-9-yl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC(CC1)C2=NC=CN2C2=C1C=CC(N(CC1)CCC11CCOCC1)=C2 VXLAWGSLADMRSU-UHFFFAOYSA-N 0.000 description 1
- OAUIQWISOIOBIR-UHFFFAOYSA-N 5-benzyl-N-[9-(7-oxa-2-azaspiro[3.5]nonan-2-yl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-1H-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NNC(CC2=CC=CC=C2)=N1)NC(CC1)C2=NC=CN2C2=C1C=CC(N(C1)CC11CCOCC1)=C2 OAUIQWISOIOBIR-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 208000036443 AIPL1-related retinopathy Diseases 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000029602 Alpha-N-acetylgalactosaminidase deficiency Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 208000025705 Axial Spondyloarthritis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 208000007050 Behr syndrome Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 208000033379 Chorioretinopathy Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 208000011518 Danon disease Diseases 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015287 Erythropenia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000013171 Fahr disease Diseases 0.000 description 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
- 208000033149 Farber disease Diseases 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 1
- 208000001905 GM2 Gangliosidoses Diseases 0.000 description 1
- 201000008905 GM2 gangliosidosis Diseases 0.000 description 1
- 208000017462 Galactosialidosis Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 208000001500 Glycogen Storage Disease Type IIb Diseases 0.000 description 1
- 208000035148 Glycogen storage disease due to LAMP-2 deficiency Diseases 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 101000733257 Homo sapiens Rho guanine nucleotide exchange factor 28 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010049933 Hypophosphatasia Diseases 0.000 description 1
- 206010021074 Hypoplastic anaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229940121740 Inosine monophosphate dehydrogenase inhibitor Drugs 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000012309 Linear IgA disease Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000003221 Lysosomal acid lipase deficiency Diseases 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 206010027910 Mononeuritis Diseases 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 1
- 208000035032 Multiple sulfatase deficiency Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001099197 Mus musculus RalA-binding protein 1 Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- 101710156256 Myosin phosphatase Rho-interacting protein Proteins 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- KGIMABVNOWQAGO-UHFFFAOYSA-N N-(1-oxo-5,6-dihydro-4H-[1,2,4]oxadiazolo[4,3-a][1]benzazepin-4-yl)-4-phenoxypyridine-2-carboxamide Chemical compound O=C(C1=NC=CC(OC2=CC=CC=C2)=C1)NC(CCC(C=CC=C1)=C1N12)C1=NOC2=O KGIMABVNOWQAGO-UHFFFAOYSA-N 0.000 description 1
- FCABECZHBFGUEK-UHFFFAOYSA-N N-(4,5-dihydroimidazo[1,2-a]quinolin-4-yl)-4-phenoxypyridine-2-carboxamide Chemical compound O=C(C1=NC=CC(OC2=CC=CC=C2)=C1)NC1C2=NC=CN2C2=CC=CC=C2C1 FCABECZHBFGUEK-UHFFFAOYSA-N 0.000 description 1
- RMIGGJAWRSCZLB-UHFFFAOYSA-N N-(5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepin-4-yl)-4-phenoxypyridine-2-carboxamide Chemical compound O=C(C1=NC=CC(OC2=CC=CC=C2)=C1)NC(CC1)C2=NN=CN2C2=C1C=CC=C2 RMIGGJAWRSCZLB-UHFFFAOYSA-N 0.000 description 1
- QLNVOZHTRCGCGE-UHFFFAOYSA-N N-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-1-[(2-fluorophenyl)methyl]-1,2,4-triazole-3-carboxamide Chemical compound O=C(C1=NN(CC(C=CC=C2)=C2F)C=N1)NC(CC1)C2=NC=CN2C2=C1C=CC=C2 QLNVOZHTRCGCGE-UHFFFAOYSA-N 0.000 description 1
- TUELUWNGEBZHLO-UHFFFAOYSA-N N-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-4-phenoxypyridine-2-carboxamide Chemical compound O=C(C1=NC=CC(OC2=CC=CC=C2)=C1)NC(CC1)C2=NC=CN2C2=C1C=CC=C2 TUELUWNGEBZHLO-UHFFFAOYSA-N 0.000 description 1
- JQKPXZVZVHXYIG-UHFFFAOYSA-N N-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl)-4-phenylpyrimidine-2-carboxamide Chemical compound O=C(C1=NC=CC(C2=CC=CC=C2)=N1)NC(CC1)C2=NC=CN2C2=C1C=CC=C2 JQKPXZVZVHXYIG-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 description 1
- HHXIOVPOYIGGBZ-UHFFFAOYSA-N N-[9-(3-hydroxy-3-methylbut-1-ynyl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-4-phenoxypyridine-2-carboxamide Chemical compound CC(C)(C#CC1=CC(N2C(C(CC3)NC(C4=NC=CC(OC5=CC=CC=C5)=C4)=O)=NC=C2)=C3C=C1)O HHXIOVPOYIGGBZ-UHFFFAOYSA-N 0.000 description 1
- JVBMQQIYGZRAMI-UHFFFAOYSA-N N-[9-(3-oxa-9-azaspiro[5.5]undecan-9-yl)-5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-yl]-4-phenoxypyridine-2-carboxamide Chemical compound O=C(C1=NC=CC(OC2=CC=CC=C2)=C1)NC(CC1)C2=NC=CN2C2=C1C=CC(N(CC1)CCC11CCOCC1)=C2 JVBMQQIYGZRAMI-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- LUZWXMGSPXIQHB-UHFFFAOYSA-N OC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=C(OC1=O)C=CC=C2 Chemical compound OC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=C(OC1=O)C=CC=C2 LUZWXMGSPXIQHB-UHFFFAOYSA-N 0.000 description 1
- ZUKXEQDCLXWSNI-UHFFFAOYSA-N OP(O)(OP(O)(O)=O)=O.OP(O)(OP(O)(O)=O)=O.OP(O)(OP(O)(O)=O)=O.N.N.N.N Chemical group OP(O)(OP(O)(O)=O)=O.OP(O)(OP(O)(O)=O)=O.OP(O)(OP(O)(O)=O)=O.N.N.N.N ZUKXEQDCLXWSNI-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000002804 Osteochondritis Diseases 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 101150038994 PDGFRA gene Proteins 0.000 description 1
- 101150093908 PDGFRB gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000028561 Primary cutaneous T-cell lymphoma Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102100027716 RanBP-type and C3HC4-type zinc finger-containing protein 1 Human genes 0.000 description 1
- 101710164093 RanBP-type and C3HC4-type zinc finger-containing protein 1 Proteins 0.000 description 1
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 201000004854 SAPHO syndrome Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 208000013608 Salla disease Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 208000000828 Sialic Acid Storage Disease Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 231100000265 Toxic optic neuropathy Toxicity 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010067774 Tumour necrosis factor receptor-associated periodic syndrome Diseases 0.000 description 1
- 108700001567 Type I Schindler Disease Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 229960002054 acenocoumarol Drugs 0.000 description 1
- OUCXYSRPMBQONT-UHFFFAOYSA-N acetamide;phenol Chemical compound CC(N)=O.OC1=CC=CC=C1 OUCXYSRPMBQONT-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 201000008333 alpha-mannosidosis Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003926 antimycobacterial agent Chemical class 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- VLAXZGHHBIJLAD-UHFFFAOYSA-N arsphenamine Chemical compound [Cl-].[Cl-].C1=C(O)C([NH3+])=CC([As]=[As]C=2C=C([NH3+])C(O)=CC=2)=C1 VLAXZGHHBIJLAD-UHFFFAOYSA-N 0.000 description 1
- 229940003446 arsphenamine Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- FKQQKMGWCJGUCS-UHFFFAOYSA-N atromentin Chemical compound O=C1C(O)=C(C=2C=CC(O)=CC=2)C(=O)C(O)=C1C1=CC=C(O)C=C1 FKQQKMGWCJGUCS-UHFFFAOYSA-N 0.000 description 1
- AAEDGQBSNHENEM-UHFFFAOYSA-N atromentin Natural products OCC1(O)C2=C(C(=O)C(=C(C2=O)c3ccc(O)cc3)O)c4ccc(O)cc14 AAEDGQBSNHENEM-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 229950009579 axicabtagene ciloleucel Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229940022777 azasan Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- 201000002922 basal ganglia calcification Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- SSWTVBYDDFPFAF-DKOGRLLHSA-N ceftibuten dihydrate Chemical compound O.O.S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 SSWTVBYDDFPFAF-DKOGRLLHSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000012094 cell viability reagent Substances 0.000 description 1
- 229940107810 cellcept Drugs 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 208000024042 cholesterol ester storage disease Diseases 0.000 description 1
- 208000013760 cholesteryl ester storage disease Diseases 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 cilastatin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229950002334 clenoliximab Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 201000004897 cough variant asthma Diseases 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002615 dalfopristin Drugs 0.000 description 1
- SUYRLXYYZQTJHF-VMBLUXKRSA-N dalfopristin Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1 SUYRLXYYZQTJHF-VMBLUXKRSA-N 0.000 description 1
- 108700028430 dalfopristin Proteins 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 description 1
- 229960003701 dextromoramide Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 description 1
- 229960002500 dipipanone Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 229960000895 doripenem Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 201000009320 ethmoid sinusitis Diseases 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003487 fedratinib Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229950010512 fezakinumab Drugs 0.000 description 1
- 101150016624 fgfr1 gene Proteins 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 206010049444 fibromatosis Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 201000010103 fibrous dysplasia Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229950010043 fletikumab Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000006916 frontal sinusitis Diseases 0.000 description 1
- 201000008049 fucosidosis Diseases 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940062737 gengraf Drugs 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229950006304 gilteritinib Drugs 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 108010005808 hementin Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 239000003667 hormone antagonist Chemical class 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229940075628 hypomethylating agent Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 229940045207 immuno-oncology agent Drugs 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 239000002584 immunological anticancer agent Substances 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 229940045426 kymriah Drugs 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960000812 linaclotide Drugs 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229940084408 linzess Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 229950011263 lirilumab Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229960003640 mafenide Drugs 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 229950007254 mavrilimumab Drugs 0.000 description 1
- 201000008836 maxillary sinusitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- CTUAQTBUVLKNDJ-OBZXMJSBSA-N meropenem trihydrate Chemical compound O.O.O.C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 CTUAQTBUVLKNDJ-OBZXMJSBSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 208000013734 mononeuritis simplex Diseases 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Natural products O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 201000007769 mucolipidosis Diseases 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- DOZYTHNHLLSNIK-JOKMOOFLSA-M mycophenolate sodium Chemical compound [Na+].OC1=C(C\C=C(/C)CCC([O-])=O)C(OC)=C(C)C2=C1C(=O)OC2 DOZYTHNHLLSNIK-JOKMOOFLSA-M 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940083410 myfortic Drugs 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000021597 necroptosis Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 201000005799 nutritional optic neuropathy Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000007892 occupational asthma Diseases 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000012753 partial hepatectomy Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- CSOMAHTTWTVBFL-OFBLZTNGSA-N platensimycin Chemical compound C([C@]1([C@@H]2[C@@H]3C[C@@H]4C[C@@]2(C=CC1=O)C[C@@]4(O3)C)C)CC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-OFBLZTNGSA-N 0.000 description 1
- CSOMAHTTWTVBFL-UHFFFAOYSA-N platensimycin Natural products O1C2(C)CC3(C=CC4=O)CC2CC1C3C4(C)CCC(=O)NC1=C(O)C=CC(C(O)=O)=C1O CSOMAHTTWTVBFL-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010070701 procolipase Proteins 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ABBQGOCHXSPKHJ-WUKNDPDISA-N prontosil Chemical compound NC1=CC(N)=CC=C1\N=N\C1=CC=C(S(N)(=O)=O)C=C1 ABBQGOCHXSPKHJ-WUKNDPDISA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229950001626 quizartinib Drugs 0.000 description 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000004003 siderosis Diseases 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229950006094 sirukumab Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 201000006923 sphenoid sinusitis Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229950008188 sulfamidochrysoidine Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960005240 telavancin Drugs 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 229950007137 tisagenlecleucel Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 208000029517 toxic amblyopia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Chemical group 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
- 229960001522 ximelagatran Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229940045208 yescarta Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Abstract
本發明揭示激酶抑制性化合物,諸如受體相互作用蛋白-1 (RIP1)激酶抑制劑化合物,以及包含該等抑制性化合物之醫藥組合物及組合。所揭示之該等化合物、醫藥組合物及/或組合可用於治療或預防激酶相關疾病或病狀,尤其RIP1相關疾病或病狀。
Description
本發明係關於化合物以及製造及使用該等化合物之方法,諸如用於抑制受體相互作用蛋白-1激酶(「RIP1」)及用於治療與RIP1相關之疾病及/或病狀。
受體相互作用蛋白-1激酶(在本文中稱為「RIP1」)屬於酪胺酸激酶樣家族且為參與先天性免疫信號傳導之絲胺酸/蘇胺酸蛋白激酶。RIP1在調節細胞信號傳導中起主要作用且其在計劃性細胞死亡中之作用與各種發炎性疾病有關,諸如發炎性腸病、牛皮癬及其他與發炎及/或壞死性細胞死亡相關之疾病及/或病狀。
本文揭示根據下式之化合物:
其中
X係選自CH
2、O、S、S(O)、S(O)
2及NR
a;
R
a在每次出現時選自氫、C
1 - 6烷基及C
1 - 6醯基;
Y
1、Y
2及Y
3係獨立地選自由N、N(R
a)、O、C(R
b)
1 - 2及C=O組成之群;
R
b係選自氫、C
1 - 6烷基及鹵基;
Z為C(R
c)或NR
c;
R
c為視情況經一或多個R
1基團取代之C
1 - 4不飽和碳鏈,視情況間雜有1或2個選自O、N及S之雜原子;
R
z為N、CH或C(R
1),且與ZR
c及其所鍵結之碳一起形成視情況經m個R
1基團取代之5或6員雜芳基或6員芳環;
R
1為鹵素、連接基-R
6基團,其中該連接基為鍵、(C1-C4)烷基(alkanyl)、(C1-C4)烯基或(C1-C4)炔基,其視情況經一或多個R
b取代,且R
6為R
e、-C(R
f)
3或-C(R
f)=C(R
f)
2;
R
2為R
a;
環B為5至10員雜芳基;
R
3在每次出現時獨立地選自R
b及OR
a;
L為O、NR
a或伸烷基;
W為視情況經p個R
4取代之5至10員芳基或雜芳基;
R
4在每次出現時選自R
b及OR
a;
R
d在每次出現時獨立地選自氫、C
1 - 6烷基、芳烷基、C
5 - 10芳基或雜芳基,或兩個R
d與其所連接之氮一起形成視情況經一或多個R
e取代之C
3 - 10雜環基;
R
e在每次出現時獨立地為鹵基、-OR
d、-SR
d、-S(O)
2R
d、-NR
dR
d、-Si(R
a)
3、-C(O)OH、-C(O)OR
a或-C(O)NR
dR
d;
R
f在每次出現時獨立地為R
a、R
b或R
e,或兩個R
f基團與其所鍵結之碳原子一起提供C
3 - 6環烷基或C
3 - 10雜環基,其各自視情況經一或多個R
e取代;
m為1、2、3或4;
n為0、1或2;及
p為0、1、2、3、4或5。另外,揭示用於製造化合物之方法及中間物以及醫藥調配物及使用該等化合物及調配物之方法。
自以下實施方式,本發明之前述及其他目標、特徵及優勢將變得更顯而易見。
本申請案根據35 U.S.C. §119(e)主張2020年7月1日申請的美國臨時申請案序列號63/047,194之權益,其揭示內容以引用之方式併入本文中。
I. 術語綜述提供術語及方法之以下解釋以便較好地描述本發明且指導一般熟習此項技術者來實踐本發明。除非上下文另外明確規定,否則單數形式「一個(種)(a/an)」及「該(the)」係指一個(種)或超過一個(種)。除非上下文另外明確指明,否則術語「或」係指所述替代要素中之單一要素或兩種或更多種要素之組合。如本文所用,「包含(comprise)」意謂「包括(include)」。因此,「包含A或B」意謂「包括A、B或A及B」而不排除其他要素。所有參考文獻,包括本文所引用之專利及專利申請案,均以引用之方式併入。
除非另外指明,否則如本說明書或申請專利範圍中所用之所有表示組分數量、分子量、百分比、溫度、時間等之數值均應理解為由術語「約」修飾。因此,除非另外含蓄地或明確地指明,否則所述數值參數為可視所尋求之所需特性及/或在標準測試條件/方法下之偵測極限而定的近似值。當直接且明確地區分實施例與所述先前技術時,除非用字語「約」明確地敍述,否則實施例數值為非近似值。
除非另外解釋,否則本文中所用之所有技術及科學術語均具有與本發明所屬領域之一般技術者通常所理解含義相同的含義。儘管類似或等效於本文中所述之方法及材料可用於實踐或測試本發明,但下文描述適合方法及材料。材料、方法及實例僅為說明性的,且並不意欲為限制性的。
如本文所用,術語「
經取代」係指術語中之所有後續修飾語,例如在術語「經取代之芳基C
1 - 8烷基」中,取代可能發生在「C
1 - 8烷基」部分、「芳基」部分或芳基C
1 - 8烷基之兩個部分上。
「經取代」在用於修飾指定基團或部分時意謂指定基團或部分之至少一個且可能兩個或更多個氫原子獨立地經如下文所定義之相同或不同取代基置換。在一特定實施例中,除非明確定義為「未經取代」或「經取代」,否則基團、部分或取代基可經取代或未經取代。因此,除非上下文另外指示或特定結構式排除取代,否則本文中指定之基團中之任一者可未經取代或經取代。在特定實施例中,取代基可或可不明確地定義為經取代,但仍考慮為視情況經取代。舉例而言,「脂族」或「環狀」部分可未經取代或經取代,但「未經取代之脂族」或「未經取代之環狀」者則未經取代。
「取代基(substituent/substituent group)」用於取代指定基團或部分中之飽和碳原子上之一或多個氫原子。如本文所用,術語「
經取代」係指術語中之所有後續修飾語,例如在術語「經取代之芳基C
1 - 8烷基」中,取代可能發生在「C
1 - 8烷基」部分、「芳基」部分或芳基C
1 - 8烷基之兩個部分上。
「經取代」在用於修飾指定基團或部分時意謂指定基團或部分之至少一個且可能兩個或更多個氫原子獨立地經如下文所定義之相同或不同取代基置換。在一特定實施例中,除非明確定義為「未經取代」或「經取代」,否則基團、部分或取代基可經取代或未經取代。因此,除非上下文另外指示或特定結構式排除取代,否則本文中指定之基團中之任一者可未經取代或經取代。在特定實施例中,取代基可或可不明確地定義為經取代,但仍考慮為視情況經取代。舉例而言,「脂族」或「環狀」部分可未經取代或經取代,但「未經取代之脂族」或「未經取代之環狀」者則未經取代。
除非另外指定,否則用於取代本文所述的指定基團或部分中之飽和碳原子上之一或多個氫原子的「取代基」可為-R
60、鹵基、=O、-OR
70、-SR
70、-N(R
80)
2、鹵烷基、全鹵烷基、-CN、-NO
2、=N
2、-N
3、-SO
2R
70、-SO
3 -M
+、-SO
3R
70、-OSO
2R
70、-OSO
3 -M
+、-OSO
3R
70、-P(O)(O
-)
2(M
+)
2、-P(O)(O
-)
2M
2+、-P(O)(OR
70)O
-M
+、-P(O)(OR
70)
2、-C(O)R
70、-C(S)R
70、-C(NR
70)R
70、-CO
2 -M
+、-CO
2R
70、-C(S)OR
70、-C(O)N(R
80)
2、-C(NR
70)(R
80)
2、-OC(O)R
70、-OC(S)R
70、-OCO
2 -M
+、-OCO
2R
70、-OC(S)OR
70、-NR
70C(O)R
70、-NR
70C(S)R
70、-NR
70CO
2 -M
+、-NR
70CO
2R
70、-NR
70C(S)OR
70、-NR
70C(O)N(R
80)
2、-NR
70C(NR
70)R
70及-NR
70C(NR
70)N(R
80)
2,其中R
60係C
1 - 10脂族基、雜脂族基或環脂族基,通常為C
1 - 6脂族基,更通常為C
1 - 6烷基,其中R
60視情況可經取代;各R
70在每次出現時獨立地為氫或R
60;各R
80在每次出現時獨立地為R
70或替代地,兩個R
80基團與其所鍵結之氮原子一起形成3至7員雜環脂族基,其視情況包括1至4個選自O、N及S之相同或不同的其他雜原子,其中N視情況具有R
70取代,諸如H或C
1-C
3烷基取代;且各M
+為具有單一淨正電荷之相對離子。各M
+在每次出現時獨立地為例如鹼金屬離子,諸如K
+、Na
+、Li
+;銨離子,諸如
+N(R
60)
4;質子化胺基酸離子,諸如離胺酸離子或精胺酸離子;或鹼土金屬離子,諸如[Ca
2 +]
0 . 5、[Mg
2 +]
0 . 5或[Ba
2 +]
0 . 5(下標「0.5」意謂例如該等二價鹼土金屬離子之相對離子中之一者可為本發明化合物之離子化形式,且另一者為典型相對離子,諸如氯離子;或兩種離子化化合物可充當該等二價鹼土金屬離子之相對離子;或雙重離子化化合物可充當該等二價鹼土金屬離子之相對離子)。作為特定實例,-N(R
80)
2包括-NH
2、-NH-烷基、-NH-吡咯啶-3-基、
N-吡咯啶基、
N-哌𠯤基、4
N-甲基-哌𠯤-1-基、
N -嗎啉基及其類似者。單一碳上之任兩個氫原子亦可用例如=O、=NR
70、=N-OR
70、=N
2或=S置換。
除非另外指定,否則用於置換含有不飽和碳之基團中的不飽和碳原子上之氫原子的取代基為-R
60、鹵基、-O
-M
+、-OR
70、-SR
70、-S
-M
+、-N(R
80)
2、全鹵烷基、-CN、-OCN、-SCN、-NO、-NO
2、-N
3、-SO
2R
70、-SO
3 -M
+、-SO
3R
70、-OSO
2R
70、-OSO
3 -M
+、-OSO
3R
70、-PO
3 -2(M
+)
2、-PO
3 -2M
2+、-P(O)(OR
70)O
-M
+、-P(O)(OR
70)
2、-C(O)R
70、-C(S)R
70、-C(NR
70)R
70、-CO
2 -M
+、-CO
2R
70、-C(S)OR
70、-C(O)NR
80R
80、-C(NR
70)N(R
80)
2、-OC(O)R
70、-OC(S)R
70、-OCO
2 -M
+、-OCO
2R
70、-OC(S)OR
70、-NR
70C(O)R
70、-NR
70C(S)R
70、-NR
70CO
2 -M
+、-NR
70CO
2R
70、-NR
70C(S)OR
70、-NR
70C(O)N(R
80)
2、-NR
70C(NR
70)R
70及-NR
70C(NR
70)N(R
80)
2,其中R
60、R
70、R
80及M
+係如先前所定義。在一獨立實施例中,取代基不為-O
-M
+、-OR
70、-SR
70或-S
-M
+。
除非另外規定,否則用於置換含有氮原子之基團中的該等氮原子上之氫原子的取代基為-R
60、-O
-M
+、-OR
70、-SR
70、-S
-M
+、-N(R
80)
2、全鹵烷基、-CN、-NO、-NO
2、-S(O)
2R
70、-SO
3 -M
+、-SO
3R
70、-OS(O)
2R
70、-OSO
3 -M
+、-OSO
3R
70、-PO
3 2-(M
+)
2、-PO
3 2-M
2+、-P(O)(OR
70)O
-M
+、-P(O)(OR
70)(OR
70)、-C(O)R
70、-C(S)R
70、-C(NR
70)R
70、-CO
2R
70、-C(S)OR
70、-C(O)NR
80R
80、-C(NR
70)NR
80R
80、-OC(O)R
70、-OC(S)R
70、-OCO
2R
70、-OC(S)OR
70、-NR
70C(O)R
70、-NR
70C(S)R
70、-NR
70CO
2R
70、-NR
70C(S)OR
70、-NR
70C(O)N(R
80)
2、-NR
70C(NR
70)R
70及-NR
70C(NR
70)N(R
80)
2,其中R
60、R
70、R
80及M
+係如先前所定義。
在一個實施例中,經取代之基團具有至少一個選自上文所述之取代基,至多特定部分可能的取代基之數目的取代基,諸如一至五個取代基、一個取代基、兩個取代基、三個取代基、四個取代基或五個取代基。
另外,在基團或部分係被經取代之取代基取代之實施例中,該等經取代之取代基之入駐(nesting)限於三個,由此防止形成聚合物。因此,在包含第一基團之基團或部分中,該第一基團為第二基團上之取代基,而該第二基團本身為與母結構連接之第三基團上之取代基,第一(最外)基團可僅被未經取代之取代基取代。例如,在包含-(芳基-1)-(芳基-2)-(芳基-3)之基團中,芳基-3可僅被自身並未經取代之取代基取代。
如一般熟習此項技術者將理解,除非明確地陳述或由上下文暗示基團或部分與結構之另一部分的連接性,否則本文中所定義之任何基團或部分可連接至所揭示結構之任何其他部分,諸如母結構或核心結構,諸如藉由考慮化合價規則、與例示性物種之比較及/或考慮官能性。
「
脂族」係指實質上基於烴之基團或部分。脂族基或部分可為非環狀的,包括
烷基、
烯基或
炔基(以及伸烷基、伸烯基或伸炔基);其環狀形式,諸如
環脂族基或部分,包括
環烷基、
環烯基或
環炔基,且進一步包括直鏈及分支鏈配置以及所有立體異構體及位置異構體。除非另外明確陳述,否則脂族基含有一至二十五個碳原子(C
1 - 25);例如對於非環狀脂族基或部分,一至十五個(C
1 - 15)、一至十個(C
1 - 10)、一至六個(C
1 - 6)或一至四個(C
1 - 4)碳原子,或對於環脂族基或部分,三至十五個(C
3 - 15)、三至十個(C
3 - 10)、三至六個(C
3 - 6)或三至四個((C
3 - 4))碳原子。脂族基可經取代或未經取代,除非明確地稱為「未經取代之脂族基」或「經取代之脂族基」。脂族基可經一或多個取代基取代(對於脂族鏈中之各亞甲基碳,至多兩個取代基;或對於脂族鏈中之-C=C-雙鍵之各碳,至多一個取代基;或對於末端次甲基之碳,至多一個取代基)。
「
低級脂族」係指含有一至十個碳原子(C
1 - 10),諸如一至六個(C
1 - 6)或一至四個(C
1 - 4)碳原子之脂族基;或對於低級環脂族基,三至十個(C
3 - 10),諸如三至六個(C
3 - 6)碳原子。
「
烷氧基」係指基團-OR,其中R為經取代或未經取代之烷基或經取代或未經取代之環烷基。在某些實施例中,R為C
1 - 6烷基或C
3 - 6環烷基。甲氧基(-OCH
3)及乙氧基(-OCH
2CH
3)為例示性烷氧基。在經取代之烷氧基中,R為經取代之烷基或經取代之環烷基,其實例在本發明所揭示之化合物中包括鹵烷氧基,諸如OCF
2H。
「
烷氧基烷基」係指基團-烷基-OR,其中R為經取代或未經取代之烷基或經取代或未經取代之環烷基;-CH
2CH
2-O-CH
2CH
3為例示性烷氧基烷基。
「
烷基」係指具有1至至少25個(C
1 - 25)碳原子,更通常1至10個(C
1 - 10)碳原子,諸如1至6個(C
1 - 6)碳原子之飽和脂族烴基。烷基部分可經取代或未經取代。此術語包括例如直鏈及分支鏈烴基,諸如甲基(CH
3)、乙基(-CH
2CH
3)、正丙基(-CH
2CH
2CH
3)、異丙基(-CH(CH
3)
2)、正丁基(-CH
2CH
2CH
2CH
3)、異丁基(-CH
2CH
2(CH
3)
2)、二級丁基(-CH(CH
3)(CH
2CH
3)、三級丁基(-C(CH
3)
3)、正戊基(-CH
2CH
2CH
2CH
2CH
3)及新戊基(-CH
2C(CH
3)
3)。
「
伸烷基」係指二價烷基或烷基鏈。與上文所述之烷基相同,該等伸烷基視情況經一或多個如上文所述之取代基取代。舉例而言,該等伸烷基包括(但不限於)-CH
2、-CH(Me)、-C(Me)
2、-CF
2-、-CH(F)、-CH
2CH
2-及其類似者。如本文所揭示,該等伸烷基部分係適用作鍵聯基。
類似地,術語「
伸烯基」及「
伸炔基」分別係指含有至少一個烯烴或至少一個炔烴之二價脂族鏈。該等伸烯基及伸炔基可經上文所述之一或多個取代基取代。
「
胺基」係指基團-NH
2、-NHR或-NRR,其中各R獨立地選自H;脂族基;雜脂族基;芳族基,包括芳基及雜芳基;或雜環脂族基,或兩個R基團與其所連接之氮一起形成雜環。該等雜環之實例包括其中兩個R基團與其所連接之氮一起形成-(CH
2)
2 - 5-環的彼等雜環,其視情況間雜有一或兩個雜原子基團,諸如-O-或-N(R
g),諸如在基團
及
中,其中R
g為R
70、-C(O)R
70、-C(O)OR
60或-C(O)N(R
80)
2。
「
醯胺」係指基團-N(R)醯基,其中R為氫、雜脂族基或脂族基,諸如烷基,尤其C
1 - 6烷基。
除非另外規定,否則「
芳族」係指5至15個環原子之環狀共軛基團或部分具有連續非定域π電子系統,該基團或部分具有單一環(例如苯基、吡啶基或吡唑基)或多個稠環,其中至少一個環為芳族的(例如萘基、吲哚基或吡唑并吡啶基),亦即至少一個環及視情況選用之多個稠環。通常,平面外π電子之數量對應於休克爾規則(Hückel rule) (4n + 2)。與母結構之連接點通常係經由稠環系統之芳族部分。例如,
。然而,在某些實例中,上下文或明確的揭示內容可指示連接點係經由稠環系統之非芳族部分。例如,
。芳族基或部分可僅包含環中之碳原子,諸如在芳基或部分中,或其可包含一或多個環碳原子及一或多個包含非共用電子對之環雜原子(例如S、O、N、P或Si),諸如在雜芳基或部分中。除非另外陳述,否則芳族基可經取代或未經取代。
除非另外規定,否則「
芳基」係指6至15個碳原子之芳族碳環基,其具有單一環(例如苯基)或多個稠環,其中至少一個環為芳族的(例如1,2,3,4-四氫喹啉、苯并間二氧雜環戊烯及其類似者)。若任何芳環部分含有雜原子,則該基團為雜芳基且不為芳基。芳基可為例如單環、雙環、三環或四環的。除非另外陳述,否則芳基可經取代或未經取代。
「
芳脂族」係指經由脂族部分連接至母體之芳基。芳脂族包括芳烷基或芳基烷基,諸如苯甲基及苯乙基。
「
羧基」係指-CO
2H。
「
羧醯胺」係指-C(O)胺基。
「
羧基酯 ( carboxyl ester / carboxy ester )」係指基團-C(O)OR,其中R為脂族、雜脂族或芳族的(包括芳基及雜芳基)。
「
羧酸根」係指-C(O)O
-或其鹽。
「
氰基」係指基團-CN。
「
環脂族」係指具有單一環(例如,環己基)或多個環,諸如呈稠合、橋接或螺環系統之環脂族基團,環或系統中之至少一個環為脂族的。通常,與母結構之連接點係經由多環系統之脂族部分。環脂族包括飽和及不飽和系統,包括
環烷基、
環烯基及
環炔基。環脂族基可含有三至二十五個碳原子;例如三至十五個、三至十個或三至六個碳原子。除非另外陳述,否則環脂族基可經取代或未經取代。例示性環脂族基包括(但不限於)環丙基、環丁基、環戊基、環己基、環庚基、環戊烯基或環己烯基。
「
鹵基」、「
鹵」或「
鹵素」係指氟、氯、溴或碘。
「
鹵烷基」係指經一或多個鹵素取代之烷基部分。例示性鹵烷基部分包括-CH
2F、-CHF
2及-CF
3。
「
雜脂族」係指具有至少一個雜原子及至少一個碳原子,亦即來自包含至少兩個碳原子之脂族化合物或基團的至少一個碳原子已經具有至少一個非共用電子對之原子,通常氮、氧、磷、矽或硫置換的脂族化合物或基團。雜脂族化合物或基團可為經取代或未經取代、分支鏈或非分支鏈、對掌性或非對掌性及/或非環狀或環狀的,諸如雜環脂族基。
除非另外規定,否則「
雜芳基」係指具有5至15個包含至少一個碳原子及至少一個雜原子,諸如N、S、O、P或Si之環原子的芳族基或部分。雜芳基或部分可包含單一環(例如,吡啶基、嘧啶基或吡唑基)或多個稠環(例如,吲哚基、苯并吡唑基或吡唑并吡啶基)。雜芳基或部分可為例如單環、雙環、三環或四環的。除非另外陳述,否則雜芳基或部分可經取代或未經取代。
「
雜環基」、「
雜環 ( heterocyclo )」及「
雜環 ( heterocycle )」係指芳環及非芳環系統,且更特定言之,係指包含至少一個碳原子,且通常複數個碳原子及至少一個,諸如一至五個雜原子的穩定之三至十五員環部分。雜原子可為氮原子、磷原子、氧原子、矽原子或硫原子。雜環基部分可為單環部分,或可包含多個環,諸如在雙環或三環系統中,其限制條件為該等環中之至少一者含有雜原子。此類多環部分可包括稠合或橋接環系統以及螺環系統;且雜環基部分中之任何氮原子、磷原子、碳原子、矽原子或硫原子可視情況氧化成各種氧化態。出於方便起見,氮,尤其(但非排他地)定義為環形芳族氮之彼等者意謂包括其相應的N-氧化物形式,儘管在特定實例中並未如此明確地定義。因此,對於具有例如吡啶基環之化合物,除非明確排除或由上下文排除,否則相應的吡啶基-N-氧化物作為另一種本發明化合物包括在內。此外,環形氮原子可視情況四級銨化。雜環包括
雜芳基部分及
雜脂環基或
雜環脂族部分,其為部分或完全飽和之雜環基環。雜環基之實例包括(但不限於)氮雜環丁烷基、氧雜環丁烷基、吖啶基、苯并間二氧雜環戊烯基、苯并二㗁烷基、苯并呋喃基、肼甲醯基、㖕啉基、二氧戊環基、吲哚𠯤基、㖠啶基、全氫氮呯基、啡𠯤基、啡噻𠯤基、啡㗁𠯤基、呔𠯤基、喋啶基、嘌呤基、喹唑啉基、喹喏啉基、喹啉基、異喹啉基、四唑基、四氫異喹啉基、哌啶基、哌𠯤基、2-側氧基哌𠯤基、2-側氧基哌啶基、2-側氧基吡咯啶基、2-側氧基氮呯基、氮呯基、吡咯基、4-哌啶酮基、吡咯啶基、吡唑基、吡唑烷基、咪唑基、咪唑啉基、咪唑啶基、二氫吡啶基、四氫吡啶基、吡啶基、吡𠯤基、嘧啶基、嗒𠯤基、㗁唑基、㗁唑啉基、㗁唑啶基、三唑基、異㗁唑基、異㗁唑啶基、嗎啉基、噻唑基、噻唑啉基、噻唑啶基、異噻唑基、啶基、異噻唑啶基、吲哚基、異吲哚基、吲哚啉基、異吲哚啉基、八氫吲哚基、八氫異吲哚基、喹啉基、異喹啉基、十氫異喹啉基、苯并咪唑基、噻二唑基、苯并哌喃基、苯并噻唑基、苯并㗁唑基、呋喃基、二氮雜雙環庚烷、二氮環庚烷、二氮呯、四氫呋喃基、四氫哌喃基、噻吩基、苯并噻吩基、噻嗎啉基、噻嗎啉基亞碸、噻嗎啉基碸、二氧雜磷㖦基及㗁二唑基。
「
羥基」係指基團-OH。
「
硝基」係指基團-NO
2。
「
磷酸根」係指基團-O-P(O)(OR')
2,其中各-OR'獨立地為-OH;-O-脂族基,諸如-O-烷基或-O-環烷基;-O-芳族基,包括-O-芳基及-O-雜芳基;-O-芳烷基;或-OR'為-O-M
+,其中M
+為具有單一正電荷之相對離子。各M
+可為鹼金屬離子,諸如K
+、Na
+、Li
+;銨離子,諸如
+N(R'')
4,其中R''為H、脂族基、雜脂族基或芳族基(包括芳基及雜芳基);或鹼土金屬離子,諸如[Ca
2+]
0.5、[Mg
2+]
0.5或[Ba
2+]
0.5。膦醯氧基烷基係指基團-烷基-磷酸根,諸如-CH
2OP(O)(OH)
2或其鹽,諸如-CH
2OP(O)(O
-Na
+)
2,且(((二烷氧基磷醯基)氧基)烷基)係指膦醯氧基烷基之二烷基酯,諸如-CH
2OP(O)(O-三級丁基)
2。
「
膦酸根」係指基團-P(O)(OR')
2,其中各-OR'獨立地為-OH;-O-脂族基,諸如-O-烷基或-O-環烷基;-O-芳族基,包括-O-芳基及-O-雜芳基;或-O-芳烷基;或-OR'為-O-M
+,且M
+為具有單一正電荷之相對離子。各M
+為帶正電荷之相對離子,且可為例如鹼金屬離子,諸如K
+、Na
+、Li
+;銨離子,諸如
+N(R'')
4,其中R''為H、脂族基、雜脂族基或芳族基(包括芳基及雜芳基);或鹼土金屬離子,諸如[Ca
2+]
0.5、[Mg
2+]
0.5或[Ba
2+]
0.5。膦醯基烷基係指基團-烷基-膦酸根,諸如-CH
2P(O)(OH)
2或-CH
2P(O)(O
-Na
+)
2,且((二烷氧基磷醯基)烷基)係指膦醯基烷基之二烷基酯,諸如-CH
2P(O)(O-三級丁基)
2。
「
患者」或「
個體」可通常指任何生物,但更通常指哺乳動物及其他動物,尤其人類。因此,所揭示方法適用於人類療法及獸醫學應用。
「
醫藥學上可接受之賦形劑」係指除活性成分外的包括於包含活性成分之組合物中的物質。如本文所用,賦形劑可併入醫藥組合物之顆粒內,或其可以物理方式與醫藥組合物之顆粒混合。賦形劑可用於例如稀釋活性劑及/或調節醫藥組合物之特性。賦形劑可包括(但不限於)抗黏劑、黏合劑、包衣、腸溶包衣、崩解劑、調味劑、甜味劑、著色劑、潤滑劑、助滑劑、吸附劑、防腐劑、載劑或媒劑。賦形劑可為澱粉及改質澱粉、纖維素及纖維素衍生物、醣類及其衍生物(諸如雙醣、多醣及糖醇)、蛋白質、合成聚合物、交聯聚合物、抗氧化劑、胺基酸或防腐劑。例示性賦形劑包括(但不限於)硬脂酸鎂、硬脂酸、植物硬脂、蔗糖、乳糖、澱粉、羥丙基纖維素、羥丙基甲基纖維素、木糖醇、山梨糖醇、麥芽糖醇、明膠、聚乙烯吡咯啶酮(PVP)、聚乙二醇(PEG)、生育酚聚乙二醇1000丁二酸酯(亦稱為維生素E TPGS或TPGS)、羧甲基纖維素、二軟脂醯基磷脂醯膽鹼(DPPC)、維生素A、維生素E、維生素C、棕櫚酸視黃酯、硒、半胱胺酸、甲硫胺酸、檸檬酸、檸檬酸鈉、對羥基苯甲酸甲酯、對羥基苯甲酸丙酯、糖、二氧化矽、滑石、碳酸鎂、羥基乙酸澱粉鈉、酒石黃、阿斯巴甜糖、氯化苯甲烴銨、芝麻油、沒食子酸丙酯、偏亞硫酸氫鈉或羊毛脂。
「
佐劑」為調節其他(通常活性成分)之作用的組分。佐劑通常為藥用及/或免疫藥劑。佐劑可藉由增加免疫反應來調節活性成分之作用。佐劑亦可充當調配物之穩定劑。例示性佐劑包括(但不限於)氫氧化鋁、礬、磷酸鋁、滅活細菌、角鯊烯、清潔劑、細胞介素、石蠟油及複合佐劑,諸如完全弗氏佐劑或不完全弗氏佐劑。
「
醫藥學上可接受之載劑」係指作為載劑或媒劑之賦形劑,諸如懸浮助劑、溶解助劑或氣溶膠化助劑。以引用方式併入本文中之
Remington: The Science and Practice of Pharmacy, The University of the Sciences in Philadelphia, Lippincott, Williams及Wilkins(編), Philadelphia, PA, 第21版(2005)描述了適於在醫藥學上遞送一或多種治療性組合物及其他藥劑之例示性組合物及調配物。
一般而言,載劑之性質將視採用之特定投與模式而定。舉例而言,非經腸調配物通常包含包括醫藥學上及生理學上可接受之流體的可注射流體,諸如水、生理鹽水、平衡鹽溶液、右旋糖水溶液、甘油或其類似者作為媒劑。在一些實例中,醫藥學上可接受之載劑可為無菌的以適用於向個體投與(例如藉由非經腸、肌肉內或皮下注射)。除生物學中性載劑以外,待投與之醫藥組合物亦可含有少量無毒輔助物質,諸如濕潤劑或乳化劑、防腐劑及pH緩衝劑及其類似者,例如乙酸鈉或脫水山梨醇單月桂酸酯。
「
醫藥學上可接受之鹽」係指化合物之醫藥學上可接受之鹽,其係衍生自如一般熟習此項技術者將已知之多種有機及無機相對離子,且包括(僅舉例而言)鈉、鉀、鈣、鎂、銨、四烷基銨及其類似者,且當分子含有鹼性官能基時,有機酸或無機酸之鹽,諸如鹽酸鹽、氫溴酸鹽、酒石酸鹽、甲磺酸鹽、乙酸鹽、順丁烯二酸鹽、草酸鹽及其類似者。「醫藥學上可接受之酸加成鹽」為藉由酸搭配物形成的同時保留游離鹼之生物學有效性之一小類「醫藥學上可接受之鹽」。詳言之,所揭示之化合物係用多種醫藥學上可接受之酸形成鹽,該等酸包括(但不限於)無機酸,諸如鹽酸、氫溴酸、硫酸、硝酸、磷酸及其類似者,以及有機酸,諸如胺基酸、甲酸、乙酸、三氟乙酸、丙酸、乙醇酸、丙酮酸、草酸、順丁烯二酸、丙二酸、丁二酸、反丁烯二酸、酒石酸、檸檬酸、苯甲酸、肉桂酸、杏仁酸、苯磺酸、羥乙基磺酸、甲磺酸、乙磺酸、對甲苯磺酸、水楊酸、昔奈酸(xinafoic acid)及其類似者。「醫藥學上可接受之鹼加成鹽」為衍生自無機鹼,諸如鈉鹽、鉀鹽、鋰鹽、銨鹽、鈣鹽、鎂鹽、鐵鹽、鋅鹽、銅鹽、錳鹽、鋁鹽及其類似者之一小類「醫藥學上可接受之鹽」。例示性鹽為銨鹽、鉀鹽、鈉鹽、鈣鹽及鎂鹽。衍生自醫藥學上可接受之有機鹼之鹽包括(但不限於)以下之鹽:一級胺、二級胺及三級胺;經取代之胺,包括天然存在之經取代之胺;環胺及鹼性離子交換樹脂,諸如異丙胺、三甲胺、二乙胺、三乙胺、三丙胺、參(羥甲基)胺基甲烷(Tris)、乙醇胺、2-二甲胺基乙醇、2-二乙胺基乙醇、二環己胺、離胺酸、精胺酸、組胺酸、咖啡鹼、普魯卡因(procaine)、海卓胺、膽鹼、甜菜鹼、乙二胺、葡糖胺、甲基葡糖胺、可可豆鹼、嘌呤、哌𠯤、哌啶、
N -乙基哌啶、聚胺樹脂及其類似者。例示性有機鹼為異丙胺、二乙胺、參(羥甲基)胺基甲烷(Tris)、乙醇胺、三甲胺、二環己胺、膽鹼及咖啡鹼。(參見例如,S. M. Berge等人, 「Pharmaceutical Salts」, J. Pharm. Sci., 1977; 66:1-19,其以引用之方式併入本文中。) 在特定的所揭示之實施例中,化合物可為甲酸鹽、三氟乙酸鹽、鹽酸鹽或鈉鹽。
關於化合物或醫藥組合物之「
有效量」係指足夠達成特定所需結果,諸如抑制蛋白質或酶的化合物或醫藥組合物之量。在特定實施例中,「有效量」為足夠抑制RIP1;引起組織、系統、個體或患者之所需生物或醫學反應;治療指定病症或疾病;改善或根除一或多種其症狀;及/或預防疾病或病症發生之量。如將由所屬領域普通技術人員所理解,構成「有效量」的化合物之量可視化合物、所需結果、疾病病況及其嚴重程度、待治療之患者之身材、年齡及性別及其類似者而變化。
「
前藥」係指經活體內轉變得到生物活性化合物或比母化合物更具生物活性之化合物的化合物。活體內轉變可例如藉由水解或酶促轉化進行。前藥部分之常見實例包括(但不限於)具有帶有羧酸部分之活性形式之化合物的酯及醯胺形式。本發明化合物之醫藥學上可接受之酯的實例包括(但不限於)磷酸類及羧酸之酯,諸如脂族酯,尤其烷基酯(例如C
1 - 6烷基酯)。其他前藥部分包括磷酸酯,諸如-CH
2-O-P(O)(OR')
2或其鹽,其中R'為H或C
1 - 6烷基。可接受之酯亦包括環烷基酯及芳烷基酯,諸如(但不限於)苯甲基。本發明化合物之醫藥學上可接受之醯胺之實例包括(但不限於)一級醯胺以及二級及三級烷基醯胺(例如具有約一個與約六個之間的碳)。根據本發明之化合物之所揭示例示性實施例的醯胺及酯可根據習知方法製備。前藥之透徹論述係提供於T. Higuchi及V. Stella, 「Pro-drugs as Novel Delivery Systems」, A.C.S. Symposium Series之第14卷;及Bioreversible Carriers in Drug Design, Edward B. Roche編, American Pharmaceutical Association and Pergamon Press, 1987中,出於所有目的,兩者均以引用之方式併入本文中。
「
溶劑合物」係指藉由組合溶劑分子與溶質之分子或離子而形成的複合物。溶劑可為有機溶劑、無機溶劑或兩者之混合物。例示性溶劑包括(但不限於)醇,諸如甲醇、乙醇、丙醇;醯胺,諸如N,N-二脂族醯胺,諸如N,N-二甲基甲醯胺;四氫呋喃;烷基亞碸,諸如二甲亞碸;水;及其組合。當與醫藥學上可接受或不可接受之溶劑,諸如水、乙醇及其類似者之溶劑組合時,本文所述之化合物可以未溶合以及溶合形式存在。本發明所揭示之化合物之溶合形式在本文所揭示之實施例之範疇內。
「
磺醯胺」係指基團或部分-SO
2胺基或-N(R)磺醯基,其中R為H、脂族基、雜脂族基或芳族基(包括芳基及雜芳基)。
「
硫基」係指基團或部分-SH、-S-脂族基、-S-雜脂族基、-S-芳族基(包括-S-芳基及-S-雜芳基)。
「
亞磺醯基」係指基團或部分-S(O)H、-S(O)脂族基、-S(O)雜脂族基或-S(O)芳族基(包括-S(O)芳基及-S(O)雜芳基)。
「
磺醯基」係指基團:-SO
2H、-SO
2脂族基、-SO
2雜脂族基、-SO
2芳族基(包括-SO
2芳基及-SO
2雜芳基)。
如本文所用,「
治療 ( treating / treatment )」涉及治療患者或個體之所關注之疾病或病狀,尤其患有所關注之疾病或病狀之人類,且包括例如且不限於:
(i) 預防患者或個體中出現該疾病或病狀,詳言之,當該患者或個體易患該病狀但尚未經診斷為患有該病狀時;
(ii) 抑制該疾病或病狀,例如遏制或減緩其發展;
(iii) 緩解該疾病或病狀,例如引起症狀減弱或疾病或病狀或其症狀消退;或
(iv) 使該疾病或病狀穩定。
如本文所用,術語「疾病」及「病狀」可互換使用,或其不同之處可在於特定不適(malady)或病狀可能不具有已知病原體(使得病因尚未判定)且因此尚未被認可為疾病而僅被認可為不當病狀或症候群,其中一組或多或少之特定症狀已由臨床醫師鑑別出。
以上定義及以下通式並不意欲包括不容許之取代模式(例如,經5個氟基取代之甲基)。一般熟習此項技術者容易認識到此類不容許之取代模式。
一般熟習此項技術者應瞭解,特定化合物可展現互變異構、構形異構、幾何異構及/或光學異構現象。舉例而言,某些所揭示之化合物可包括一或多個對掌性中心及/或雙鍵且因此可以立體異構體形式存在,諸如雙鍵異構體(亦即幾何異構體)、對映異構體、非對映異構體及其混合物,諸如外消旋混合物。作為另一實例,某些所揭示之化合物可以若干互變異構形式存在,包括烯醇形式、酮形式及其混合物。由於本說明書及申請專利範圍內之各種化合物名稱、式及化合物圖式可僅表示可能的互變異構、構形異構、光學異構或幾何異構形式中之一者,所以一般熟習此項技術者應瞭解,所揭示之化合物涵蓋本文所述之化合物之任何互變異構、構形異構、光學異構及/或幾何異構形式,以及此等各種不同異構形式之混合物。可使用一般熟習此項技術者已知之技術,尤其利用本發明提供之方法,諸如用於分離此類混合物之對掌性HPLC,分離不同異構形式之混合物,包括對映異構體及/或立體異構體之混合物,以提供單獨的各對映異構體及/或立體異構體。替代地,化合物可以如一般熟習有機合成技術者已知的對映體純或對映體增濃形式合成。在例如圍繞醯胺鍵或在兩個直接連接之環(諸如吡啶基環、聯苯基及其類似者)之間旋轉受限之情況下,滯轉異構體亦為可能的且亦特定地包括於本發明化合物中。
在任何實施例中,化合物中或化合物中之特定基團或部分中所存在的任何或所有氫可經氘或氚置換。因此,對烷基之敍述包括氘化烷基,其中相對於其天然豐度,該基團富含氘,或其中一個至最大數目個之存在之氫可經氘置換。例如,乙基係指C
2H
5或C
2H
5,其中1至5個氫係經氘置換,諸如在C
2D
xH
5 - x中。
II. RIP1 活性化合物及包含 RIP1 活性化合物之醫藥組合物 A. 化合物本文揭示適用於抑制RIP1及/或用於治療與RIP1相關之疾病及/或病狀的化合物及包含該等化合物之醫藥組合物。在一些實施例中,化合物為選擇性激酶抑制劑。舉例而言,例示性化合物能夠相對於其他激酶(包括RIP2、RIP3或兩者)選擇性地抑制RIP1。
在一些實施例中,本發明化合物具有根據式I之結構:
式 I其中
X係選自鍵、CH
2、O、S、S(O)、S(O)
2及NR
a;
R
a在每次出現時選自氫及C
1 - 6烷基;
Y
1、Y
2及Y
3係獨立地選自由N、N(R
a)、O、C(R
b)
1 - 2及C=O組成之群;
R
b係選自氫、C
1 - 6烷基及鹵基;
Z為C(R
c)或NR
c;
R
c為視情況經一或多個R
1基團取代之C
1 - 4不飽和碳鏈,視情況間雜有1或2個選自O、N及S之雜原子;
R
z為N、CH或C(R
1),且與ZR
c及其所鍵結之碳一起形成視情況經m個R
1基團取代之5或6員雜芳基或6員芳環;
R
1為鹵素、連接基-R
6基團,其中該連接基為鍵、(C1-C4)烷基、(C1-C4)烯基或(C1-C4)炔基,其視情況經一或多個R
b取代,且R
6為R
e、-C(R
f)
3或-C(R
f)=C(R
f)
2;
R
2為R
a;
環B為5至10員雜芳基;
R
3在每次出現時獨立地選自R
b及OR
a;
L為O、NR
a或伸烷基;
W為視情況經p個R
4取代之5至10員芳基或雜芳基;
R
4在每次出現時選自R
b及OR
a;
R
d在每次出現時獨立地選自氫、C
1 - 6烷基、芳烷基、C
5 - 10芳基或雜芳基,或兩個R
d與其所連接之氮一起形成視情況經一或多個R
e取代之C
3 - 10雜環基;
R
e在每次出現時獨立地為鹵基、-OR
d、-SR
d、-S(O)
2R
d、-NR
dR
d、-Si(R
a)
3、-C(O)OH、-C(O)OR
a或-C(O)NR
dR
d;
R
f在每次出現時獨立地為R
a、R
b或R
e,或兩個R
f基團與其所鍵結之碳原子一起提供C
3 - 6環烷基或C
3 - 10雜環基,其各自視情況經一或多個R
e取代;
m為1、2、3或4;
n為0、1或2;及
p為0、1、2、3、4或5。
一般熟習此項技術者應瞭解,除非另外規定,否則式I範疇內之化合物亦包括其立體異構體、
N-氧化物、互變異構體、水合物、溶劑合物、同位素及/或前藥。參考式1,例示性化合物係分離為外消旋混合物且其他化合物係合成及/或分離為單一對映異構體。特定言之,式I中由
*標記之碳可呈
R或
S組態。
式I之某些實施例具有結構IA、IB、IC或ID
式 IA | 式 IB |
式 IC | 式 ID。 |
參考式I、IA、IB、IC及ID,R
z與ZR
c及其所鍵結之碳一起形成視情況經m個R
1基團取代之5或6員雜芳基或6員芳環,其中m為1、2、3或4。R
c為視情況間雜有1或2個選自O、N及S之雜原子的C
1 - 4不飽和碳鏈。因此,伴隨繼續參考式I、IA、IB及IC,所揭示之化合物之某些實施例具有式II、III或IV。
式 II; | 式 III |
式 IV |
參考式I、IA、IB、IC、ID、II、III及IV,m為0、1、2、3或4,諸如1、2、3或4,且在某些實例中,m為1或2,諸如1。在其他實施例中,m為0或1。特定言之,在其中B為以下之式I、IA、IB、IC、ID、II、III及IV之實施例中:
或
,m為0、1、2、3或4,諸如0或1。
參考式IV,Z
1係選自C及N;且Z
2、Z
3及Z
4獨立地選自O、S、S(O)
2、CH、N、N(R
a)及CR
1。繼續參考式IV,m為0、1、2或3,且在式IV之某些實施例中,m為0或1。在式IV之一個實施例中,Z
2及Z
4中之至少一者為CH或CR
1,且具有式IVA
,在式IV及IVA之一個實施例中,Z
1為N且Z
3為CH或CR
1。該等化合物具有式IVB
式 IVB。
在所揭示之RIP1K抑制劑化合物(包括式I、IA、IB、IC、ID、II以及III、IV、IVA及IVB以及下文所述之式V、VA、VB、VC、VD及VI中之彼等化合物)之實施例中,R
1在各實例中可為連接基-R
6。在此類實施例中,連接基-R
6部分之連接基為C
1、C
2、C
3或C
4脂族基,諸如C
2伸烷基、伸烯基或伸炔基;或C
1、C
2、C
3或C
4鹵脂族基,諸如C
2鹵伸烷基或鹵伸烯基。在一些實施例中,R
1之連接基為R
a,其中R
a為C
1 -C
4伸烷基,諸如-CH
2-、-CH
2CH
2-、-CH
2CH
2CH
2-或-CH
2CH
2CH
2CH
2-;或連接基為C
2 -C
4伸烯基,諸如-CH=CH-、-CH=CHCH
2-、-CH
2CH=CH-或-CH
2CH=CHCH
2-;或連接基為C
2 -C
4伸炔基,諸如-C
C-、-C
CCH
2-、-CH
2C
C-或-CHC
C-CH
2-。此類基團視情況諸如經一或多個R
b取代,其中R
b係選自C
1 - 6烷基及鹵基。在一些實施例中,連接基為C
2 -C
4鹵伸烯基,諸如-CF=CH-、-CCl=CH-、-CH=CCl-、-CH=CF-、-CCl=CCl-、-CF=CF-或-CCl=CF-、-CF=CCl-。在一些實施例中,連接基為-CH
2-、-CH
2CH
2-、-CH
2CH
2CH
2-、-CH
2CH
2CH
2CH
2-、-CH=CH-、-CCl=CH-、-CH=CCl-或-C
C-。
在一些實施例中,R
1之R
6基團為C(R
f)
3,其中一個R
f為R
e,其中R
e為-OR
a(例如,羥基或OMe),且各其他R
f獨立地為R
a,其中R
a為C
1 - 4脂族基,且較佳各其他R
f為R
a,其中R
a在每次出現時獨立地為C
1 - 4烷基。在特定實施例中,各其他R
f為R
a,其中R
a為甲基或CD
3。在其他實施例中,R
6為-C(R
f)
3,其中各R
f為R
a,其中R
a為甲基或H,或其中各R
f為R
a,其中R
a為甲基或R
b,其中R
b為-C(O)OR
c。在一些其他實施例中, R
f之一者為R
e,其為-OR
a(例如,羥基或OMe),且其他兩個R
f基團與其所鍵結之碳原子連接在一起提供脂環基(例如,環丙基、環丁基、環戊基或環己基)或雜環基(例如,環氧基、氧雜環丁烷、四氫呋喃、四氫哌喃、哌啶基、哌𠯤基、六氫呋喃并[3,2-b]呋喃)或其類似者。在一些此類實施例中,脂環基及/或雜環基可經取代,其中一些特定實施例係經一或多個羥基或苯甲基-羰基取代。
一些化合物實施例具有呈C
2 - 4基團之連接基,其可包含炔烴。在特定實施例中,R
1為-連接基-R
6且連接基為R
a,其中R
a為-CH
2-、-CH
2CH
2-、-CH
2CH
2CH
2-、-CH
2CH
2CH
2CH
2-、-CH=CH-或-C
C-或-CH
2C
C-,且R
6為R
b,其中R
b為-C(O)OEt或為-C(O)NR
dR
d或-NR
dR
d,其中各R
d在每次出現時獨立地為氫、C
5 - 10雜芳基、C
3 - 6環烷基或兩個R
d基團與其所鍵結之氮原子連接在一起提供雜環基,除R
d基團所鍵結之氮原子以外,其可進一步包含一或多個其他雜原子。在一些實施例中,一個R
d為氫且另一R
d為C
5 - 10雜芳基,其可經一或多個R
e取代,諸如以下中之一者:
。
在式I、IA、IB、IC、ID、II以及III、IV、IVA及IVB之特定實施例中,至少一個R
1部分為
。
在其他實施例中,R
1為雜環基,諸如-NR
dR
d,其中兩個R
d基團與其所鍵結之氮一起提供C
3 - 10雜環基。在一些實施例中,當兩個R
d基團與其所鍵結之氮一起提供C
3 - 10雜環基時,該C
3 - 10雜環基係經一或多個R
e基團取代,及/或在某些實施例中,除兩個R
d基團所鍵結之氮以外,亦具有一或多個其他雜原子。在一些實施例中,C
3 - 10雜環基係經兩個連接在一起以提供C
3 - 10雜環基之R
e基團取代,且此C
3 - 10雜環基連同R
b基團可提供螺環基團或雙環基團。某些所揭示之螺環基團包含至少兩個環,其中各環在環中具有不同數目之原子。在一些實施例中,螺環基團包含至少兩個環,其中螺環基團之第一環及第二環具有不同數目個碳原子、不同數目個雜原子或兩者。在又其他實施例中,螺環基團之各環在環中包含雜原子,且螺環基團之各環在環中可具有不同雜原子或在環中包含相同雜原子,諸如至少一個氧原子及至少一個氮原子。在一些實施例中,螺環基團包含含有氮原子之第一環及含有氧原子之第二環。螺環基團包含偶合至環A苯基之第一環,其中該第一環具有3至7個原子且第二環具有3至7個原子。通常,螺環基團在螺環系統中包含超過7個總原子,其中一些實施例具有在螺環系統中包含9個總原子之螺環基團。由兩個R
e基團形成之C
3 - 10雜環基及由R
b之兩個R
d基團形成之C
3 - 10雜環基可提供雙環基團,諸如在雙環基團中包含兩個或更多個雜原子,諸如氮及/或氧之雙環基團。雙環基團可經由雙環基團之氮原子連接至環A苯基。在一些實施例中,雙環基團可為稠合雙環基團或橋接雙環基團。
在式I、IA、IB、IC、ID、II以及III、IV、IVA及IVB中以及下文所述之式V、VA、VB、VC、VD及VI中之任一者或全部中,R
1係選自
。
關於式I、IA、IB、IC、II、III、IV、IVA及IVB,Y
1、Y
2及Y
3獨立地選自由以下組成之群:N、N(R
a)、O、C(R
b)
1 - 2及C=O。在上式之一個實施例中,所揭示之化合物具有式V
式 V其中Y
2與Y
3之間的鍵為單鍵或雙鍵,諸如在下文所示之式VA、VB、VC或VD中。繼續參考式V,在某些實施例中,Y
2及Y
3各自為CH
2。在式V之其他實施例中,Y
2及Y
3獨立地選自由CH
2及CHCl組成之群,諸如當Y
2為CH
2且Y
3為CHCl,或Y
2為CHCl且Y
3為CH
2時。
式 VA、 | 式 VB |
式 VC | 式 VD |
在式I、IA、IB、II、III、IV、IVA及IVB之另一實施例中,所揭示之化合物具有式VI
式 VI。
參考上式,R
2可為任何適合之取代基,諸如R
a部分,諸如氫、C
1 - 6烷基或C
1 - 6醯基,例如氫或甲基。當R
2為甲基時,甲基部分可為-CD
3-,亦即,相對於其天然豐度,甲基可富含氘。
關於式IA、IB、II、III、IV、IVA、IVB、V、VA、VB、VC、VD及VI,環B為雜芳基,諸如5至10員雜芳基,例如5員或6員雜芳基。在一些實施例中,環B為5員或6員雜芳基,其中該雜芳基具有一或兩個環或三個氮原子且其餘環原子為碳,諸如吡咯、二唑或三唑。在其他實施例中,環B為㗁唑、噻唑或異㗁唑。在某些實施例中,環B為吡唑基,且在其他特定實施例中,環B為吡啶基或嘧啶基。在某些實施例中,環B為雙環系統,其中至少一個環為芳族的。B之此類雙環系統之實例包括(但不限於)二氫吡咯并三唑、三唑并吡啶、咪唑并吡啶、四氫三唑并吡𠯤、四氫吡唑并吡啶及其類似者。在某些實施例中,基團B具有下式
。
在式IA、IB、II、III、IV、IVA、IVB、V、VA、VB、VC、VD及VI之特定實施例中,其中環B為5員雜芳基,環B可具有滿足下式之結構:
,其中至少一個W為氮,且各其餘W獨立地選自碳、CH、氧、硫、氮或NH。在一些實施例中,5員雜芳基為二唑、三唑、㗁二唑或㗁唑。例示性三唑包括以下中之任一者:
。
例示性二唑係選自以下中之任一者:
。
例示性㗁唑係選自以下中之任一者:
。
例示性㗁二唑係選自以下中之任一者:
。
如上文參考I、IA、IB、II、III、IV、IVA、IVB、V、VA、VB、VC、VD及VI所指出,「B」環係視情況經諸如R
b及OR
a取代,其中在每次出現時R
b係選自C
1 - 6烷基,諸如甲基及鹵基,諸如氟或氯。
繼續參考式I、IA、IB、II、III、IV、IVA、IVB、V、VA、VB、VC、VD及VI,L為連接部分,諸如O、N(R
a)、-NR
a-、伸烷基、環烷基或其組合。伸烷基部分可視情況間雜有一或多個-O-、-N(R
a)-或-NR
a-。舉例而言,此類連接部分包括(但不限於)-(CH
2)
m -R
e、-(CHR
a)
m -R
e、-O-(CH
2)
m -R
e、-C(O)NH-(CH
2)
m -R
e、-C(O)NH-(CHR
a)
m -R
e、-O-(CH
2)
m -C(O)NH-(CH
2)
m -R
e,諸如-CH
2、-CH(Me)、-C(Me)
2、-CH
2CH
2-、-CH
2CH
2CH
2-、-CH
2CH
2CH
2CH
2-、-CF
2-、-CH(F);以及視情況經一或多個R
b取代之環烷基,諸如環丙基、環丁基、環戊基及環己基。
在式IA、IB、II、III、IV、IVA、IVB、V、VA、VB、VC、VD及VI中,W部分為視情況經p個R
4基團取代之5至10員芳基或雜芳基,其中:
R
4在每次出現時選自R
b及OR
a。在所揭示之化合物之某些實施例中,W係選自
。
在式I、IA、IB、II、III、IV、IVA、IVB、V、VA、VB、VC、VD及VI中之一或多者之範疇內的某些所揭示之例示性化合物係列於表1中。
表 1
一般熟習此項技術者應瞭解,本文所揭示之某些化合物可展現互變異構、構形異構、幾何異構及/或光學異構現象。舉例而言,某些所揭示之化合物可包括一或多個對掌性中心及/或雙鍵且因此可以立體異構體形式存在,諸如雙鍵異構體(亦即幾何異構體)、對映異構體、非對映異構體及其混合物,諸如外消旋混合物。作為另一實例,某些所揭示之化合物可以若干互變異構形式存在,包括烯醇形式、酮形式及其混合物。由於本說明書及申請專利範圍內之各種化合物名稱、式及化合物圖式可僅表示可能的互變異構、構形異構、光學異構或幾何異構形式中之一者,所以一般熟習此項技術者應瞭解,所揭示之化合物涵蓋本文所述之化合物之任何互變異構、構形異構、光學異構及/或幾何異構形式,以及此等各種不同異構形式之混合物。可使用一般熟習此項技術者已知之技術,尤其本發明中所示之技術分離不同異構形式之混合物,包括對映異構體及/或立體異構體之混合物,以提供單獨的各立體異構體。在例如圍繞醯胺鍵或在兩個直接連接之環(諸如吡啶基環、聯苯基及其類似者)之間旋轉受限之情況下,滯轉異構體亦為可能的且為本發明化合物之簡單互換形式。
B. 醫藥組合物在一些實施例中,化合物中之一或多者可包括於醫藥組合物或藥劑中,且在一些實施例中,一或多種化合物可呈母化合物或其醫藥學上可接受之鹽、共晶體、立體異構體、N-氧化物、互變異構體、水合物、溶劑合物、同位素或前藥形式。除所揭示之一或多種化合物以外,醫藥組合物通常包括至少一種其他組分,諸如醫藥學上可接受之賦形劑、佐劑、額外治療劑(描述於以下章節中)或其任何組合。
醫藥學上可接受之賦形劑可基於多種目的而包括於醫藥組合物中,諸如稀釋用於向個體遞送之醫藥組合物;促進調配物加工;為調配物提供有利的物質特性;促進自遞送裝置分散;使調配物穩定(例如抗氧化劑或緩衝劑);向調配物提供合意的或適口的味道或稠度;或其類似者。醫藥學上可接受之賦形劑可包括醫藥學上可接受之載劑。例示性賦形劑包括(但不限於)單醣、雙醣及多醣、糖醇及其他多元醇,諸如乳糖、葡萄糖、棉子糖、松三糖、乳糖醇、麥芽糖醇、海藻糖、蔗糖、甘露糖醇、澱粉或其組合;界面活性劑,諸如山梨糖醇、二磷脂醯膽鹼及卵磷脂;膨化劑;緩衝劑,諸如磷酸鹽及檸檬酸鹽緩衝劑;抗黏劑,諸如硬脂酸鎂;黏合劑,諸如醣類(包括雙醣,諸如蔗糖及乳糖)、多醣(諸如澱粉、纖維素、微晶纖維素、纖維素醚(諸如羥丙基纖維素))、明膠、合成聚合物(諸如聚乙烯吡咯啶酮、聚伸烷基二醇);包衣(諸如纖維素醚,包括羥丙基甲基纖維素、蟲膠、玉米蛋白(corn protein zein)及明膠);釋放助劑(諸如腸溶包衣);崩解劑(諸如交聯普維酮(crospovidone)、交聯羧甲基纖維素鈉及羥基乙酸澱粉鈉);填充劑(諸如磷酸氫鈣、植物脂肪及油、乳糖、蔗糖、葡萄糖、甘露糖醇、山梨糖醇、碳酸鈣及硬脂酸鎂);調味劑及甜味劑(諸如薄荷、櫻桃、大茴香、桃、杏或甘草、覆盆子及香草劑);潤滑劑(諸如礦物質,由滑石或二氧化矽例示;脂肪,由植物硬脂、硬脂酸鎂或硬脂酸例示);防腐劑(諸如抗氧化劑,由維生素A、維生素E、維生素C、棕櫚酸視黃酯及硒例示;胺基酸,由半胱胺酸及甲硫胺酸例示;檸檬酸及檸檬酸鈉;對羥基苯甲酸酯,由對羥基苯甲酸甲酯及對羥基苯甲酸丙酯例示);著色劑;壓縮助劑;乳化劑;囊封劑;膠;造粒劑;及其組合。
III. 使用化合物之方法 A. 疾病 / 病症所揭示之化合物以及其組合及/或醫藥組合物可用於藉由活體內或離體使激酶與本發明之一或多種化合物或包含本發明之一或多種化合物之組合物接觸來抑制RIP1激酶。所揭示之一或多種化合物或包含所揭示之一或多種化合物之組合物亦可用於改善、治療或預防多種疾病及/或病症。在特定實施例中,所揭示之化合物、所揭示之化合物之組合或其醫藥組合物可適用於治療其中RIP1或涉及RIP1之路徑之抑制在治療上適用之病狀。在一些實施例中,化合物直接抑制RIP1激酶活性。在某些實施例中,所揭示之化合物適用於治療自體免疫疾病、發炎性病症、心血管疾病、神經病症、神經退化性病症、過敏性病症、呼吸疾病、腎病、癌症、缺血性病狀、紅血球缺乏症、肺及腦損傷(例如,由缺血再灌注或順鉑及/或腦血管意外誘發)以及細菌及病毒感染。
在一些實施例中,所揭示之化合物、所揭示之化合物之組合或其醫藥組合物可用於治療或預防過敏性疾病、肌肉萎縮性側索硬化(ALS)、脊髓性肌萎縮、全身性紅斑性狼瘡、類風濕性關節炎、I型糖尿病、發炎性腸病、膽汁性肝硬化、葡萄膜炎、多發性硬化症、克羅恩氏病(Crohn's disease)、潰瘍性結腸炎、大皰性類天疱瘡、類肉瘤病、牛皮癬、自體免疫性肌炎、韋格納氏肉芽腫病(Wegener's granulomatosis)、魚鱗癬、格雷夫斯氏眼病(Graves ophthalmyopathy)或哮喘。
所揭示之化合物、所揭示之化合物之組合或其醫藥組合物亦可適用於治療與骨髓或器官移植排斥或移植物抗宿主病相關之免疫調節病症。可用化合物(或醫藥組合物或其組合)治療之發炎性及免疫調節病症之實例包括(但不限於)器官或組織移植;移植所引起之移植物抗宿主病;自體免疫性症候群,包括類風濕性關節炎、全身性紅斑性狼瘡、橋本氏甲狀腺炎(Hashimoto's thyroiditis)、多發性硬化症、全身性硬化症、全身性發炎反應症候群、重症肌無力、I型糖尿病、葡萄膜炎、後葡萄膜炎、過敏性腦脊髓炎、絲球體腎炎;感染後自體免疫疾病,包括風濕熱及感染後絲球體腎炎;發炎性及過度增生性皮膚病、牛皮癬、異位性皮膚炎、接觸性皮膚炎、濕疹性皮膚炎、脂溢性皮炎、化膿性汗腺炎、扁平苔癬、天疱瘡、大皰性類天疱瘡、大皰性表皮鬆懈、蕁麻疹、血管性水腫、血管炎、紅斑、皮膚嗜伊紅血球增多症、紅斑狼瘡、痤瘡、斑禿、角膜結膜炎、春季結膜炎、與白塞氏病(Behcet's disease)相關之葡萄膜炎、角膜炎、疱疹性角膜炎、圓錐形角膜、角膜上皮營養不良、角膜白斑、眼天疱瘡、穆倫氏潰瘍(Mooren's ulcer)、鞏膜炎、格雷夫斯氏眼病、沃格特-小柳-原田症候群(Vogt-Koyanagi-Harada syndrome)、類肉瘤病、花粉過敏、可逆性阻塞性氣管疾病、支氣管哮喘、過敏性哮喘、內源性哮喘、外源性哮喘、塵埃性哮喘、慢性或頑固性哮喘、遲發型哮喘及氣管過度反應、支氣管炎、胃潰瘍、由缺血性疾病所引起之血管損傷及血栓形成、缺血性腸病、缺血再灌注損傷、發炎性腸病、壞死性小腸結腸炎、與熱燒傷相關之腸道病變、腹瀉病、直腸炎、嗜伊紅血球性胃腸炎、肥大細胞增多症、克羅恩氏病、潰瘍性結腸炎、偏頭痛、鼻炎、濕疹、間質性腎炎、古巴斯德氏症候群(Goodpasture's syndrome)、溶血性尿毒症候群、糖尿病性腎病變、多發性肌炎、格-巴二氏症候群(Guillain-Barre syndrome)、梅尼爾氏病(Meniere's disease)、多神經炎、多發性神經炎、單神經炎、神經根病變、甲狀腺高能症、巴西多氏病(Basedow's disease)、純紅血球形成不全、再生不全性貧血、低形成性貧血、特發性血小板減少性紫癜、自體免疫溶血性貧血、顆粒性球缺乏症、惡性貧血、巨紅血球貧血、紅細胞發生不能、骨質疏鬆症、類肉瘤病、纖維樣肺、特發性間質性肺炎、皮肌炎、尋常性白斑病、尋常性魚鱗癬、敏感性光過敏、皮膚T細胞淋巴瘤、慢性淋巴球性白血病、動脈硬化、動脈粥樣硬化、主動脈炎症候群、結節性多動脈炎、非炎性心肌病或心肌梗塞、硬皮病(包括全身性硬皮病)、抗磷脂症候群、韋格納氏肉芽腫、休格連氏症候群(Sjögren's syndrome)、肥胖症、嗜酸性筋膜炎、牙齦病變、牙周組織病變、齒槽骨病變、牙骨質病變、絲球體腎炎、男性型禿髮或老年性禿髮(藉由預防脫髮或提供毛髮胚髮及/或促進毛髮產生及毛髮生長)、肌肉萎縮症、膿皮病及塞澤里症候群(Sezary's syndrome)、艾迪森氏病(Addison's disease)、器官在保存、移植或缺血性疾病時發生之缺血再灌注損傷、內毒素休克、偽膜性結腸炎、由藥物或放射所引起之結腸炎、缺血性急性腎功能衰竭、慢性腎功能衰竭、由肺-氧或藥物所引起之毒素病、肺癌、肺氣腫、白內障、鐵質沈著病、色素性視網膜炎、視網膜變性、視網膜脫落、老年性黃斑變性、玻璃體疤痕、角膜鹼燒傷、皮膚炎多形性紅斑、線性IgA大皰性皮膚炎及水泥性皮膚炎、齒齦炎、齒根骨膜炎、敗血症、胰臟炎、由環境污染所引起之疾病、衰老、癌發生、癌瘤之癌轉移及低氣壓病、由組織胺或白三烯-C4釋放所引起之疾病、白塞氏病、自體免疫肝炎、原發性膽汁性肝硬化症、硬化性膽管炎、部分肝臟切除、急性肝臟壞死、由毒素所引起之壞死、病毒性肝炎、休克或缺氧症、B型病毒肝炎、非A型/非B型肝炎、肝硬化、酒精性肝病(包括酒精性肝硬化、酒精性脂肪變性肝炎)、非酒精性脂肪變性肝炎(NASH)、自體免疫肝膽疾病、乙醯胺苯酚毒性、肝毒性、肝衰竭、爆發性肝衰竭、晚發型肝衰竭、「慢加急性」肝衰竭、慢性腎病、腎損傷(kidney damage/injury) (由例如腎炎、腎臟移植、手術、投與腎毒性藥物、急性腎損傷所引起)、增強之化學治療作用、細胞巨大病毒感染、HCMV感染、AIDS、癌症、老年癡呆症、帕金森氏病、外傷或慢性細菌感染。
在某些實施例中,本發明化合物適用於治療神經疼痛,包括神經痛及炎症誘發之疼痛。
在某些實施例中,化合物適用於治療介白素-1轉化酶相關發熱症候群、腫瘤壞死因子受體相關週期性症候群、NEMO缺乏症候群、HOIL-1缺乏症、線性泛素鏈裝配複合物缺乏症候群、溶酶體貯積病(例如,高歇氏病(Gaucher disease)、GM2神經節苷脂貯積病、α-甘露糖苷貯積病、天冬胺醯葡萄糖胺尿症、膽甾醇酯貯積病、慢性己醣胺酶A缺乏症、胱胺酸症、達農病(Danon disease)、法布立病(Fabry disease)、法伯病(Farber disease)、岩藻糖苷貯積症、半乳糖唾液酸貯積症、GM1神經節苷脂貯積病、黏脂貯積症、嬰兒游離唾液酸貯積病、青少年己醣胺酶A缺乏症、克拉培病(Krabbe disease)、溶酶體酸性脂肪酶缺乏症、異染性腦白質營養不良(metachromatic leukodystrophy)、黏多醣貯積症、多發性硫酸酯酶缺乏症、尼曼-匹克病(Niemann-Pick disease)、神經元蠟樣質脂褐質沈積症(neuronal ceroid lipofuscinosis)、龐貝症(Pompe disease)、密骨發育障礙、桑多霍夫病(Sandhoff disease)、辛德勒病(Schindler disease)、唾液酸貯積病、戴-薩克斯病(Tay-Sach disease)及沃爾曼氏病(Wolman disease))。
在某些實施例中,所揭示之化合物、所揭示之化合物之組合或其醫藥組合物適用於治療及/或預防類風濕性關節炎、牛皮癬性關節炎、骨關節炎、全身性紅斑性狼瘡、狼瘡性腎炎、僵直性脊椎炎、骨質疏鬆症、全身性硬化症、多發性硬化症、牛皮癬(尤其膿皰型牛皮癬)、I型糖尿病、II型糖尿病、發炎性腸病(克羅恩氏病及潰瘍性結腸炎)、高免疫球蛋白D症候群及週期性發熱症候群,諸如隱熱蛋白相關週期性症候群、家族性地中海熱(FMF)症候群、施尼茨勒氏症候群(Schnitzler's syndrome)及TNF-受體相關週期性發熱症候群(TRAPS)、全身型幼年特發性關節炎、成人發病史迪爾氏病(adult's onset Still's disease)、痛風、痛風發作、假性痛風、sapho症候群、卡索氏病(Castleman's disease)、敗血症、中風、動脈粥樣硬化、乳糜瀉、IL-1受體拮抗劑缺乏症(DIRA)。
所揭示之RIP1K抑制劑尤其適用於治療神經病症,包括如上文所提及之神經退化性病症。舉例而言,本發明化合物可用於治療阿茲海默氏病、ALS、亨廷頓氏病(Huntington's disease)及帕金森氏病。
可藉由所揭示之化合物、所揭示之化合物之組合或其醫藥組合物治療之增生性疾病包括良性或惡性腫瘤、實體腫瘤、腦癌、腎癌、肝癌、腎上腺癌、膀胱癌、乳癌、胃癌、胃腫瘤、卵巢癌、結腸癌、直腸癌、前列腺癌、胰臟癌、肺癌、陰道癌、子宮頸癌、睾丸癌、生殖泌尿道癌、食道癌、喉癌、皮膚癌、骨癌或甲狀腺癌、肉瘤、神經膠母細胞瘤、神經母細胞瘤、多發性骨髓瘤、胃腸癌,尤其結腸癌或大腸直腸腺瘤、頸部及頭部腫瘤、表皮過度增生、牛皮癬、前列腺增生、贅瘤、上皮性贅瘤、腺瘤、腺癌、角化棘皮瘤、表皮樣癌瘤、大細胞癌、非小細胞肺癌、淋巴瘤、霍奇金氏及非霍奇金氏瘤、乳癌、濾泡性癌瘤、未分化性瘤、乳頭狀癌、精原細胞瘤、黑素瘤、IL-1驅動病症、MyD88驅動病症(諸如ABC彌漫性大B細胞淋巴瘤(DLBCL)、瓦爾登斯特倫巨球蛋白血症(Waldenström's macroglobulinemia)、霍奇金氏淋巴瘤、原發性皮膚T細胞淋巴瘤或慢性淋巴球性白血病)、和緩性或惰性多發性骨髓瘤、或血液惡性病(包括白血病、急性骨髓白血病(AML)、DLBCL、ABC DLBCL、慢性淋巴球性白血病(CLL)、慢性骨髓白血病(CML)、原發性滲出性淋巴瘤、伯基特淋巴瘤(Burkitt lymphoma)/白血病、急性淋巴球性白血病、B細胞前淋巴球性白血病、淋巴漿細胞淋巴瘤、骨髓發育不良/骨髓增生性腫瘤(MDS/MPN),諸如慢性骨髓單核細胞性白血病(CMML,包括CMML-0、CMML-1及CMML-2)、骨髓纖維化、真性紅血球增多症、卡堡氏肉瘤(Kaposi's sarcoma)、瓦爾登斯特倫巨球蛋白血症(WM)、脾邊緣區淋巴瘤、多發性骨髓瘤、漿細胞瘤、血管內大B細胞淋巴瘤)。特定言之,本發明所揭示之化合物適用於治療耐藥性惡性病,諸如對JAK抑制劑或BTK抑制劑具有抗性之惡性病,諸如抗依魯替尼(ibrutinib)性惡性病,包括抗依魯替尼血液惡性病,諸如抗依魯替尼性CLL及抗依魯替尼性瓦爾登斯特倫巨球蛋白血症。
儘管CMML具有骨髓增生性腫瘤(MPN)及骨髓發育不良症候群(MDS)之某些臨床及病理學特徵,但CMML被世界衛生組織(WHO)歸入MDS/MPN重疊組的單獨類別中。(Arber等人 「
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia」 Blood, 第127卷, 第20期, 第2391-2405頁, 2016年5月19日。) 根據WHO,CMML之診斷現需要同時存在≥ 1×10
9/L之持久外周血液單核球增多症及佔≥白血球(WBC)分類計數之10%之單核球。另外,當排除PDGFRA、PDGFRB或FGFR1基因之重排時,可僅根據定義診斷CMML,且在2016更新版中,添加PCM1-JAK2融合基因作為排除標準。在一些實施例中,用於治療CMML之方法包含鑑別具有WHO診斷標準(亦即,≥ 1×10
9/L之持久外周血液單核球增多症及佔≥白血球分類計數之10%之單核球),且排除PDGFRA、PDGFRB、FGFR1或PCM1-JAK2基因之重排之個體,且藉由投與本文所揭示之RIP1抑制劑、此類化合物之組合及/或其組合物來治療該個體。
可使用所揭示之化合物、所揭示之化合物之組合或其醫藥組合物治療的過敏性病症之實例包括(但不限於)哮喘(例如異位性哮喘、過敏性哮喘、異位性支氣管IgE介導之哮喘、非異位性哮喘、支氣管哮喘、非過敏性哮喘、原發性哮喘、真性哮喘、由病理生理學紊亂引起之內源性哮喘、未知或不明病因之原發性哮喘、肺氣腫性哮喘、運動誘發之哮喘、情緒誘發之哮喘、由環境因素引起之外源性哮喘、冷空氣誘發之哮喘、職業性哮喘、由細菌、真菌、原蟲或病毒感染引起或與其相關之感染性哮喘、初期哮喘、喘鳴嬰兒症候群、細支氣管炎、咳嗽變異性哮喘或藥物誘發之哮喘)、過敏性支氣管與肺之麴菌病(ABPA)、過敏性鼻炎、常年性過敏性鼻炎、常年性鼻炎、血管舒縮性鼻炎、鼻後滴流症、化膿性或非化膿性鼻竇炎、急性或慢性鼻竇炎及篩竇炎、額竇炎、上頜竇炎或蝶竇炎。
作為另一實例,類風濕性關節炎(RA)通常導致全身目標關節腫脹、疼痛、無法運動及觸痛。RA之特徵在於與淋巴細胞密佈的長期發炎之滑膜。通常為一個細胞層厚的滑膜變得細胞密集且呈現類似於淋巴組織之形式,包括樹突狀細胞、T細胞、B細胞及NK細胞、巨噬細胞及漿細胞群。此過程以及多種免疫病理學機制(包括抗原-免疫球蛋白複合物之形成)最終導致關節完整性之破壞,導致關節處或附近之變形、功能之永久喪失及/或骨侵蝕。所揭示之化合物、所揭示之化合物之組合或其醫藥組合物可用於治療、改善或預防RA之此等症狀中之任一者、若干者或全部。因此,在RA之情形下,當達成通常與RA相關之症狀中之任一者減少或改善時,化合物被視為提供治療益處,不管該治療是否引起潛在RA之伴隨治療及/或循環類風濕因子(「RF」)之量減少。
美國風濕病學會(ACR)已建立關於界定RA之改善及臨床緩解之標準。此類參數中有一個為ACR20 (20%臨床改善之ACR標準),需要觸痛及腫脹關節計數改善20%,以及以下5個參數中有3個改善20%:患者之總體評定、醫師之總體評定、患者之疼痛評定、失能程度及急性期反應物含量。此等標準已擴展至ACR50及ACR70中分別有50%及70%改善。其他標準包括保羅斯氏標準(Paulu's criteria)及放射照相進展(例如夏普評分(Sharp score))。
在一些具體例中,當患者展現ACR20時,達成罹患RA之患者之治療益處。在特定實施例中,可達成ACRC50或甚至ACR70之ACR改善。
可使用本發明之化合物及組合物治療及/或預防之其他疾病或病症包括脊椎關節炎,包括中軸性脊椎關節炎,諸如僵直性脊椎炎、SoJIA、自體免疫肝炎、自體免疫肝膽疾病、自體免疫ITP、腦血管意外、心肌梗塞、過敏性疾病、慢性阻塞性肺病、心臟梗塞、HIV相關癡呆、青光眼、弗里德希氏共濟失調(Friedreich's ataxia)、路易體疾病(Lewy body disease)、脊髓損傷、糖尿病神經病變、聚麩醯胺酸(polyQ)病、中風、華氏病(Fahr disease)、孟克斯氏病(Menke's disease)、威爾森氏病(Wilson's disease)、腦缺血、朊病毒病症、破壞性骨病症,諸如骨骼再吸收病、多發性骨髓瘤相關骨病症;增生性病症,諸如急性骨髓性白血病、慢性骨髓性白血病;血管生成病症,諸如包括實體腫瘤、眼血管再生及嬰兒血管瘤之血管生成病症;傳染病,諸如敗血症、敗血性休克及志賀桿菌病(Shigellosis);神經退化性疾病,諸如轉移性黑素瘤、HIV感染及CMV視網膜炎;纖維變性病狀,諸如非酒精性脂肪變性肝炎;及心臟病狀,諸如缺血再灌注;過敏、成人呼吸窘迫症候群、慢性阻塞性肺病、絲球體腎炎、紅斑、慢性甲狀腺炎、葛瑞夫茲氏病、格雷夫斯氏病、自體免疫胃炎、自體免疫嗜中性球減少症、血小板減少、移植物抗宿主疾病、由內毒素誘發之發炎反應、肺結核、動脈粥樣硬化、肌肉退化、惡病質、萊特爾氏症候群(Reiter's syndrome)、風疹性關節炎、急性滑膜炎、胰臟β-細胞疾病;特徵為大規模嗜中性白血球浸潤之疾病;類風濕性脊椎炎、痛風性關節炎及其他關節炎病狀、大腦瘧疾、慢性肺發炎疾病、矽肺病、肺結節病、同種異體移植排斥反應、感染所致之發熱及肌痛、瘢痕瘤形成、疤痕組織形成、潰瘍性結腸炎、發熱、流行性感冒、慢性骨髓性白血病;血管生成病症,包括實體腫瘤;病毒性疾病,包括急性肝炎感染(包括A型肝炎、B型肝炎及C型肝炎)、AIDS、ARC或惡性病、疱疹;中風、心肌缺血、中風心臟病發作中之缺血、器官低氧、血管增生、心臟及腎臟再灌注性損傷、心臟肥大、凝血酶誘發之血小板凝集、內毒素血症及/或毒性休克症候群、與前列腺素內過氧化酶合成酶2相關之病狀、尋常天疱瘡、缺血再灌注性損傷,包括由中風引起之腦缺血再灌注損傷、由心肌梗塞引起之心臟缺血再灌注性損傷;多發性系統萎縮症、帕金森疊加症候群、額顳葉型癡呆、顱內出血、腦出血、進行性肌肉萎縮、假延髓性麻痹、進行性延髓麻痹、脊髓性肌萎縮、遺傳性肌萎縮、外周神經病變、進行性核上麻痹、皮質基底核退化症、脫髓鞘疾病、椎關節炎、全身發作幼年特發性關節炎(SoJIA)、全身性紅斑狼瘡(SLE)、休格連氏症候群、抗磷脂症候群(APS)、原發性硬化性膽管炎(PSC)、腎臟移植、手術、急性腎損傷(AKI)、全身性發炎反應症候群(SIRS)、腦血管意外(CVA)、肺類肉瘤病、介白素-1轉化酶(ICE,亦稱為凋亡蛋白酶-1)相關發熱症候群、慢性阻塞性肺病(COPD)、齒根骨膜炎、NEMO缺乏症候群(F-κ-B必需調節基因(亦稱為IKK γ或IKKG)缺乏症候群)、血液及實體器官惡性病、溶酶體貯積病、青光眼、脊椎關節炎、視網膜退化疾病、視網膜缺血/再灌注性損傷、腎臟缺血再灌注性損傷、炭疽致死性毒素誘發之敗血性休克、由LPS誘發之細胞死亡、傳染性腦病、腦炎、自體免疫葡萄膜視網膜炎、巨大細胞動脈炎、區域性腸炎、肉芽腫性腸炎、遠端迴腸炎、局部迴腸炎、末端迴腸炎、胰島素依賴型糖尿病、硬皮病、全身性紅斑性狼瘡、黃斑水腫、糖尿病性視網膜病變、中心性暈輪狀脈絡膜營養不良、貝斯特氏病(BEST disease)、成人卵黃樣病、圖形樣營養不良(pattern dystrophy)、近視性退化、中心漿液性視網膜病變、斯特格氏病(Stargardt's disease)、視錐-視桿細胞營養不良、北卡羅萊納營養不良、傳染性視網膜炎、發炎性視網膜炎、葡萄膜炎、毒性視網膜炎及光誘發性毒性、黃斑水腫、糖尿病性視網膜病變、中心性暈輪狀脈絡膜營養不良、圖形樣營養不良、視神經損傷、視神經炎、視神經病變、糖尿病性視網膜病變、視網膜中央動脈堵塞、缺血性視神經病變(例如,動脈炎性或非動脈炎性前部缺血性神經病變及後部缺血性視神經病變)、壓迫性視神經病變、浸潤性視神經病變、創傷性視神經病變、粒線體視神經病變(例如,雷伯氏視神經病變(Leber's optic neuropathy))、營養性視神經病變、毒性視神經病變及遺傳性視神經病變、顯性視萎縮症、貝爾氏症候群(Behr's syndrome)、庫賈氏病(Creutzfeldt-Jakob disease))、進行性核上麻痹、遺傳性痙攣性不全麻痹、蛛膜下出血、外周腦損傷、亞臨床腦損傷、脊髓損傷、缺氧-缺血性腦損傷、病灶性腦缺血、全腦缺血及乏氧性缺氧、腹膜透析流體(PDF)及PD相關副作用引起之腹膜損傷、腎絲球病、腎小管間質性疾病、阻塞、多囊性腎病)、病灶性腎小球硬化、免疫複合性腎病變、肝細胞癌、胰臟癌、泌尿癌、膀胱癌、大腸直腸癌、大腸癌、乳癌、前列腺癌、腎癌、甲狀腺癌、膽囊癌、腹膜癌、卵巢癌、子宮頸癌、胃癌、子宮內膜癌、食道癌、頭頸癌、神經內分泌癌、CNS癌、腦瘤(例如,神經膠質瘤、多形性寡樹突狀神經膠質瘤、成人多形性膠質母細胞瘤及成人多形性星形細胞瘤)、骨癌、軟組織肉瘤、視網膜胚細胞瘤、神經母細胞瘤、腹膜積液、惡性胸膜積液、間皮瘤、威爾姆斯腫瘤(Wilms tumor)、滋養細胞贅瘤、血管外皮細胞瘤、黏液癌瘤、圓細胞癌、鱗狀細胞癌、食道鱗狀細胞癌、口癌、外陰癌、腎上腺皮質癌、ACTH產生腫瘤、淋巴瘤及白血病、呼吸傳染性病毒,諸如流感病毒、鼻病毒、冠狀病毒、副流感病毒、RS病毒、腺病毒、呼腸孤病毒及其類似者)、由疱疹病毒引起之帶狀疱疹、由輪狀病毒引起之腹瀉、病毒性肝炎、AIDS、細菌性傳染病,諸如蠟樣芽胞桿菌(
Bacillus cereus)、腸炎弧菌(
Vibrio parahaemolyticus)、腸出血性大腸桿菌(
Enterohemorrhagic Escherichia coli)、金黃色葡萄球菌(
Staphylococcus aureus)、MRS A、沙門氏菌屬(
Salmonella)、肉毒桿菌屬(
Botulinus)、念珠菌屬(
Candida)、佩吉特氏病(Paget's disease)、軟骨發育不全、骨軟骨炎、副甲狀腺高能症、成骨不全、先天性低磷酸酶症、纖維瘤病變、纖維性結構不良、骨骼轉換、溶骨性骨病、牙周病、創傷性骨手術後治療、假體關節手術後治療、整形性骨手術後治療、牙科手術後治療、骨化療治療或骨放射線療法治療、骨癌、易損性斑塊、病症、阻塞性病症、狹窄、冠狀動脈病症、外周動脈病症、動脈阻塞、動脈瘤形成、創傷後動脈瘤形成、再狹窄、術後移植物阻塞、自體免疫特發性血小板減少性紫癜(自體免疫ITP)、膜性腎炎、自體免疫甲狀腺炎、冷及熱凝集素病、艾瓦氏症候群(Evan's syndrome)、溶血性尿毒症候群/血栓性血小板減少性紫癜(HUS/TTP)及尋常天疱瘡。
B. 治療劑之組合一般熟習此項技術者應瞭解,上文針對用本發明所揭示之RIP1K抑制劑治療所述之病狀可受益於用一或多種其他治療劑與RIP1K抑制劑之組合治療。實際上,本文所述之RIP1K抑制劑化合物可單獨、彼此組合、以單獨醫藥組合物形式、一起以單一醫藥組合物形式或作為其他現有療法之佐劑或與其他現有療法組合使用。一或多種化合物或包含該化合物(或多種化合物)之組合物可投與一次,或以複數次投與。在一些實施例中,本發明化合物可與適用於所治療之病症或病狀的其他治療劑組合使用。此等其他治療劑可同時、以任何次序依序、藉由相同投藥途徑或藉由與本發明所揭示之化合物不同的途徑投與。對於依序投與,可投與一或多種化合物及一或多種治療劑以使得至少一種化合物及治療劑之有效時段與至少一種其他化合物及/或治療劑之有效時段重疊。在一包含四種組分之組合的例示性實施例中,所投與之第一組分之有效時段可與第二、第三及第四組分之有效時段重疊,但第二、第三及第四組分之各有效時段獨立地可或可不彼此重疊。在包含四種組分之組合的另一例示性實施例中,所投與之第一組分之有效時段與第二組分之有效時段重疊,但不與第三或第四組分之有效時段重疊;第二組分之有效時段與第一及第三組分之有效時段重疊;且第四組分之有效時段僅與第三組分之有效時段重疊。在一些實施例中,所有化合物及/或治療劑之有效時段均彼此重疊。
在一些實施例中,化合物與另一治療劑一起投與,該治療劑諸如鎮痛劑、抗生素、抗凝血劑、抗體、消炎劑、免疫抑制劑、鳥苷酸環化酶-C促效劑、腸促泌素、抗病毒劑、抗癌劑、抗真菌劑或其組合。消炎劑可為類固醇或非類固醇消炎劑。在某些實施例中,非類固醇消炎劑係選自胺基水楊酸、環加氧酶抑制劑、雙氯芬酸、依託度酸(etodolac)、法莫替丁(famotidine)、非諾洛芬(fenoprofen)、氟比洛芬(flurbiprofen)、酮洛芬(ketoprofen)、酮咯酸(ketorolac)、布洛芬、吲哚美辛(indomethacin)、甲氯芬那酸(meclofenamate)、甲芬那酸(mefenamic acid)、美洛昔康(meloxicam)、萘丁美酮(nambumetone)、萘普生(naproxen)、奧沙普嗪(oxaprozin)、吡羅昔康(piroxicam)、雙水楊酸、舒林酸(sulindac)、托美丁(tolmetin)或其組合。在一些實施例中,免疫抑制劑為巰基嘌呤、皮質類固醇、烷基化劑、鈣調神經磷酸酶抑制劑、肌核苷單磷酸脫氫酶抑制劑、抗淋巴球球蛋白、抗胸腺細胞球蛋白、抗T細胞抗體或其組合。在一個實施例中,抗體為英利昔單抗(infliximab)。
本文所述之化合物可與用於以上適應症中之任一者之其他消炎劑或免疫調節劑組合投與,包括口服或局部用皮質類固醇、抗TNF劑、5-胺基水楊酸及美沙拉明(mesalamine)製劑、羥基氯喹(hydroxycloroquine)、硫代嘌呤、甲胺喋呤、環磷醯胺、環孢靈(cyclosporine)、鈣調神經磷酸酶抑制劑、黴酚酸、mTOR抑制劑、JAK抑制劑、Syk抑制劑、消炎性生物劑,包括抗IL6生物製劑、抗-ILl劑、抗-ILl7生物製劑、抗-CD22、抗整合素劑、抗-IFNa、抗-CD20或CD4生物製劑及T細胞或B細胞受體或介白素之其他細胞介素抑制劑或生物製劑。
特定言之,在類風濕性關節炎之治療中,本發明RIP1K抑制劑適用於與布洛芬、萘普生、普賴松(prednisone)、甲胺喋呤、來氟米特(leflunomide)、羥基氯喹、柳氮磺胺吡啶(sulfasalazine)、阿巴西普(abatacept)、阿達木單抗(adalimumab)、阿那白滯素(anakinra)、巴瑞替尼(baracitinib)、賽妥珠單抗(certolizumab)、依那西普(etanercept)、福他替尼(fostamatinib)、戈利木單抗(golimumab)、英利昔單抗、利妥昔單抗(rituximab)、托西利單抗(tocilizumab)及托法替尼(tofacitinib)組合。
在一些實施例中,本發明化合物可與抗癌劑或細胞毒素劑一起使用。各種類別之抗癌及抗贅生性化合物包括(但不限於)烷基化劑、抗代謝物、BCL-2抑制劑、長春花生物鹼、紫杉烷、抗生素、酶、細胞介素、鉑配位錯合物、蛋白酶體抑制劑、經取代之脲、激酶抑制劑、激素及激素拮抗劑以及低甲基化劑、例如DNMT抑制劑,諸如氮胞苷及地西他濱(decitabine)。例示性烷基化劑包括(但不限於)甲基二(氯乙基)胺(mechlorothamine)、環磷醯胺、依弗醯胺(ifosfamide)、美法侖(melphalan)、氯芥苯丁酸、伸乙亞胺、甲基三聚氰胺、磺酸烷酯(例如,白消安(busulfan))及卡莫司汀(carmustine)。例示性抗代謝物包括例如(但不限於)葉酸類似物甲胺喋呤;嘧啶類似物氟尿嘧啶、胞嘧啶阿拉伯醣;嘌呤類似物巰基嘌呤、硫鳥嘌呤及硫唑嘌呤。例示性長春花生物鹼包括例如(但不限於)長春鹼、長春新鹼、紫杉醇及秋水仙鹼。例示性抗生素包括例如(但不限於)放線菌素D、道諾黴素(daunorubicin)及博萊黴素(bleomycin)。作為抗贅生劑有效之例示性酶包括L-天冬醯胺酶。例示性配位化合物包括例如(但不限於)順鉑及卡鉑。例示性激素及激素相關化合物包括例如(但不限於)腎上腺皮質類固醇普賴松及地塞米松(dexamethasone);芳香酶抑制劑胺麩精(amino glutethimide)、福美司坦(formestane)及阿那曲唑(anastrozole);孕激素化合物羥基孕酮己酸鹽、甲羥孕酮;及抗雌激素化合物他莫昔芬(tamoxifen)。
在一個態樣中,本發明化合物適用於阻斷細胞介素反應。促炎性細胞介素之過度產生可導致「細胞介素風暴」,在其期間炎症經由循環擴散至整個身體。此等細胞介素包括干擾素、介白素、趨化細胞素、群落刺激因子及腫瘤壞死因子,且其在免疫反應中產生。此等細胞介素之過度產生可導致稱作細胞介素反應症候群或CRS之病狀。本發明化合物可用於抑制細胞介素產生且因此改善其在CRS中之破壞性作用。CRS可在用其中細胞表現重組受體(諸如嵌合抗原受體(CAR))及/或其他轉殖基因受體(諸如T細胞受體(TCR))之療法治療期間發生。因此,本發明化合物適用於與CAR-T療法組合。與本發明化合物組合使用之例示性CAR-T療法包括活化T細胞;抗體,包括活化T細胞之抗體;YESCARTA;及KYMRIAH,其為可商購之實例。CRS亦可響應於嚴重的細菌感染及病毒感染而發生。特定言之,響應於COVID-19之CRS之後果為急性肺損傷,其可導致引起稱為急性呼吸窘迫症候群之病狀的嚴重肺損傷。在一個態樣中,本發明化合物用於患有或疑似患有COVID-19之患者以抑制CRS。在此情形下,本發明化合物可與諸如瑞德西韋(remdesivir)之抗病毒劑組合使用。類似地,本發明化合物可與抗生素組合使用以調節與細菌感染相關之CRS。
此等及其他適用之抗癌化合物係描述於Merck Index, 第13版 (O'Neil M. J.等人編) Merck Publishing Group (2001)及Goodman及Gilman The Pharmacological Basis of Therapeutics, 第12版, Brunton L.L.編, 第60-63章, McGraw Hill, (2011)中,兩者均以引用之方式併入本文中。
可與本發明所揭示之抑制劑組合使用之CTLA 4抗體為伊匹單抗(ipilimumab),其由Bristol-Myers Squibb以YERVOY
®出售。
用於組合之其他化學治療劑包括免疫腫瘤學藥劑,諸如檢查點路徑抑制劑,例如PD-1抑制劑,諸如納武單抗(nivolumab)及蘭利珠單抗(lambrolizumab);及PD-L1抑制劑,諸如帕博利珠單抗(pembrolizumab)、MEDI-4736及MPDL3280A/RG7446。用於與本文所揭示之化合物組合的另外之檢查點抑制劑包括抗LAG-3劑,諸如BMS-986016 (MDX-1408)。
用於與本發明所揭示之抑制劑組合的其他化學治療劑包括抗SLAMF7劑,諸如人類化單株抗體埃羅妥珠單抗(elotuzumab) (BMS-901608);抗KIR劑,諸如抗KIR單株抗體利瑞路單抗(lirilumab) (BMS-986015);及抗CD137劑,諸如完全人類單株抗體優瑞路單抗(urelumab) (BMS-663513)。
本發明所揭示之化合物亦可宜與CAR-T療法一起使用。當前可獲得的CAR-T療法之實例為阿基侖賽(axicabtagene ciloleucel)及替沙侖賽(tisagenlecleucel)。
適用於與本發明化合物組合之其他抗增生化合物包括例如(但不限於)針對生長因子受體之抗體(例如抗Her2);及細胞介素,諸如干擾素-α及干擾素-γ、介白素-2及GM-CSF。
適用於與本發明化合物組合之其他化學治療劑包括蛋白酶體抑制劑,諸如硼替佐米(bortezomib)、卡非佐米(carfilzomib)、馬瑞佐米(marizomib)及其類似者。
適用於與本發明所揭示之化合物組合尤其治療惡性病的激酶抑制劑之實例包括:Btk抑制劑,諸如依魯替尼;CDK抑制劑,諸如帕泊昔布(palbociclib);EGFR抑制劑,諸如阿法替尼(afatinib)、埃羅替尼(erlotinib)、吉非替尼(gefitinib)、拉帕替尼(lapatinib)、奧希替尼(osimertinib)及凡德替尼(vandetinib);Mek抑制劑,諸如曲美替尼(trametinib);Raf抑制劑,諸如達拉非尼(dabrafenib)、索拉非尼(sorafenib)及維羅非尼(vemurafenib);VEGFR抑制劑,諸如阿西替尼(axitinib)、樂伐替尼(lenvatinib)、尼達尼布(nintedanib)、帕唑帕尼(pazopanib);BCR-Abll抑制劑,諸如伯舒替尼(bosutinib)、達沙替尼(dasatinib)、伊馬替尼(imatinib)及尼羅替尼(nilotinib);FLT-3抑制劑,諸如吉列替尼(gilteritinib)及奎紮替尼(quizartinib);PI3-激酶抑制劑,諸如艾德昔布(idelalisib);Syk抑制劑,諸如福他替尼;及JAK抑制劑,諸如魯索替尼(ruxolitinib)及非達替尼(fedratinib)。
在其他實施例中,第二治療劑可選自以下中之任一者:
鎮痛劑-嗎啡、芬太尼(fentanyl)、氫嗎啡酮(hydromorphone)、羥考酮(oxycodone)、可待因(codeine)、乙醯胺苯酚(acetaminophen)、氫可酮(hydrocodone)、丁基原啡因(buprenorphine)、曲馬多(tramadol)、文拉法辛(venlafaxine)、氟魯匹汀(flupirtine)、嘜啶(meperidine)、戊唑星(pentazocine)、右旋嗎拉邁得(dextromoramide)、地匹哌酮(dipipanone);
抗生素-胺基糖苷(aminoglycoside) (例如,阿米卡星(amikacin)、慶大黴素(gentamicin)、卡那黴素(kanamycin)、新黴素(neomycin)、奈替黴素(netilmicin)、妥布黴素(tobramycin)及巴龍黴素(paromycin));碳青黴烯(carbapenem) (例如,厄他培南(ertapenem)、多尼培南(doripenem)、亞胺培南(imipenem)、西司他汀(cilastatin)及美羅培南(meropenem));頭孢菌素(例如,頭孢羥胺苄(cefadroxil)、頭孢若林(cefazolin)、頭孢噻吩(cefalotin)、頭孢力新(cephalexin)、頭孢克洛(cefaclor)、頭孢孟多(cefamandole)、頭孢西丁(cefoxitin)、頭孢丙烯(cefprozil)、頭孢呋辛(cefuroxime)、頭孢克肟(cefixime)、頭孢地尼(cefdinir)、頭孢托侖(cefditoren)、頭孢哌酮(cefoperazone)、頭孢噻肟(cefotaxime)、頭孢泊肟(cefpodoxime)、頭孢他啶(ceftazidime)、頭孢布坦(ceftibuten)、頭孢唑肟(ceftizoxime)、頭孢曲松(ceftriaxone)、頭孢吡肟(cefepime)及頭孢比普(cefobiprole));醣肽(例如,替考拉寧(teicoplanin)、萬古黴素(vancomycin)及特拉萬星(telavancin));林可醯胺類(lincosamides) (例如,克林達黴素(clindamycin)及林肯黴素(incomysin));脂肽(例如,達托黴素(daptomycin));巨環內酯(阿奇黴素(azithromycin)、克拉黴素(clarithromycin)、地紅黴素(dirithromycin)、紅黴素、羅紅黴素(roxithromycin)、醋竹桃黴素(troleandomycin)、泰利黴素(telithromycin)及奇黴素(spectinomycin));單醯胺菌素(例如,安曲南(aztreonam));硝基呋喃(例如,呋喃唑酮(furazolidone)及硝基呋喃妥因(nitrofurantoin));青黴素(例如,阿莫西林、安比西林(ampicillin)、阿洛西林(azlocillin)、卡本西林(carbenicillin)、氯唑西林(cloxacillin)、雙氯西林(dicloxacillin)、氟氯西林(flucloxacillin)、美洛西林(mezlocillin)、二甲氧苯青黴素(methicillin)、萘夫西林(nafcillin)、苯唑西林(oxacillin)、青黴素G、青黴素V、哌拉西林(piperacillin)、替莫西林(temocillin)及替卡西林(ticarcillin));青黴素組合(例如,阿莫西林/棒酸鹽、安比西林/舒巴坦(sulbactam)、哌拉西林/他唑巴坦(tazobactam)及替卡西林/棒酸鹽);多肽(例如,桿菌肽、可利斯汀(colistin)及多黏菌素B (polymyxin B));喹啉酮(例如,環丙沙星(ciprofloxacin)、依諾沙星(enoxacin)、加替沙星(gatifloxacin)、左氧氟沙星(levofloxacin)、洛美沙星(lomefloxacin)、莫西沙星(moxifloxacin)、萘啶酸(nalidixic acid)、諾氟沙星(norfloxacin)、氧氟沙星(ofloxacin)、曲伐沙星(trovafloxacin)、格帕沙星(grepafloxacin)、司帕沙星(sparfloxacin)及替馬沙星(temafloxacin));磺醯胺(例如,磺胺米隆(mafenide)、磺醯胺基柯衣定(sulfonamidochrysoidine)、磺胺醋醯胺(sulfacetamide)、磺胺嘧啶(sulfadiazine)、磺胺嘧啶銀、磺胺甲二唑(sulfamethizole)、磺胺甲基異㗁唑(sulfamethoxazole)、胺苯磺胺(sulfanilimide)、柳氮磺胺吡啶、磺胺異㗁唑、甲氧苄啶(trimethoprim)及甲氧苄啶-磺胺甲㗁唑(trimethoprim-sulfamethoxaxzole));四環素(例如,地美環素(demeclocycline)、強力黴素、二甲胺四環素、土黴素及四環素);抗分支桿菌化合物(例如,氯法齊明(clofazimine)、二胺苯碸(dapsone)、卷麴黴素(capreomycin)、環絲胺酸、乙胺丁醇(ethambutol)、乙硫異菸胺(ethionamide)、異菸肼(isoniazid)、吡𠯤甲醯胺(pyrazinamide)、立複黴素(rifampicin) (利福平(rifampin))、利福布汀(rifabutin)、利福噴丁(rifapentine)及鏈黴素);及其他抗生素,諸如阿斯凡納明(arsphenamine)、氯黴素、磷黴素、梭鏈孢酸(fusidic acid)、利奈唑胺(linezolid)、甲硝噠唑(metronidazole)、莫匹羅星(mupirocin)、平板黴素(platensimycin)、奎奴普汀(quinuprisin)/達福普汀(dalfopristin)、利福昔明(rifaximin)、甲碸黴素(thiamphenicol)、替加環素(tigecycline)及替硝唑(timidazole);
抗體-抗TNF-α抗體,例如英利昔單抗(Remicade
TM)、阿達木單抗、戈利木單抗、賽妥珠單抗;抗B細胞抗體,例如利妥昔單抗;抗IL-6抗體,例如托西利單抗;抗IL-1抗體,例如阿那白滯素;抗PD-1及/或抗PD-L1抗體,例如納武單抗、帕博利珠單抗、皮立珠單抗(pidilizumab)、BMS-936559、MPDL3280A、AMP-224、MEDI4736;伊科奇單抗(ixekizumab)、布羅達單抗(brodalumab)、奧伐木單抗(ofatumumab)、思魯庫單抗(sirukumab)、克立昔單抗(clenoliximab)、克拉紮克單抗(clazakiumab)、非紮奴單抗(fezakinumab)、夫來庫單抗(fletikumab)、馬瑞利單抗(mavrilimumab)、奧克珠單抗(ocrelizumab)、賽瑞單抗(sarilumab)、塞庫金單抗(secukinumab)、托珠單抗(toralizumab)、紮木單抗(zanolimumab);
抗凝血劑-華法林(Coumadin
TM)、醋硝香豆醇(acenocoumarol)、苯丙香豆醇(phenprocoumon)、裂盒蕈色素(atromentin)、苯茚二酮、肝素、磺達肝素(fondaparinux)、艾卓肝素(idraparinux)、利伐沙班(rivaroxaban)、阿派沙班(apixaban)、水蛭素、來匹盧定(lepirudin)、比伐盧定(bivalirudin)、阿加曲班(argatrobam)、達比加群(dabigatran)、希美加群(ximelagatran)、巴曲酶(batroxobin)、吻蛭素(hementin);
消炎劑-類固醇,例如布地奈德(budesonide);非類固醇消炎劑,例如胺基水楊酸(例如,柳氮磺胺吡啶、美沙拉明、奧沙拉嗪(olsalazine)及巴柳氮(balsalazide))、環加氧酶抑制劑(COX-2抑制劑,諸如羅非昔布(rofecoxib)、塞內昔布(celecoxib))、雙氯芬酸、依託度酸、法莫替丁、非諾洛芬、氟比洛芬、酮洛芬、酮咯酸、布洛芬、吲哚美辛、甲氯芬那酸、甲芬那酸、美洛昔康、萘丁美酮、萘普生、奧沙普嗪、吡羅昔康、雙水楊酸、舒林酸、托美丁;
免疫抑制劑-巰基嘌呤;皮質類固醇,諸如地塞米松、氫皮質酮、普賴松、甲基普賴蘇穠及普賴蘇穠;烷基化劑,諸如環磷醯胺;鈣調神經磷酸酶抑制劑,諸如環孢靈、西羅莫司(sirolimus)及他克莫司(tacrolimus);肌核苷單磷酸脫氫酶(IMPDH)抑制劑,諸如黴酚酸酯、黴酚酸嗎啉乙酯(mycophenolate mofetil)及硫唑嘌呤;及經設計以抑制細胞免疫同時使接受者體液免疫反應保持完好之藥劑,包括各種抗體(例如抗淋巴球球蛋白(ALG)、抗胸腺細胞球蛋白(ATG)、單株抗T細胞抗體(OKT3))及照射。硫唑嘌呤目前可以商品名Azasan購自Salix Pharmaceuticals公司;巰基嘌呤目前可以商品名Purinethol購自Gate Pharmaceuticals公司;普賴松及普賴蘇穠目前可購自Roxane Laboratories公司;甲基普賴蘇穠目前可購自Pfizer;西羅莫司(雷帕黴素)目前可以商品名Rapamune購自Wyeth-Ayerst;他克莫司目前可以商品名Prograf購自Fujisawa;環孢靈目前可以商品名Sandimmune購自Novartis以及以商品名Gengraf購自Abbott;諸如黴酚酸嗎啉乙酯及黴酚酸之IMPDH抑制劑目前可以商品名Cellcept購自Roche以及以商品名Myfortic購自Novartis;硫唑嘌呤目前可以商品名Imuran購自Glaxo Smith Kline;以及抗體目前可以商品名Orthoclone購自Ortho Biotech,以商品名Simulect (巴利昔單抗(basiliximab))購自Novartis,以及以商品名Zenapax (達利珠單抗(daclizumab))購自Roche;及
鳥苷酸環化酶-C受體促效劑或腸促泌素,例如利那洛肽(linaclotide),其以商品名Linzess出售。
此等各種藥劑可根據其標準或常用劑量使用,如可商購之藥物形式所附帶之處方資訊(亦參見醫師案頭參考(Physician's Desk Reference)之2006版中的處方資訊)中所指定,其揭示內容係以引用之方式併入本文中。
IV. 製造化合物之方法所揭示之化合物可藉由如一般熟習此項技術者所理解之任何適合方法來製備。本發明化合物之三環核部分之組裝的綜述提供於以下流程1中。
流程 1 :三環核之構造 流程2提供合成本文所揭示之RIP1K抑制性化合物之方法的另一綜述。
流程 2 : 用於形成三環之通用方法 流程3提供用於使本文中所述之三環中間物官能化之方法的綜述。此類方法可用於引入本文所述之R
1部分、B環及R
3、L及W基團。
流程 3 : 用於使三環核官能化之方法之綜述 下文參考實例中之特定化合物提供一種例示性適合方法,闡述於流程4中。此實例提供用於將三環核分子(如流程1中所闡述製備)連接至式I中所闡述之B環的通用方法。
流程 4 :醯胺形成之通用方法 參考流程4,使胺/胺鹽酸鹽(1當量)、芳基/雜芳基酸/鹽(1.2當量)及HATU (1.3至1.4當量)於無水DMF (0.3至0.8 mL/0.1 mmol)中之攪拌混合物真空脫氣且用氬氣回充。在三個脫氣循環之後,在0℃或室溫下將
i-Pr
2NEt (4至7當量)添加至以上攪拌混合物中,且攪拌直至胺消耗。將反應溶液在諸如以下方法中之一者中處理:
a)在用冰水稀釋之後,用EtOAc或CH
2Cl
2進行通常的萃取處理;
b)反應溶液濃度至乾燥之後,進行通常的處理;或
c)用冰水稀釋粗濃縮物,音波處理,使漿液升溫至室溫,且過濾,在抽吸乾燥後獲得灰色/深色粗固體。藉由正相矽膠或逆相層析自處理方法中之任一者純化粗物質,得到各別醯胺化合物。(產率:31-82%)。
參考流程1、2、3及4,變數X、Y
1、Y
2、Y
3及Z係如上文所述;P為如熟習此項技術者已知且如本文進一步例示之保護基。R為熟習此項技術者已知之任何適合取代基中之一或多者,諸如本文所述之R
1部分或其前驅體。
流程5描述用於鹵化某些中間化合物以產生本文所述之RIP1K抑制劑之方法。
流程 5 :用於氯化 5,6- 二氫 -4
H-
苯并 [
f]
咪唑并 [1,2-
a]
氮呯核之咪唑環之通用方法 . 參考流程5,將5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯核(0.1 mmol)、
N-氯代丁二醯亞胺(0.11 mmol)及無水乙腈((1 mL/0.1 mmol)之混合物在50℃下攪拌隔夜,用水稀釋且過濾。在乾燥後將漏斗上之固體溶解於CH
2Cl
2中,且裝載至矽膠管柱上。進行急驟矽膠管柱層析純化,分別得到經二氯取代之化合物(快速溶離)及經單氯取代之化合物(緩慢溶離)。
使用本文所揭示之方法及一般熟習有機合成及醫藥化學技術者已知之方法合成以下化合物。
I-1(±)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 7.94 (d,
J= 9.0 Hz, 1H), 7.45 - 7.17 (m, 9H), 7.11 (d,
J= 1.4 Hz, 1H), 6.70 (s, 1H), 5.32 - 5.21 (m, 1H), 4.11 (s, 2H), 2.76 - 2.66 (m, 2H), 2.58 - 2.48 (m, 1H), 2.22 (td,
J= 11.7, 7.6 Hz, 1H)。LCMS:純度95%, MS (m/e) 385 (M+H)
+。
I-2(±)-
N-(5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-4-苯基嘧啶-2-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 9.44 (d,
J= 7.5 Hz, 1H), 8.93 (d,
J= 5.3 Hz, 1H), 8.25 - 8.16 (m, 2H), 7.81 (d,
J= 5.3 Hz, 1H), 7.62 - 7.50 (m, 3H), 7.44 - 7.29 (m, 4H), 7.23 (d,
J= 1.4 Hz, 1H), 7.18 (d,
J= 1.4 Hz, 1H), 5.22 (dt,
J= 10.2, 7.7 Hz, 1H), 3.19 - 3.05 (m, 1H), 2.74 (ddd,
J= 14.0, 6.7, 2.0 Hz, 1H), 2.64 (td,
J= 13.1, 7.4 Hz, 1H), 2.27 - 2.14 (m, 1H)。LCMS:純度99%, MS (m/e) 382 (M+H)
+。
I-6(±)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-5-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.69 (d,
J= 7.5 Hz, 1H), 7.84 (s, 1H), 7.44 - 7.30 (m, 6H), 7.28 - 7.19 (m, 2H), 7.17 (d,
J= 1.4 Hz, 1H), 6.15 (app q,
J= 17.7 Hz, 2H), 5.10 (dt,
J= 10.4, 7.6 Hz, 1H), 3.02 (tt,
J= 12.6, 7.2 Hz, 1H), 2.82 - 2.58 (m, 2H), 2.28 - 2.16 (m, 1H)。LCMS:純度98%, MS (m/e) 454 (M+H)
+。
I-7(±)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.44 (d,
J= 7.7 Hz, 1H), 7.95 (s, 1H), 7.46 - 7.27 (m, 7H), 7.20 (d,
J= 1.4 Hz, 1H), 7.15 (d,
J= 1.4 Hz, 1H), 5.71 (s, 2H), 5.15 (dt,
J= 10.5, 7.7 Hz, 1H), 3.10 - 2.95 (m, 1H), 2.73 - 2.56 (m, 2H), 2.17 (app td,
J= 11.1, 7.2 Hz, 1H)。LCMS:純度98%, MS (m/e) 454 (M+H)
+。
I-9(±)-5-苯甲基-
N-(5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)異㗁唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.10 (d,
J= 7.4 Hz, 1H), 7.41 - 7.25 (m, 8H), 7.25 - 7.21 (m, 2H), 7.19 (d,
J= 1.4 Hz, 1H), 7.13 (d,
J= 1.4 Hz, 1H), 6.33 (t,
J= 0.8 Hz, 1H), 5.06 (dt,
J= 10.3, 7.6 Hz, 1H), 4.11 (s, 2H), 2.97 (tdd,
J= 12.7, 7.8, 6.8 Hz, 1H), 2.70 (ddd,
J= 14.0, 6.8, 1.8 Hz, 1H), 2.60 (td,
J= 13.2, 7.5 Hz, 1H), 2.19 - 2.09 (m, 1H)。LCMS:純度98%, MS (m/e) 385 (M+H)
+。
I-14(±)-
N-(5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1-(2-氟苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
LCMS:純度98%, MS (m/e) 403(M+H)
+。
I-19(±)-5-(2,6-二氯苯甲基)-
N-(5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.03 (br s, 1H), 7.44 - 7.29 (m, 6H), 7.19 - 7.10 (m, 2H), 6.91 (s, 1H), 5.14 (dt,
J= 10.7, 8.0 Hz, 1H), 4.48 (s, 2H), 2.87 - 2.71 (m, 2H), 2.57 (app td,
J= 13.2, 7.3 Hz, 1H), 2.32 - 2.22 (m, 1H)。LCMS:純度98%, MS (m/e) 454 (M+H)
+。
I-27(±)-1-(2,6-二氯苯甲基)-
N-(6,7-二氫苯并[b]吡咯并[1,2-
d][1,4]㗁氮呯-7-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 7.93 (d,
J= 0.6 Hz, 1H), 7.43 - 7.16 (m, 8H), 7.00 (t,
J= 2.3 Hz, 1H), 6.28 (d,
J= 2.3 Hz, 2H), 5.66 (s, 2H), 5.62 (ddd,
J= 9.1, 6.7, 6.0 Hz, 1H), 4.68 (dd,
J= 10.8, 6.0 Hz, 1H), 4.35 (dd,
J= 10.8, 6.8 Hz, 1H)。LCMS:純度99%, MS (m/e) 455 (M+H)
+。
I-29(±)-1-(2,6-二氯苯甲基)-
N-(4,5-二氫咪唑并[1,2-
d]吡咯并[2,1-
b][1,3,4]噻二氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.38 (d,
J= 7.9 Hz, 1H), 7.96 (s, 1H), 7.43 (d,
J= 1.2 Hz, 1H), 7.41 (s, 1H), 7.33 (dd,
J= 8.9, 7.1 Hz, 1H), 7.27 (d,
J= 1.5 Hz, 1H), 7.16 (d,
J= 1.5 Hz, 1H), 7.11 (dd,
J= 3.2, 1.7 Hz, 1H), 6.52 (dd,
J= 4.0, 1.7 Hz, 1H), 6.31 (dd,
J= 4.0, 3.2 Hz, 1H), 5.71 (s, 2H), 5.22 (ddd,
J= 10.2, 7.9, 6.7 Hz, 1H), 3.97 (dd,
J= 11.4, 6.7 Hz, 1H), 2.76 (dd,
J= 11.4, 10.2 Hz, 1H)。LCMS:純度99%, MS (m/e) 461 (M+H)
+。
I-34(±)-5-苯甲基-
N-(6,7-二氫苯并[
b]吡咯并[1,2-
d][1,4]㗁氮呯-7-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 11.86 (s, 1H), 7.47 - 7.35 (m, 2H), 7.34 - 7.18 (m, 8H), 7.02 (t,
J= 2.3 Hz, 1H), 6.33 - 6.26 (app m, 2H), 5.58 (dt,
J= 8.9, 6.4 Hz, 1H), 4.65 (dd,
J= 10.9, 6.0 Hz, 1H), 4.36 (dd,
J= 10.9, 6.9 Hz, 1H), 4.14 (s, 2H)。LCMS:純度96%, MS (m/e) 386 (M+H)
+。
I-35(±)-1-(2,6-二氯苯甲基)-
N-(2-甲基-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.41 (d,
J= 7.5 Hz, 1H), 7.96 (d,
J= 0.7 Hz, 1H), 7.47 - 7.20 (m, 7H), 6.90 (q,
J= 1.0 Hz, 1H), 5.71 (app s, 2H), 5.09 (dt,
J= 10.4, 7.6 Hz, 1H), 3.03 (tt,
J= 12.6, 7.3 Hz, 1H), 2.72 - 2.54 (m, 2H), 2.30 (d,
J= 1.0 Hz, 3H), 2.18 - 2.05 (m, 1H)。LCMS:純度95%, MS (m/e) 468 (M+H)
+。
I-36(±)-1-(2,6-二氯苯甲基)-
N-(1-側氧基-2,4,5,6-四氫-1
H-苯并[
f][1,2,4]三唑并[4,3-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 8.53 (s, 1H), 7.58 (dd,
J= 8.0, 1.4 Hz, 1H), 7.53 - 7.34 (m, 7H), 5.79 (s, 2H), 4.89 (dd,
J= 10.3, 8.0 Hz, 1H), 2.89 - 2.68 (m, 2H), 2.66 - 2.51 (m, 1H), 2.37 - 2.25 (m, 1H)。純度95%, MS (m/e) 471 (M+H)
+。
I-37(±)-
N-(6,7-二氫苯并[
b]吡咯并[1,2-
d][1,4]㗁氮呯-7-基)-5-(4-氟苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 13.40 (br s, 1H), 7.50 (d,
J= 9.0 Hz, 1H), 7.44 - 7.36 (m, 1H), 7.30 - 7.17 (m, 3H), 7.17 (dd,
J= 8.6, 5.4 Hz, 2H), 7.02 (dd,
J= 2.9, 1.7 Hz, 1H), 6.91 (t,
J= 8.6 Hz, 2H), 6.32 - 6.23 (m, 2H), 5.55 (dt,
J= 9.0, 6.4 Hz, 1H), 4.63 (dd,
J= 10.9, 6.0 Hz, 1H), 4.36 (dd,
J= 10.9, 6.8 Hz, 1H), 4.12 (s, 2H)。
19F NMR (376 MHz, 氯仿-
d) δ -115.74。純度98%, MS (m/e) 404 (M+H)
+。
I-38(±)-
N-(6,7-二氫苯并[
b]吡咯并[1,2-
d][1,4]㗁氮呯-7-基)-1-(2-氟苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.06 (d,
J= 0.9 Hz, 1H), 7.45 - 7.32 (m, 3H), 7.37 - 7.29 (m, 1H), 7.28 - 7.19 (m, 3H), 7.23 - 7.06 (m, 2H), 7.01 (t,
J= 2.3 Hz, 1H), 6.29 (app d,
J= 2.4 Hz, 2H), 5.63 (ddd,
J= 9.1, 6.9, 6.0 Hz, 1H), 5.41 (app d,
J= 1.2 Hz, 2H), 4.68 (dd,
J= 10.8, 6.0 Hz, 1H), 4.35 (dd,
J= 10.8, 6.9 Hz, 1H)。
19F NMR (376 MHz, 氯仿-
d) δ -118.06 - -118.09 (m)。純度97%, MS (m/e) 404 (M+H)
+。
I-39(±)-5-苯甲基-
N-(9-((4-(吡啶-4-基)哌𠯤-1-基)甲基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 8.10 - 8.06 (m, 2H), 7.47 (d,
J= 1.6 Hz, 1H), 7.44 - 7.36 (m, 3H), 7.33 - 7.19 (m, 5H), 7.03 (d,
J= 1.5 Hz, 1H), 6.85 - 6.80 (m, 2H), 5.03 (dd,
J= 10.6, 7.5 Hz, 1H), 4.14 (s, 2H), 3.62 (app q,
J= 17.3 Hz, 2H), 3.41 (app t,
J= 5.2 Hz, 4H), 2.82 - 2.74 (m, 1H), 2.74 - 2.62 (m, 1H), 2.59 (app t,
J= 5.2 Hz, 4H), 2.56 - 2.47 (m, 1H), 2.37 - 2.32 9 (m, 1H)。純度96%, MS (m/e) 560 (M+H)
+。
I-40(±)-5-苯甲基-
N-(1-甲基-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.50 - 7.43 (m, 2H), 7.43 - 7.35 (m, 2H), 7.33 - 7.17 (m, 5H), 6.77 (q,
J= 1.0 Hz, 1H), 4.88 (dd,
J= 11.2, 7.5 Hz, 1H), 4.14 (s, 2H), 2.73 (dd,
J= 13.4, 6.2 Hz, 1H), 2.63 - 2.53 (m, 1H), 2.43 - 2.34 (m, 1H), 2.27 - 2.19 (m, 1H), 2.22 (d,
J= 1.1 Hz, 3H)。純度95%, MS (m/e) 399 (M+H)
+。
I-44(±)-1-(2,6-二氯苯甲基)-
N-(1-甲基-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.49 - 8.42 (app m, 1H), 7.91 (s, 1H), 7.44 - 7.26 (m, 6H), 7.24 - 7.17 (m, 1H), 6.85 (t,
J= 1.1 Hz, 1H), 5.69 (s, 2H), 5.06 - 4.95 (m, 1H), 3.01 - 2.87 (m, 1H), 2.67 - 2.57 (m, 1H), 2.48 - 2.44 (m, 1H), 2.23 (d,
J= 1.1 Hz, 3H), 2.10 - 1.97 (m, 1H)。純度92%, MS (m/e) 468 (M+H)
+。
I-45(±)-5-苯甲基-
N-(4,5-二氫咪唑并[1,2-d]吡咯并[2,1-
b][1,3,4]噻二氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 9.09 (s, 1H), 7.35 - 7.20 (m, 6H), 7.18 (d,
J= 1.6 Hz, 1H), 7.15 (dd,
J= 3.3, 1.7 Hz, 1H), 6.63 (s, 1H), 6.50 (dd,
J= 4.0, 1.7 Hz, 1H), 6.31 (dd,
J= 4.0, 3.2 Hz, 1H), 5.29 (q,
J= 9.1 Hz, 1H), 4.18 (s, 2H), 3.74 (dd,
J= 11.3, 6.7 Hz, 1H), 2.80 (t,
J= 11.2 Hz, 1H)。純度96%, MS (m/e) 392 (M+H)
+。
I-47(±)-1-(2,6-二氯苯甲基)-
N-(9-((4-(吡啶-4-基)哌𠯤-1-基)甲基)-5,6-二氫-4
H-苯并[f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.44 (d,
J= 7.7 Hz, 1H), 8.28 - 8.21 (m, 2H), 7.93 (d,
J= 0.6 Hz, 1H), 7.41 (dd,
J= 8.0, 0.9 Hz, 2H), 7.36 - 7.24 (m, 4H), 7.19 (d,
J= 1.4 Hz, 1H), 7.12 (d,
J= 1.4 Hz, 1H), 6.67 - 6.60 (m, 2H), 5.70 (s, 2H), 5.15 (dt,
J= 10.5, 7.8 Hz, 1H), 3.63 - 3.50 (m, 2H), 3.39 - 3.31 (m, 4H), 3.07 - 2.92 (m, 1H), 2.68 (dd,
J= 13.9, 6.4 Hz, 1H), 2.62 - 2.52 (m, 5H), 2.12 - 2.08 (m, 1H)。純度97%, MS (m/e) 629 (M+H)
+。
(±)-5-苯甲基-
N-(1-側氧基-5,6-二氫-1
H,4
H-苯并[
f][1,2,4]㗁二唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.58 (dd,
J= 7.9, 1.4 Hz, 1H), 7.50 - 7.36 (m, 3H), 7.36 - 7.16 (m, 5H), 4.94 (dd,
J= 10.4, 8.3 Hz, 1H), 4.15 (s, 2H), 2.91 - 2.84 (m, 2H), 2.60 - 2.50 (m, 1H), 2.48 - 2.32 (m, 1H)。純度93%, MS (m/e) 403 (M+H)
+。
I-51(±)-
N-(5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 9.21 (d,
J= 7.7 Hz, 1H), 8.46 (dd,
J= 5.6, 0.6 Hz, 1H), 7.65 (d,
J= 2.6 Hz, 1H), 7.43 - 7.26 (m, 5H), 7.25 - 7.19 (m, 2H), 7.18 (d,
J= 1.4 Hz, 1H), 7.15 (d,
J= 1.4 Hz, 1H), 7.08 - 7.03 (m, 2H), 6.93 (dd,
J= 5.6, 2.5 Hz, 1H), 5.07 (dt,
J= 10.5, 7.7 Hz, 1H), 3.01 - 2.92 (m, 1H), 2.72 - 2.56 (m, 2H), 2.19 - 2.11 (m, 1H)。純度94%, MS (m/e) 397 (M+H)
+。
I-52(±)-
N-(1-側氧基-5,6-二氫-1
H,4
H-苯并[
f][1,2,4]㗁二唑并[4,3-
a]氮呯-4-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.53 (d,
J= 8.8 Hz, 1H), 8.38 (d,
J= 5.6 Hz, 1H), 7.62 (d,
J= 2.5 Hz, 1H), 7.58 (dd,
J= 7.9, 1.3 Hz, 1H), 7.48 - 7.30 (m, 5H), 7.24 (app dt,
J= 14.9, 1.2 Hz, 1H), 7.10 - 7.01 (m, 2H), 6.95 (dd,
J= 5.6, 2.5 Hz, 1H), 5.10 (dt,
J= 9.8, 8.3 Hz, 1H), 2.91 - 2.80 (m, 2H), 2.80 - 2.56 (m, 1H), 2.33 - 2.12 (m, 1H)。純度95%, MS (m/e) 415 (M+H)
+。
I-54(±)-
N-(6,7-二氫苯并[
b]吡咯并[1,2-
d][1,4]㗁氮呯-7-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.38 - 8.29 (m, 2H), 7.66 - 7.61 (m, 1H), 7.46 - 7.36 (m, 3H), 7.29 - 7.18 (m, 4H), 7.10 - 7.02 (m, 2H), 7.00 (t,
J= 2.3 Hz, 1H), 6.93 (dd,
J= 5.6, 2.5 Hz, 1H), 6.32 - 6.25 (m, 2H), 5.54 (ddd,
J= 9.2, 7.3, 6.1 Hz, 1H), 4.67 (dd,
J= 10.7, 6.1 Hz, 1H), 4.35 (dd,
J= 10.7, 7.3 Hz, 1H)。純度99%, MS (m/e) 398 (M+H)
+。
I-55(±)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.49 (d,
J= 1.4 Hz, 1H), 7.43 - 7.36 (m, 3H), 7.34 - 7.19 (m, 5H), 7.03 (d,
J= 1.5 Hz, 1H), 5.02 (dd,
J= 10.7, 7.5 Hz, 1H), 4.15 (s, 2H), 2.84 - 2.76 (m, 1H), 2.73 - 2.61 (m, 1H), 2.52 -2.48 (m, 1H), 2.38 - 2.34 (m, 1H), 1.55 (s, 6H)。純度96%, MS (m/e) 467 (M+H)
+。
I-56(±)-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 8.49 (dd,
J= 5.6, 0.5 Hz, 1H), 7.51 - 7.37 (m, 7H), 7.29 (ddt,
J= 7.9, 7.0, 1.1 Hz, 1H), 7.18 - 7.09 (m, 2H), 7.13 - 7.02 (m, 2H), 5.02 (dd,
J= 10.3, 7.3 Hz, 1H), 2.84 - 2.66 (m, 2H), 2.60 - 2.48 (m, 1H), 2.39 - 2.26 (m, 1H), 1.55 (s, 6H)。純度97%, MS (m/e) 479 (M+H)
+。
I-57(±)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f][1,2,4]三唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 8.84 (s, 1H), 7.70 - 7.38 (m, 4H), 7.38 - 7.08 (m, 5H), 5.13 (dd,
J= 10.6, 7.9 Hz, 1H), 4.16 (s, 2H), 2.90 - 2.81 (m, 1H), 2.77 - 2.63 (m, 1H), 2.64 - 2.52 (m, 1H), 2.48 - 2.37 (m, 1H)。純度90%, MS (m/e) 386 (M+H)
+。
I-58(±)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4
H-苯并[
f][1,2,4]三唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 8.83 (s, 1H), 8.52 (s, 1H), 7.58 - 7.43 (m, 6H), 7.47 - 7.35 (m, 1H), 5.78 (s, 2H), 5.13 (dd,
J= 10.5, 7.9 Hz, 1H), 2.85 (ddd,
J= 13.6, 5.9, 2.2 Hz, 1H), 2.77 - 2.63 (m, 1H), 2.64 - 2.52 (m, 1H), 2.49 - 2.36 (m, 1H)。純度91%, MS (m/e) 455 (M+H)
+。
I-59(±)-
N-(5,6-二氫-4
H-苯并[
f][1,2,4]三唑并[4,3-a]氮呯-4-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 8.84 (s, 1H), 8.50 (d,
J= 5.6 Hz, 1H), 7.58 - 7.41 (m, 7H), 7.33 - 7.24 (m, 1H), 7.18 - 7.10 (m, 2H), 7.07 (dd,
J= 5.6, 2.6 Hz, 1H), 5.13 (dd,
J= 10.3, 7.9 Hz, 1H), 2.86 (ddd,
J= 13.5, 6.2, 2.3 Hz, 1H), 2.82 - 2.68 (m, 1H), 2.68 - 2.55 (m, 1H), 2.49 - 2.36 (m, 1H)。純度90%, MS (m/e) 398 (M+H)
+。
I-60(±)-1-(2,6-二氯苯甲基)-
N-(2-甲基-1-側氧基-2,4,5,6-四氫-1
H-苯并[
f][1,2,4]三唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 7.96 (s, 1H), 7.76 (d,
J= 8.4 Hz, 1H), 7.60 (dt,
J= 7.9, 1.0 Hz, 1H), 7.45 - 7.25 (m, 6H), 5.70 (s, 2H), 5.08 (dt,
J= 10.2, 8.1 Hz, 1H), 3.52 (s, 3H), 2.90 - 2.75 (m, 1H), 2.74 - 2.71 (m, 2H), 2.12 - 2.00 (m, 1H)。純度96%, MS (m/e) 485 (M+H)
+。
I-61(±)-
N-(9-(3-氧雜-9-氮雜螺[5.5]十一-9-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1-(2,6-二氯苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.41 (d,
J= 7.8 Hz, 1H), 7.92 (d,
J= 0.6 Hz, 1H), 7.41 (dd,
J= 8.0, 0.9 Hz, 2H), 7.31 (dd,
J= 8.9, 7.1 Hz, 1H), 7.22 - 7.14 (m, 2H), 7.11 (d,
J= 1.4 Hz, 1H), 6.85 (dd,
J= 8.4, 2.5 Hz, 1H), 6.80 (d,
J= 2.6 Hz, 1H), 5.70 (s, 2H), 5.14 (dt,
J= 10.4, 7.7 Hz, 1H), 3.72 - 3.65 (m, 4H), 3.19 (dd,
J= 7.0, 4.6 Hz, 4H), 3.02 - 2.87 (m, 1H), 2.63 - 2.54 (m, 1H), 2.48 (td,
J= 13.3, 7.4 Hz, 1H), 2.12 - 2.00 (m, 1H), 1.74 - 1.66 (m, 4H), 1.59 - 1.51 (m, 4H)。純度99%, MS (m/e) 607 (M+H)
+。
I-62(±)-
N-(9-(3-氧雜-9-氮雜螺[5.5]十一-9-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 9.19 (d,
J= 7.8 Hz, 1H), 8.46 (dd,
J= 5.6, 0.6 Hz, 1H), 7.68 - 7.63 (m, 1H), 7.44 - 7.35 (m, 2H), 7.24 - 7.18 (m, 2H), 7.15 (dd,
J= 15.9, 1.4 Hz, 2H), 7.09 - 7.04 (m, 2H), 6.93 (dd,
J= 5.6, 2.6 Hz, 1H), 6.86 (dd,
J= 8.4, 2.5 Hz, 1H), 6.81 (d,
J= 2.5 Hz, 1H), 5.09 (dt,
J= 10.5, 7.8 Hz, 1H), 3.72 - 3.65 (m, 4H), 3.23 - 3.14 (m, 4H), 2.97 - 2.79 (m, 1H), 2.64 - 2.41 (m, 2H), 2.16 - 2.04 (m, 1H), 1.74 - 1.67 (m, 4H), 1.57 - 1.53 (m, 4H)。純度99%, MS (m/e) 550 (M+H)
+。
I-63(±)-1-苯甲基-
N-(5,6-二氫-4
H-苯并[
f][1,2,4]三唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.40 (s, 1H), 8.37 (d,
J= 8.1 Hz, 1H), 8.01 (s, 1H), 7.46 - 7.31 (m, 7H), 7.31 - 7.25 (m, 2H), 5.38 (s, 2H), 5.30 (dt,
J= 10.4, 8.1 Hz, 1H), 3.10 - 2.93 (m, 1H), 2.83 - 2.67 (m, 1H), 2.67 - 2.47 (m, 1H), 2.25 - 2.11 (m, 1H)。純度98%, MS (m/e) 386 (M+H)
+。
I-64(±)-
N-(9-(3-氧雜-9-氮雜螺[5.5]十一-9-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-5-苯甲基-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.02 (d,
J= 8.8 Hz, 1H), 7.33 - 7.26 (m, 1H), 7.30 - 7.23 (m, 2H), 7.26 - 7.18 (m, 2H), 7.17 (d,
J= 8.4 Hz, 1H), 7.11 (d,
J= 1.4 Hz, 1H), 6.90 - 6.80 (m, 2H), 6.76 (s, 1H), 5.31 - 5.17 (m, 1H), 4.10 (s, 2H), 3.73 - 3.66 (m, 5H), 3.24 - 3.17 (m, 5H), 2.74 - 2.55 (m, 2H), 2.50 - 2.37 (m, 1H), 2.21 - 2.09 (m, 1H), 1.74 - 1.69 (m, 4H), 1.56 - 1.52 (m, 4H)。
1H NMR (400 MHz, 甲醇-
d 4) δ 7.41 (d,
J= 1.5 Hz, 1H), 7.36 - 7.20 (m, 6H), 7.05 - 6.95 (m, 3H), 5.05 (dd,
J= 10.4, 7.1 Hz, 1H), 4.16 (s, 2H), 3.73 - 3.66 (m, 4H), 3.28 - 3.20 (m, 4H), 2.73 - 2.56 (m, 2H), 2.49 - 2.36 (m, 1H), 2.32 - 2.24 (m, 1H), 1.76 - 1.68 (m, 4H), 1.60 - 1.53 (m, 4H)。純度99%, MS (m/e) 538 (M+H)
+。
I-65(±)-5-苯甲基-
N-(1-側氧基-9-(3-氧雜-9-氮雜螺[5.5]十一-9-基)-5,6-二氫-1
H,4
H-苯并[
f][1,2,4]㗁二唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 11.13 (br s, 1H), 7.61 (d,
J= 8.9 Hz, 1H), 7.38 - 7.24 (m, 5H), 7.15 (d,
J= 8.5 Hz, 1H), 7.06 (d,
J= 2.5 Hz, 1H), 6.87 (dd,
J= 8.5, 2.6 Hz, 1H), 5.13 (q,
J= 9.0 Hz, 1H), 4.16 (s, 2H), 3.72 - 3.65 (m, 4H), 3.20 (app dd,
J= 7.3, 4.6 Hz, 4H), 2.76 - 2.59 (m, 3H), 2.20 - 2.09 (m, 1H), 1.72 - 1.65 (m, 4H), 1.57 - 1.52 (m, 4H)。純度94%, MS (m/e) 556 (M+H)
+。
I-66(±)-5-苯甲基-
N-(4,5-二氫咪唑并[1,2-a]喹啉-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.77 (d,
J= 1.6 Hz, 1H), 7.58 - 7.54 (m, 1H), 7.42 - 7.35 (m, 2H), 7.33 - 7.17 (m, 6H), 7.10 (d,
J= 1.6 Hz, 1H), 5.54 (dd,
J= 9.2, 6.1 Hz, 1H), 4.12 (s, 2H), 3.35 - 2.87 (app m, 2H)。純度95%, MS (m/e) 371 (M+H)
+。
I-67(±)-
N-(4,5-二氫咪唑并[1,2-a]喹啉-4-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ8.43 (d,
J= 5.6 Hz, 1H), 7.77 (d,
J= 1.6 Hz, 1H), 7.59 (d,
J= 2.5 Hz, 1H), 7.58 - 7.54 (m, 1H), 7.51 - 7.44 (m, 2H), 7.43 - 7.35 (m, 2H), 7.34 - 7.27 (m, 1H), 7.23 (td,
J= 7.5, 1.2 Hz, 1H), 7.17 - 7.13 (m, 2H), 7.09 (d,
J= 1.5 Hz, 1H), 7.05 (dd,
J= 5.6, 2.6 Hz, 1H), 5.48 (dd,
J= 9.2, 6.1 Hz, 1H), 3.38 - 3.24 (app m, 2H)。純度96%, MS (m/e) 383 (M+H)
+。
I-68(±)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ7.97 (d,
J= 8.5 Hz, 1H), 7.31 - 7.27 (m, 1H), 7.26 (d,
J= 0.9 Hz, 1H), 7.25 - 7.19 (m, 4H), 7.17 - 7.14 (m, 2H), 7.11 (d,
J= 1.4 Hz, 1H), 6.72 (s, 1H), 5.28 - 5.20 (app m, 1H), 4.10 (s,2H), 2.80 - 2.62 (m, 5H), 2.54 -2.45 (m, 1H), 2.22 -2.18 (m, 1H), 1.86 - 1.77 (m, 2H), 1.31 (s, 6H)。純度93%, MS (m/e) 471 (M+H)
+。
I-72(±)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-5,6-二氫-4
H-苯并[
f][1,2,4]三唑并[4,3-a]氮呯-4-基)-1H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 8.86 (s, 1H), 7.63 (d,
J= 1.2 Hz, 1H), 7.49 (s, 2H), 7.36 - 7.20 (m, 5H), 5.15 (dd,
J= 10.5, 7.9 Hz, 1H), 4.17 (s, 2H), 2.92 - 2.82 (m, 1H), 2.78 - 2.64 (m, 1H), 2.64 - 2.52 (m, 1H), 2.50 - 2.38 (m, 1H), 1.56 (s, 6H)。純度98%, MS (m/e) 468 (M+H)
+。
I-77(±)-
N-(9-(3-氧雜-9-氮雜螺[5.5]十一-9-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1-苯甲基-1
H-吡唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.11 (d,
J= 7.9 Hz, 1H), 7.41 - 7.28 (m, 4H), 7.24 (d,
J= 2.0 Hz, 1H), 7.26 - 7.17 (m, 3H), 7.15 (d,
J= 1.4 Hz, 1H), 6.88 (dd,
J= 8.4, 2.5 Hz, 1H), 6.83 (d,
J= 2.5 Hz, 1H), 6.77 (d,
J= 2.3 Hz, 1H), 5.32 (app q,
J= 17.3 Hz, 2H), 5.17 (dt,
J= 10.5, 7.8 Hz, 1H), 3.74 - 3.66 (m, 4H), 3.24 - 3.17 (m, 4H), 2.96 - 2.82 (m, 1H), 2.65 - 2.56 (m, 1H), 2.43 - 2.45 (app m, 1H), 2.21 - 2.09 (m, 1H), 1.75 - 1.68 (m, 4H), 1.60 - 1.53 (m, 4H)。純度95%, MS (m/e) 537 (M+H)
+。
I-82(
S)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.50 (d,
J= 1.3 Hz, 1H), 7.45 - 7.40 (m, 3H), 7.35 - 7.21 (m, 5H), 7.05 (d,
J= 1.5 Hz, 1H), 5.04 (dd,
J= 10.7, 7.5 Hz, 1H), 4.16 (s, 2H), 2.85 - 2.75 (m, 1H), 2.74 - 2.65 (m, 1H), 2.58 - 2.48 (m, 1H), 2.40 - 2.30 (m, 1H), 1.56 (s, 6H)。純度97%, MS (m/e) 467 (M+H)
+。
I-83(
S)-
N-(9-(3-氧雜-9-氮雜螺[5.5]十一-9-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-5-苯甲基-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.41 (d,
J= 1.4 Hz, 1H), 7.36 - 7.18 (m, 6H), 7.03 (d,
J= 1.4 Hz, 1H), 7.02 - 6.97 (m, 2H), 5.12 - 5.01 (app m, 1H), 4.16 (s, 2H), 3.75 - 3.64 (m, 4H), 3.27 - 3.20 (m, 4H), 2.75 - 2.55 (m, 2H), 2.55 - 2.36 (m, 1H), 2.36 - 2.17 (m, 1H), 1.79 - 1.65 (m, 4H), 1.65 - 1.49 (m, 4H)。純度95%, MS (m/e) 538 (M+H)
+。
I-84(±)-
N-(9-(7-氧雜-2-氮雜螺[3.5]壬-2-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-5-苯甲基-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.39 (d,
J= 1.4 Hz, 1H), 7.35 - 7.18 (m, 6H), 7.02 (d,
J= 1.4 Hz, 1H), 6.53 (d,
J= 2.3 Hz, 1H), 6.49 (dd,
J= 8.2, 2.4 Hz, 1H), 5.05 (dd,
J= 10.5, 7.0 Hz, 1H), 4.16 (s, 2H), 3.75 - 3.57 (m, 8H), 2.72 - 2.53 (m, 2H), 2.52 - 2.33 (m, 1H), 2.34 - 2.17 (m, 1H), 1.90 - 1.76 (m, 4H)。純度97%, MS (m/e) 510 (M+H)
+。
I-85(±)-
N-(9-(7-氧雜-2-氮雜螺[3.5]壬-2-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1-苯甲基-1
H-吡唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.70 (d,
J= 2.4 Hz, 1H), 7.47 (d,
J= 1.6 Hz, 1H), 7.39 - 7.21 (m, 6H), 7.12 (d,
J= 1.5 Hz, 1H), 6.75 (d,
J= 2.4 Hz, 1H), 6.55 (d,
J= 2.3 Hz, 1H), 6.51 (dd,
J= 8.2, 2.4 Hz, 1H), 5.40 (s, 2H), 5.09 (dd,
J= 10.3, 7.1 Hz, 1H), 3.74 - 3.61 (m, 8H), 2.72 - 2.55 (m, 2H), 2.50 - 2.38 (m, 1H), 2.38 - 2.22 (m, 1H), 1.87 - 1.78 (m, 4H)。純度96%, MS (m/e) 509 (M+H)
+。
I-86(
S)-
N-(9-(7-氧雜-2-氮雜螺[3.5]壬-2-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-5-苯甲基-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.38 (d,
J= 1.5 Hz, 1H), 7.35 - 7.20 (m, 6H), 7.02 (d,
J= 1.5 Hz, 1H), 6.52 (d,
J= 2.3 Hz, 1H), 6.49 (dd,
J= 8.2, 2.4 Hz, 1H), 5.05 (dd,
J= 10.5, 7.0 Hz, 1H), 4.16 (s, 2H), 3.73 - 3.61 (m, 8H), 2.71 - 2.53 (m, 2H), 2.52 - 2.34 (m, 1H), 2.33 - 2.15 (m, 1H), 1.84 (app t,
J= 5.3 Hz, 4H)。純度96%, MS (m/e) 510 (M+H)
+。
(
R)-
N-(9-(7-氧雜-2-氮雜螺[3.5]壬-2-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-5-苯甲基-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.50 (d,
J= 1.5 Hz, 1H), 7.36 - 7.19 (m, 5H), 7.14 (d,
J= 8.7 Hz, 1H), 7.07 (d,
J= 1.5 Hz, 1H), 6.60 (d,
J= 2.7 Hz, 1H), 6.48 (dd,
J= 8.7, 2.7 Hz, 1H), 5.48 (dd,
J= 9.5, 7.0 Hz, 1H), 4.60 (dd,
J= 10.6, 7.0 Hz, 1H), 4.38 (dd,
J= 10.5, 9.5 Hz, 1H), 4.16 (s, 2H), 3.73 - 3.64 (m, 8H), 1.88 - 1.80 (m, 4H)。純度98%, MS (m/e) 512 (M+H)
+。
I-88(
R)-
N-(9-(7-氧雜-2-氮雜螺[3.5]壬-2-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 9.18 (d,
J= 7.6 Hz, 1H), 8.48 (d,
J= 5.6 Hz, 1H), 7.66 (d,
J= 2.5 Hz, 1H), 7.48 - 7.36 (m, 2H), 7.30 - 7.22 (m, 2H), 7.19 (d,
J= 1.4 Hz, 1H), 7.17 - 7.12 (m, 1H), 7.12 - 7.04 (m, 2H), 6.96 (dd,
J= 5.6, 2.5 Hz, 1H), 6.38 (app dd,
J= 6.7, 2.7 Hz, 2H), 5.43 (dt,
J= 9.8, 7.2 Hz, 1H), 4.84 (dd,
J= 10.1, 7.0 Hz, 1H), 4.25 (t,
J= 10.0 Hz, 1H), 3.72 - 3.63 (m, 8H), 1.34 - 1.20 (m, 4H)。純度97%, MS (m/e) 524 (M+H)
+。
I-89(
R)-5-苯甲基-
N-(9-(吡啶-2-基乙炔基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 8.72 (dd,
J= 2.1, 0.9 Hz, 1H), 8.53 (dd,
J= 5.0, 1.6 Hz, 1H), 7.99 (dt,
J= 7.9, 1.9 Hz, 1H), 7.88 (d,
J= 1.9 Hz, 1H), 7.65 (d,
J= 1.6 Hz, 1H), 7.57 (dd,
J= 8.3, 2.0 Hz, 1H), 7.47 (ddd,
J= 7.9, 5.0, 0.9 Hz, 1H), 7.37 - 7.19 (m, 6H), 7.13 (d,
J= 1.5 Hz, 1H), 5.60 (dd,
J= 8.8, 6.1 Hz, 1H), 4.70 (dd,
J= 11.0, 6.1 Hz, 1H), 4.54 (dd,
J= 11.0, 8.9 Hz, 1H), 4.16 (s, 2H)。純度96%, MS (m/e) 488 (M+H)
+。
I-90(±)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.67 (s, 1H), 7.58 (s, 1H), 7.40 (d,
J= 8.5 Hz, 1H), 7.33 - 7.21 (m, 6H), 7.11 (s, 1H), 5.61 - 5.51 (app m, 1H), 4.67 (app t,
J= 8.3 Hz, 1H), 4.50 (app t,
J= 10.0 Hz, 1H), 4.15 (s, 2H), 1.56 (s, 6H)。純度92%, MS (m/e) 469 (M+H)
+。
I-93(±)-4-(4-氟苯甲基)-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-吡唑-1-甲醯胺
1H NMR (400 MHz, 二氯甲烷-
d
2 ) δ 8.31 (d,
J= 7.2 Hz, 1H), 7.89 (q,
J= 0.9 Hz, 1H), 7.49 (d,
J= 0.9 Hz, 1H), 7.41 - 7.33 (m, 3H), 7.25 (d,
J= 1.5 Hz, 1H), 7.22 - 7.15 (m, 2H), 7.13 (d,
J= 1.4 Hz, 1H), 7.03 - 6.94 (m, 2H), 4.87 (dt,
J= 10.5, 7.5 Hz, 1H), 3.81 (s, 2H), 3.04 - 2.85 (m, 1H), 2.81 - 2.67 (m, 1H), 2.62 - 2.54 (m, 1H), 2.25 - 2.13 (m, 1H), 2.08 (s, 1H), 1.59 (s, 6H)。
19F NMR (376 MHz, 二氯甲烷-
d
2 ) δ-117.81 - -117.88 (ddd,
J= 14.2, 8.9, 5.4 Hz)。純度92%, MS (m/e) 484 (M+H)
+。
對映異構物之層析分離 :對於本文中一般熟習有機合成技術者,本文所揭示之化合物可以如本文中所教示的外消旋或對映異構性增濃形式合成。如一般熟習此項技術者已知,本文所揭示之化合物之外消旋混合物可使用以下對掌性層析程序及其調整分離成其組成性對映異構體。
I-4(
S)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺及
I-5(
R)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
(±)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺之對掌性分離係在裝配有Chiracel AD-H,10微米,10 × 250 mm管柱之Thar SFC儀器上進行。移動相為18%甲醇(0.1% DEA)及82% CO
2,總流速為12 mL/分鐘。對映異構體分離之總溶離時間為14.3分鐘。在樣本濃度為11 mg/mL(在甲醇中)下,使用疊加注射法,伴隨4.8分鐘之循環時間及0.3分鐘之間隔進行總共六十一次50 μL注射。藉由監測214 nm下之UV吸附收集樣本。峰-1 (快速溶離峰)對應於(
S)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺,而峰-2 (緩慢溶離峰)對應於(
R)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺。將濃縮各對映異構體之混合溶離份之後獲得之固體溶解於5% MeOH/EtOAc中且通過經EtOAc調節之矽膠。將濾液濃縮物溶解於乙腈/水中且凍乾。對映異構體增濃係在同一儀器上藉由分析方法量測,使用Chiralcel-IA-H,5微米,4.6 × 250 mm,伴隨20%甲醇(0.1% DEA) 80% CO
2作為移動相,以3.0 mL/分鐘之流速溶離,利用濃度為1 mg/mL之15 μL注射液,偵測器UV波長為214 nm。
I-4(
S)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺(白色固體)。98.5% ee。
1H NMR (400 MHz, 氯仿-
d) δ 8.60 (d,
J= 9.0 Hz, 1H), 7.46 - 7.39 (m, 1H), 7.36 - 7.34 (m, 3H), 7.28 (d,
J= 6.9 Hz, 1H), 7.29 - 7.17 (m, 4H), 7.10 (d,
J= 1.4 Hz, 1H), 6.59 (s, 1H), 5.30 (q,
J= 9.5 Hz, 1H), 4.16 (app q,
J= 16.1 Hz, 2H), 2.84 - 2.65 (m, 2H), 2.57 - 2.49 (m, 1H), 2.28 (td,
J= 11.4, 10.9, 7.0 Hz, 1H)。LCMS:純度99%, MS (m/e) 385 (M+H)
+。
I-5(
R)-5-苯甲基-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺(白色固體)。98.8% ee。
1H NMR (400 MHz, 氯仿-
d) δ 8.59 (d,
J= 9.0 Hz, 1H), 7.44 - 7.39 (m, 1H), 7.36 - 7.33 (m, 3H), 7.30 - 7.21 (m, 5H), 7.10 (d,
J= 1.4 Hz, 1H), 6.61 (s, 1H), 5.36 - 5.15 (m, 1H), 4.16 (app q,
J= 16.0 Hz, 2H), 2.88 - 2.63 (m, 2H), 2.57 - 2.48 (m, 1H), 2.27 (td,
J= 11.4, 11.0, 7.0 Hz, 1H)。LCMS:純度99%, MS (m/e) 385 (M+H)
+。
I-12(
R)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺及
I-13(
S)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯
(±)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺之對掌性分離係在裝配有Chiralcel OJ-H,10微米,10 × 250 mm管柱之Thar SFC儀器上進行。移動相為27%異丙醇(0.1% DEA)及73% CO
2,總流速為10.0 mL/分鐘。對映異構體分離之總溶離時間為12分鐘。在樣本濃度為25 mg/mL(在甲醇中)下,使用疊加注射法,伴隨五分鐘之循環時間及0.25分鐘之間隔進行總共六十一次40 μL注射。藉由監測214 nm下之UV吸附收集樣本。峰-1 (快速溶離峰)對應於(
R)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺,而峰-2 (緩慢溶離峰)對應於(
S)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺。將濃縮各對映異構體之混合溶離份之後獲得之固體溶解於EtOAc中且通過經EtOAc調節之矽膠。使溶解於乙腈/水中之濾液之濃縮物經歷凍乾製程。對映異構體增濃係在同一儀器上藉由分析方法量測,使用Chiralcel-OJ-H,5微米,4.6 × 250 mm,伴隨27%異丙醇(0.1% DEA) 73% CO
2作為移動相,以3.0 mL/分鐘之流速溶離,利用濃度為1 mg/mL之10 μL注射液,偵測器UV波長為214 nm。
I-12 :(
R)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺(白色固體)。98.9% ee。
1H NMR (400 MHz, 氯仿-
d) δ 8.45 (d,
J= 7.6 Hz, 1H), 7.95 (s, 1H), 7.46 - 7.26 (m, 7H), 7.20 (s, 1H), 7.14 (s, 1H), 5.71 (s, 2H), 5.14 (q,
J= 8.3 Hz, 1H), 3.11 - 2.96 (m, 1H), 2.70 (dd,
J= 13.7, 6.5 Hz, 1H), 2.60 (td,
J= 13.2, 7.4 Hz, 1H), 2.18 - 2.10 (m, 1H)。LCMS:純度99%, MS (m/e) 454 (M+H)
+。
I-13:(
S)-1-(2,6-二氯苯甲基)-
N-(5,6-二氫-4H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺(白色固體)。99.6% ee。
1H NMR (400 MHz, 氯仿-
d) δ 8.47 (d,
J= 7.7 Hz, 1H), 7.94 (s, 1H), 7.46 - 7.37 (m, 2H), 7.41 - 7.27 (m, 5H), 7.19 (d,
J= 1.4 Hz, 1H), 7.14 (d,
J= 1.4 Hz, 1H), 5.71 (s, 2H), 5.15 (dt,
J= 10.5, 7.7 Hz, 1H), 3.10 - 2.95 (m, 1H), 2.75 - 2.53 (m, 2H), 2.21 - 2.11 (m, 1H)。LCMS:純度99%, MS (m/e) 454 (M+H)
+。
I-91(
S)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺及
I-92(
R)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
在裝配有Chiralcel OJ-H,10微米,10 × 250 mm管柱之Thar SFC儀器上進行對掌性分離。移動相為18%甲醇(0.1% DEA)及82% CO
2,總流速為10.0 mL/分鐘。對映異構體分離之總溶離時間為11.3分鐘。在樣本濃度為17 mg/mL(在甲醇中)下,使用疊加注射法,伴隨2.9分鐘之循環時間及0.3分鐘之間隔進行總共四十次50 μL注射。藉由監測214 nm下之UV吸附收集樣本。峰-1 (快速溶離峰)對應於(
S)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺,而峰-2 (緩慢溶離峰)對應於(
R)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺。濃縮溶解於少量乙腈中之各對映異構體之混合溶離份之後獲得固體且用水稀釋。抽吸過濾沈澱懸浮液,且由此乾燥所收集之固體,得到各別化合物。對映異構體增濃係在同一儀器上藉由分析方法量測,使用Chiralcel-OJ-H,5微米,4.6 × 250 mm,伴隨18%甲醇(0.1% DEA) 82% CO
2作為移動相,以3.0 mL/分鐘之流速溶離,利用濃度為1 mg/mL之10 μL注射液,偵測器UV波長為214 nm。
I-91 :(
S)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺(白色固體)。99.7% ee。
1H NMR (400 MHz, 甲醇-
d 4) δ 7.67 (d,
J= 1.9 Hz, 1H), 7.58 (d,
J= 1.5 Hz, 1H), 7.39 (dd,
J= 8.3, 1.9 Hz, 1H), 7.36 - 7.18 (m, 6H), 7.10 (d,
J= 1.5 Hz, 1H), 5.56 (dd,
J= 9.0, 6.2 Hz, 1H), 4.67 (dd,
J= 11.0, 6.2 Hz, 1H), 4.49 (dd,
J= 10.9, 9.0 Hz, 1H), 4.15 (s, 2H), 1.56 (s, 6H)。純度99%, MS (m/e) 469 (M+H)
+。
I-92 :(
R)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]咪唑并[1,2-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺(白色固體)。99.7% ee。
1H NMR (400 MHz, 甲醇-
d 4) δ 7.67 (d,
J= 1.9 Hz, 1H), 7.58 (d,
J= 1.6 Hz, 1H), 7.40 (dd,
J= 8.3, 1.9 Hz, 1H), 7.33 - 7.20 (m, 6H), 7.11 (d,
J= 1.5 Hz, 1H), 5.56 (dd,
J= 9.0, 6.2 Hz, 1H), 4.67 (dd,
J= 11.0, 6.2 Hz, 1H), 4.50 (dd,
J= 10.9, 9.0 Hz, 1H), 4.15 (s, 2H), 1.56 (s, 6H)。純度95%, MS (m/e) 469 (M+H)
+。
I-60 :(±)-1-(2,6-二氯苯甲基)-
N-(2-甲基-1-側氧基-2,4,5,6-四氫-1
H-苯并[
f][1,2,4]三唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
在氮氣下在室溫下將碘甲烷(2.6 µL,6 mg,0.042 mmol)一次性添加至(±)-5-苯甲基-
N-(1-側氧基-5,6-二氫-1
H,4
H-苯并[
f][1,2,4]㗁二唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺(15 mg, 0.032 mmol)及Cs
2CO
3(11 mg, 0.033 mmol)於無水DMF (0.2 mL)中之攪拌均質懸浮液中。將反應混合物攪拌1天,用水(1 mL)稀釋且過濾。因此,將抽吸乾燥後收集之固體溶解於CH
2Cl
2中,裝載至矽膠管柱上,藉由急驟層析[Combiflash
®Teledyne RediSep
®50% EtOAc/己烷調節之矽膠管柱(4 G Gold)。且用50-100% EtOAc/己烷溶劑溶離]純化,且獲得呈白色固體狀之(±)-1-(2,6-二氯苯甲基)-
N-(2-甲基-1-側氧基-2,4,5,6-四氫-1
H-苯并[
f][1,2,4]三唑并[4,3-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺(11 mg)。
1H NMR (400 MHz, 氯仿-
d) δ 7.96 (s, 1H), 7.76 (d,
J= 8.4 Hz, 1H), 7.60 (dt,
J= 7.9, 1.0 Hz, 1H), 7.45 - 7.25 (m, 6H), 5.70 (s, 2H), 5.08 (dt,
J= 10.2, 8.1 Hz, 1H), 3.52 (s, 3H), 2.90 - 2.75 (m, 1H), 2.74 - 2.71 (m, 2H), 2.12 - 2.00 (m, 1H)。純度96%, MS (m/e) 485 (M+H)
+。
I-70(±)-5-苯甲基-
N-(1,2-二氯-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)異㗁唑-3-甲醯
1H NMR (400 MHz, 氯仿-
d) δ 7.83 (d,
J= 7.8 Hz, 1H), 7.49 - 7.20 (m, 9H), 6.32 (d,
J= 0.9 Hz, 1H), 4.99 (dt,
J= 10.7, 7.7 Hz, 1H), 4.11 (s, 2H), 2.94 - 2.79 (m, 1H), 2.76 - 2.66 (m, 1H), 2.61 - 2.52 (m, 1H), 2.17 - 2.04 (m, 1H)。純度97%, MS (m/e) 454 (M+H)
+。
I-71(±)-5-苯甲基-N-(1-氯-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)異㗁唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.02 (d,
J= 7.6 Hz, 1H), 7.47 - 7.19 (m, 9H), 7.04 (s, 1H), 6.33 (s, 1H), 4.95 (dt,
J= 10.6, 7.7 Hz, 1H), 4.11 (s, 2H), 2.96 - 2.81 (m, 1H), 2.74 - 2.64 (m, 1H), 2.59 - 2.50 (m, 1H), 2.15 - 2.02 (m, 1H)。純度93%, MS (m/e) 420 (M+H)
+。
I-73(±)-
N-(1,2-二氯-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1-(2,6-二氯苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.17 (d,
J= 8.0 Hz, 1H), 7.96 (s, 1H), 7.48 - 7.37 (m, 6H), 7.41 - 7.29 (m, 1H), 5.72 (s, 2H), 5.07 (dt,
J= 10.6, 7.8 Hz, 1H), 3.00 - 2.85 (m, 1H), 2.75 - 2.65 (m, 1H), 2.63 - 2.49 (m, 1H), 2.16 - 2.05 (m, 1H)。純度95%, MS (m/e) 523 (M+H)
+。
I-74(±)-
N-(1-氯-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-
a]氮呯-4-基)-1-(2,6-二氯苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 氯仿-
d) δ 8.36 (d,
J= 7.8 Hz, 1H), 7.94 (s, 1H), 7.46 - 7.33 (m, 6H), 7.32 (dd,
J= 8.9, 7.1 Hz, 1H), 7.05 (s, 1H), 5.71 (s, 2H), 5.03 (dt,
J= 10.5, 7.8 Hz, 1H), 3.01 - 2.87 (m, 1H), 2.73 - 2.63 (m, 1H), 2.58 - 2.50 (app m, 1H), 2.14 - 2.02 (m, 1H)。純度90%, MS (m/e) 489 (M+H)
+。
I-80(±)-5-苯甲基-
N-(1,2-二氯-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.56 - 7.43 (m, 4H), 7.36 - 7.20 (m, 5H), 4.95 - 4.86 (app m, 1H), 4.18 (s, 2H), 2.87 - 2.78 (m, 1H), 2.70 - 2.49 (m, 2H), 2.37 - 2.30 (m, 1H)。純度94%, MS (m/e) 454 (M+H)
+。
I-81(±)-5-苯甲基-
N-(1-氯-5,6-二氫-4
H-苯并[
f]咪唑并[1,2-a]氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, 甲醇-
d 4) δ 7.58 - 7.41 (m, 4H), 7.38 - 7.18 (m, 5H), 7.03 (s, 1H), 4.89 (app dd,
J= 11.2, 7.7 Hz, 1H), 4.17 (s, 2H), 2.81 (dd,
J= 13.4, 6.2 Hz, 1H), 2.63 (tt,
J= 13.0, 6.8 Hz, 1H), 2.48 (td,
J= 13.0, 7.2 Hz, 1H), 2.31 (td,
J= 11.7, 7.0 Hz, 1H)。純度93%, MS (m/e) 420 (M+H)
+。
I-751-苯甲基-5-羥基-
N-((4
R)-1-側氧基-4,5-二氫-1H-苯并[b][1,2,4]㗁二唑并[4,3-d][1,4]㗁氮呯-4-基)-1H-吡唑-3-甲醯胺
1H NMR (400 MHz, CD
3OD) δ 7.71 (d,
J= 8.0 Hz, 1H), 7.52 - 7.15 (m, 9H), 5.46 (dd,
J= 9.5, 7.9 Hz, 1H), 5.18 (s, 2H), 4.65 - 4.48 (m, 2H)。
13C NMR (100 MHz, CD
3OD) δ 164.6, 158.5, 158.1, 154.9, 150.9, 144.4, 138.2, 131.1, 129.6, 129.6, 128.7, 128.5, 127.3, 127.1, 125.0, 124.2, 75.6, 51.6, 45.8. MS (ESI,
m/e) 計算值419.1230; 實測值420 [M+H]
+。
I-76(
R)-1-苯甲基-5-羥基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]㗁氮呯-4-基)-1
H-吡唑-3-甲醯胺
1H NMR (400 MHz, CD
3OD) δ 8.31 (d,
J= 8.5 Hz, 1H), 7.41 - 7.13 (m, 8H), 5.91 (dd,
J= 6.4, 4.3 Hz, 1H), 5.14 (s, 2H), 4.56 - 4.39 (m, 2H), 1.57 (s, 6H)。
13C NMR (100 MHz, CD
3OD) δ 164.3, 155.2, 155.1, 151.3, 144.7, 138.2, 129.6, 128.9, 128.6, 128.5, 127.7, 126.5, 126.3, 123.7, 97.8, 80.7, 72.1, 65.8, 51.5, 47.1, 31.5. MS (ESI,
m/e) 計算值485.1812; 實測值486 [M+H]
+。
I-3(
R)-5-苯甲基-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 8.31 (dd,
J= 8.2, 1.6 Hz, 1H), 7.56 - 7.15 (m, 8H), 5.91 (td,
J= 7.2, 3.9 Hz, 1H), 4.50 (dd,
J= 12.3, 4.0 Hz, 1H), 4.39 (dd,
J= 12.3, 6.8 Hz, 1H), 4.12 (s, 2H)。MS (ESI,
m/e) 計算值388.1396; 實測值389.0 [M+H]
+。
I-8(
R)-5-苯甲基-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]㗁氮呯-4-基)異㗁唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.61 (d,
J= 8.1 Hz, 1H), 8.33 (dd,
J= 8.2, 1.6 Hz, 1H), 7.57 - 7.18 (m, 8H), 6.61 (d,
J= 0.8 Hz, 1H), 5.91 (ddd,
J= 8.2, 5.7, 3.7 Hz, 1H), 4.58 - 4.36 (m, 2H), 4.23 (s, 2H)。MS (ESI,
m/e) 計算值388.1284; 實測值389.0 [M+H]
+。
I-10(
R)-1-(2,6-
二氯苯甲基 )-
N-(4,5-
二氫苯并 [
b]
四唑并 [1,5-
d][1,4]
㗁氮呯 -4- 基 )-1
H-1,2,4-
三唑 -5- 甲醯胺 MS (ESI,
m/e) 計算值456.0617; 實測值457.0 [M+H]
+, 455.0 [M-H]
-。
I-11(
R)-1-(2,6-二氯苯甲基)-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.35 (d,
J= 8.3 Hz, 1H), 8.84 (s, 1H), 8.31 (dd,
J= 8.2, 1.6 Hz, 1H), 7.62 - 7.26 (m, 5H), 5.87 (ddd,
J= 8.4, 6.8, 4.0 Hz, 1H), 5.71 (s, 2H), 4.58 - 4.30 (m, 2H)。MS (ESI,
m/e) 計算值456.0617; 實測值457.0 [M+H]
+, 455.0 [M-H]
-。
I-20(
R)-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]㗁氮呯-4-基)-1-(2,6-二甲基苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.33 (d,
J= 8.3 Hz, 1H), 8.66 (s, 1H), 8.31 (dd,
J= 8.3, 1.5 Hz, 1H), 7.47 (ddd,
J= 8.1, 7.4, 1.7 Hz, 1H), 7.38 (ddd,
J= 8.2, 7.3, 1.5 Hz, 1H), 7.31 (dd,
J= 8.1, 1.5 Hz, 1H), 7.17 (dd, J = 8.3, 6.7 Hz,
1H), 7.08 (d,
J= 7.5 Hz, 2H), 5.87 (ddd,
J= 8.3, 6.9, 4.1 Hz, 1H), 5.48 (s, 2H), 4.49 (dd,
J= 12.3, 4.1 Hz, 1H), 4.37 (dd,
J= 12.3, 6.9 Hz, 1H), 2.35 (s, 6H)。MS (ESI,
m/e) 計算值416.1709; 實測值417.1 [M+H]
+, 415.1 [M-H]
-。
I-21(
R)-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]㗁氮呯-4-基)-1-(2-氟苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.37 (d,
J= 8.3 Hz, 1H), 8.83 (s, 1H), 8.31 (dd,
J= 8.2, 1.6 Hz, 1H), 7.51 - 7.29 (m, 5H), 7.29 - 7.18 (m, 2H), 5.90 (ddd,
J= 8.4, 6.7, 4.0 Hz, 1H), 5.56 (s, 2H), 4.50 (dd,
J= 12.3, 4.0 Hz, 1H), 4.38 (dd,
J= 12.3, 6.7 Hz, 1H)。MS (ESI,
m/e) 計算值406.1302; 實測值407.0 [M+H]
+, 405.0 [M-H]
-。
I-41 5- 苯甲基 -
N-((4
R)-1-
側氧基 -4,5- 二氫 -1
H-
苯并 [
b][1,2,4]
㗁二唑并 [4,3-
d][1,4]
㗁氮呯 -4- 基 )-1
H-1,2,4-
三唑 -3- 甲醯胺 1H NMR (400 MHz, DMSO-
d
6 ) δ 9.23 (br s, 1H), 7.73 (dd,
J= 7.9, 1.7 Hz, 1H), 7.49 (td,
J= 7.7, 1.8 Hz, 1H), 7.43 (td,
J= 7.7, 1.6 Hz, 1H), 7.38 (dd,
J= 7.9, 1.6 Hz, 1H), 7.33 (t,
J= 7.4 Hz, 2H), 7.26 (dt,
J= 8.1, 1.8 Hz, 3H), 5.46 - 5.33 (m, 1H), 4.83 - 4.71 (m, 1H), 4.54 (dd,
J= 10.5, 8.0 Hz, 1H), 4.13 (s, 2H)。MS (ESI,
m/e) 計算值404.1233; 實測值405.0 [M+H]
+, 403.0 [M-H]
-。
I-42 1-(2,6- 二氯苯甲基 )-
N-((4
R)-1-
側氧基 -4,5- 二氫 -1
H-
苯并 [
b][1,2,4]
㗁二唑并 [4,3-
d][1,4]
㗁氮呯 -4- 基 )-1
H-1,2,4-
三唑 -3- 甲醯胺 1H NMR (400 MHz, DMSO-
d
6 ) δ 9.25 (d,
J= 8.5 Hz, 1H), 8.88 (s, 1H), 7.73 (dd,
J= 7.9, 1.7 Hz, 1H), 7.58 (d,
J= 1.1 Hz, 1H), 7.56 (s, 1H), 7.51 - 7.45 (m, 2H), 7.42 (td,
J= 7.7, 1.6 Hz, 1H), 7.37 (dd,
J= 7.9, 1.6 Hz, 1H), 5.71 (s, 2H), 5.38 (dt,
J= 9.7, 8.1 Hz, 1H), 4.74 (t,
J= 10.2 Hz, 1H), 4.53 (dd,
J= 10.6, 7.9 Hz, 1H)。MS (ESI,
m/e) 計算值472.0454; 實測值473.0 [M+H]
+, 471.0 [M-H]
-。
I-435-苯甲基-
N-((4
R)-1-側氧基-4,5-二氫-1
H-苯并[
b][1,2,4]㗁二唑并[4,3-
d][1,4]㗁氮呯-4-基)異㗁唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.52 (d,
J= 8.2 Hz, 1H), 7.72 (dd,
J= 7.8, 1.7 Hz, 1H), 7.49 (td,
J= 7.7, 1.8 Hz, 1H), 7.43 (td,
J= 7.7, 1.6 Hz, 1H), 7.40 - 7.35 (m, 2H), 7.34 (t,
J= 1.4 Hz, 1H), 7.32 - 7.25 (m, 3H), 6.59 (d,
J= 0.8 Hz, 1H), 5.41 (dt,
J= 9.5, 8.1 Hz, 1H), 4.66 (dd,
J= 10.7, 9.6 Hz, 1H), 4.59 (dd,
J= 10.7, 8.0 Hz, 1H), 4.23 (s, 2H)。MS (ESI,
m/e) 計算值404.1121; 實測值405.0 [M+H]
+, 403.0 [M-H]
-。
I-495-(2,4-二氟苯甲基)-
N-((4
R)-1-側氧基-4,5-二氫-1
H-苯并[
b][1,2,4]㗁二唑并[4,3-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 7.74 (dd,
J= 7.8, 1.8 Hz, 1H), 7.63 (dd,
J= 7.9, 1.7 Hz, 1H), 7.52 - 7.46 (m, 1H), 7.45 - 7.42 (m, 2H), 7.38 (dd,
J= 7.7, 1.5 Hz, 2H), 7.33 (dd,
J= 7.9, 1.6 Hz, 1H), 5.45 - 5.35 (m, 1H), 4.75 (t,
J= 10.2 Hz, 1H), 4.58 - 4.51 (m, 1H), 4.25 - 4.16 (m, 2H)。MS (ESI,
m/e) 計算值440.1045; 實測值441.2 [M+H]
+。
I-50 5-(4- 氟苯甲基 )-
N-((4
R)-1-
側氧基 -4,5- 二氫 -1
H-
苯并 [
b][1,2,4]
㗁二唑并 [4,3-
d][1,4]
㗁氮呯 -4- 基 )-1
H-1,2,4-
三唑 -3- 甲醯胺 1H NMR (400 MHz, DMSO-
d
6 ) δ 9.18 (br s, 1H), 7.74 (dd,
J= 7.9, 1.7 Hz, 1H), 7.50 (dd,
J= 7.7, 1.8 Hz, 1H), 7.46 (dd,
J= 10.1, 1.8 Hz, 1H), 7.42 (dd,
J= 7.6, 1.6 Hz, 1H), 7.38 (dd,
J= 7.9, 1.6 Hz, 1H), 7.31 (ddd,
J= 8.5, 5.7, 2.7 Hz, 2H), 7.20 - 7.10 (m, 2H), 5.41 (dt,
J= 9.8, 8.1 Hz, 1H), 4.76 (t,
J= 10.2 Hz, 1H), 4.54 (dd,
J= 10.6, 7.8 Hz, 1H), 4.14 (s, 2H)。MS (ESI,
m/e) 計算值422.1139; 實測值423.2 [M+H]
+。
I-53 N-((4
R)-1-側氧基-4,5-二氫-1
H-苯并[
b][1,2,4]㗁二唑并[4,3-
d][1,4]㗁氮呯-4-基)-4-苯氧基吡啶甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.52 (d,
J= 8.5 Hz, 1H), 8.59 (d,
J= 5.6 Hz, 1H), 7.74 (dd,
J= 7.9, 1.7 Hz, 1H), 7.55 - 7.50 (m, 2H), 7.48 (dd,
J= 7.7, 1.8 Hz, 1H), 7.42 (td,
J= 7.7, 1.6 Hz, 1H), 7.39 - 7.31 (m, 3H), 7.26 - 7.21 (m, 3H), 5.42 (dt,
J= 9.7, 8.1 Hz, 1H), 4.81 (dd,
J= 10.7, 9.7 Hz, 1H), 4.55 (dd,
J= 10.6, 7.8 Hz, 1H)。MS (ESI,
m/e) 計算值416.1121; 實測值417.3 [M+H]
+。
I-69(
R)-5-苯甲基-
N-(9-(3-羥基-3-甲基丁-1-炔-1-基)-4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]㗁氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.30 (s, 1H), 8.29 (d,
J= 8.5 Hz, 1H), 7.37 (dd,
J= 8.6, 1.9 Hz, 1H), 7.34 - 7.27 (m, 2H), 7.24 (d,
J= 7.4 Hz, 3H), 5.90 (ddd,
J= 8.3, 6.3, 3.7 Hz, 1H), 4.49 (dd,
J= 12.4, 3.7 Hz, 1H), 4.40 (dd,
J= 12.4, 6.4 Hz, 1H), 4.11 (s, 2H), 1.47 (s, 6H)。MS (ESI,
m/e) 計算值470.1815; 實測值471.1 [M+H]
+, 469.1 [M-H]
-。
I-79(
R)-2-苯甲基-3-氯-5-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]㗁氮呯-4-基)-4,5-二氫吡咯并[3,4-
c]吡唑-6(2
H)-酮
1H NMR (400 MHz, DMSO-
d
6 ) δ 8.32 (dd,
J= 8.2, 1.6 Hz, 1H), 7.53 - 7.47 (m, 1H), 7.44 - 7.29 (m, 5H), 7.27 - 7.23 (m, 2H), 6.07 (dd,
J= 5.4, 4.0 Hz, 1H), 5.52 (s, 2H), 4.74 (dd,
J= 12.7, 5.5 Hz, 1H), 4.62 (dd,
J= 12.6, 4.0 Hz, 1H), 4.58 - 4.26 (m, 2H)。MS (ESI,
m/e) 計算值433.1054; 實測值434.0 [M+H]
+。
(
R)-(4,5-
二氫苯并 [
b]
四唑并 [1,5-
d][1,4]
噻氮呯 -4- 基 ) 胺基甲酸三級丁酯 ( 中間物 ) MS (ESI,
m/e) 計算值319.1103; 實測值342.1 [M+Na]
+, 264.1 [M-56+H]
+。
I-22(
R)-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]噻氮呯-4-基)-1-(4-氟苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.52 (d,
J= 8.2 Hz, 1H), 8.81 (s, 1H), 8.00 (dd,
J= 8.1, 1.3 Hz, 1H), 7.82 (dd,
J= 7.7, 1.5 Hz, 1H), 7.71 (ddd,
J= 8.0, 7.5, 1.5 Hz, 1H), 7.58 (td,
J= 7.6, 1.4 Hz, 1H), 7.45 - 7.30 (m, 2H), 7.27 - 7.14 (m, 2H), 5.75 (ddd,
J= 11.0, 8.3, 7.4 Hz, 1H), 5.47 (s, 2H), 3.69 (dd,
J= 13.4, 7.4 Hz, 1H), 3.30 - 3.16 (m, 1H)。MS (ESI,
m/e) 計算值422.1074; 實測值423.2 [M+H]
+。
I-23(
R)-5-苯甲基-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]噻氮呯-4-基)異㗁唑-3-甲醯胺
1H NMR (400 MHz, CDCl
3 ) δ 8.00 (d,
J= 8.1 Hz, 1H), 7.88 (dd,
J= 8.0, 1.4 Hz, 1H), 7.80 (dd,
J= 7.7, 1.5 Hz, 1H), 7.62 (td,
J= 7.7, 1.5 Hz, 1H), 7.51 (td,
J= 7.7, 1.4 Hz, 1H), 7.37 - 7.27 (m, 3H), 7.25 - 7.21 (m, 2H), 5.66 (ddd,
J= 10.0, 8.0, 6.7 Hz, 1H), 4.11 (s, 2H), 3.93 (dd,
J= 12.6, 6.7 Hz, 1H), 3.27 (dd,
J= 12.6, 10.0 Hz, 1H)。MS (ESI,
m/e) 計算值404.1055; 實測值405.2 [M+H]
+, 427.2 [M+Na]
+。
I-24(
R)-5-苯甲基-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]噻氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, CD
3 OD) δ 7.98 (dd,
J= 8.1, 1.4 Hz, 1H), 7.84 (dd,
J= 7.7, 1.4 Hz, 1H), 7.74 - 7.64 (m, 1H), 7.56 (td,
J= 7.6, 1.4 Hz, 1H), 7.35 - 7.18 (m, 5H), 5.72 (dd,
J= 10.5, 7.1 Hz, 1H), 4.15 (s, 2H), 3.77 (dd,
J= 13.3, 7.1 Hz, 1H), 3.38 (dd,
J= 13.3, 10.5 Hz, 1H)。MS (ESI,
m/e) 計算值404.1168; 實測值405.2 [M+H]
+。
I-25(
R)-5-苯甲基-
N-(6,6-二氧離子基-4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]噻氮呯-4-基)異㗁唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.80 (d,
J= 6.9 Hz, 1H), 8.22 - 8.07 (m, 3H), 7.95 (ddd,
J= 7.8, 6.7, 2.0 Hz, 1H), 7.40 - 7.24 (m, 5H), 6.54 (s, 1H), 5.93 (td,
J= 8.7, 6.9 Hz, 1H), 4.54 (dd,
J= 13.9, 8.3 Hz, 1H), 4.38 (dd,
J= 13.9, 9.2 Hz, 1H), 4.23 (s, 2H)。MS (ESI,
m/e) 計算值436.0954; 實測值437.2 [M+H]
+。
I-265-苯甲基-
N-((4
R)-6-氧離子基-4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]噻氮呯-4-基)異㗁唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.83 (d,
J= 7.8 Hz, 1H), 8.05 (dd,
J= 7.8, 1.3 Hz, 1H), 8.02 - 7.92 (m, 2H), 7.83 (td,
J= 7.6, 1.2 Hz, 1H), 7.42 - 7.23 (m, 5H), 6.57 (d,
J= 0.8 Hz, 1H), 5.81 (dt,
J= 9.8, 8.0 Hz, 1H), 4.23 (s, 2H), 4.19 (dd,
J= 13.9, 8.0 Hz, 1H), 3.88 (dd,
J= 13.9, 9.9 Hz, 1H)。MS (ESI,
m/e) 計算值420.1005; 實測值421.0 [M+H]
+, 443.0 [M+Na]
+。
I-285-苯甲基-
N-((4
R)-1-側氧基-4,5-二氫-1
H-苯并[
b][1,2,4]㗁二唑并[4,3-
d][1,4]噻氮呯-4-基)異㗁唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.63 (d,
J= 7.7 Hz, 1H), 7.82 (dd,
J= 7.7, 1.4 Hz, 1H), 7.76 (dd,
J= 8.0, 1.5 Hz, 1H), 7.70 (td,
J= 7.7, 1.5 Hz, 1H), 7.55 (td,
J= 7.5, 1.6 Hz, 1H), 7.39 - 7.25 (m, 5H), 6.54 (d,
J= 0.8 Hz, 1H), 5.05 (dt,
J= 10.1, 7.7 Hz, 1H), 4.22 (s, 2H), 3.74 (dd,
J= 12.1, 7.7 Hz, 1H), 3.44 (dd,
J= 12.1, 10.1 Hz, 1H)。MS (ESI,
m/e) 計算值420.0892; 實測值421.2 [M+H]
+。
I-30(
R)-
N-(4,5-二氫苯并[
b]四唑并[1,5-
d][1,4]噻氮呯-4-基)-5-(4-氟苯甲基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, CD
3 OD) δ 7.98 (dd,
J= 8.0, 1.4 Hz, 1H), 7.84 (dd,
J= 7.7, 1.5 Hz, 1H), 7.69 (td,
J= 7.8, 1.5 Hz, 1H), 7.57 (td,
J= 7.6, 1.4 Hz, 1H), 7.38 - 7.22 (m, 2H), 7.04 (t,
J= 8.8 Hz, 2H), 5.72 (dd,
J= 10.5, 7.1 Hz, 1H), 4.15 (s, 2H), 3.77 (dd,
J= 13.3, 7.1 Hz, 1H), 3.38 (dd,
J= 13.3, 10.5, 1H)。MS (ESI,
m/e) 計算值422.1074; 實測值421.3 [M-H]
-。
I-315-(4-氟苯甲基)-
N-((4
R)-1-側氧基-4,5-二氫-1
H-苯并[
b][1,2,4]㗁二唑并[4,3-
d][1,4]噻氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, CD
3 OD) δ 7.83 (dd,
J= 7.7, 1.4 Hz, 1H), 7.71 (dd,
J= 8.0, 1.5 Hz, 1H), 7.69 - 7.63 (m, 1H), 7.51 (td,
J= 7.5, 1.6 Hz, 1H), 7.33 - 7.27 (m, 2H), 7.10 - 7.01 (m, 2H), 5.15 (dd,
J= 10.3, 7.6 Hz, 1H), 4.15 (s, 2H), 3.78 (dd,
J= 12.1, 7.6 Hz, 1H), 3.35 (dd,
J= 12.1, 10.3 Hz, 1H)。MS (ESI,
m/e) 計算值438.0910; 實測值439.2 [M+H]
+。
I-321-(4-氟苯甲基)-N-((4R)-1-側氧基-4,5-二氫-1H-苯并[b][1,2,4]㗁二唑并[4,3-d][1,4]噻氮呯-4-基)-1H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, DMSO-
d
6 ) δ 9.36 (d,
J= 8.2 Hz, 1H), 8.83 (s, 1H), 7.82 (dd,
J= 7.7, 1.4 Hz, 1H), 7.76 (dd,
J= 8.0, 1.5 Hz, 1H), 7.73 - 7.67 (m, 1H), 7.55 (td,
J= 7.5, 1.6 Hz, 1H), 7.41 - 7.35 (m, 2H), 7.25 - 7.18 (m, 2H), 5.48 (s, 2H), 5.04 (dt,
J= 10.2, 7.9 Hz, 1H), 3.70 (dd,
J= 12.0, 7.8 Hz, 1H), 3.57 (dd,
J= 12.0, 10.3 Hz, 1H)。MS (ESI,
m/e) 計算值438.0910; 實測值439.2 [M+H]
+。
I-335-苯甲基-
N-((4
R)-1-側氧基-4,5-二氫-1
H-苯并[
b][1,2,4]㗁二唑并[4,3-
d][1,4]噻氮呯-4-基)-1
H-1,2,4-三唑-3-甲醯胺
1H NMR (400 MHz, CD
3 OD) δ 7.83 (dd,
J= 7.7, 1.5 Hz, 1H), 7.71 (dd,
J= 8.0, 1.6 Hz, 1H), 7.65 (td,
J= 7.7, 1.5 Hz, 1H), 7.51 (td,
J= 7.5, 1.6 Hz, 1H), 7.35 - 7.22 (m, 5H), 5.15 (dd,
J= 10.3, 7.6 Hz, 1H), 4.17 (s, 2H), 3.78 (dd,
J= 12.1, 7.5 Hz, 1H), 3.35 (dd,
J= 12.1, 10.3 Hz, 1H)。MS (ESI,
m/e) 計算值420.1005; 實測值421.2 [M+H]
+。
I-465-苯甲基-
N-((4
R)-1-側氧基-4,5-二氫-1
H-[1,2,4]㗁二唑并[4,3-
d]吡啶并[2,3-
b][1,4]㗁氮呯-4-基)異㗁唑-3-甲醯胺
MS (ESI,
m/e) 計算值405.1073; 實測值406.1 [M+H]
+。
可使用以下分析鑑別及評估本文所揭示之化合物。
生物活性之鑑別在此實例中,使用利用ADP-Glo
TM技術之生物化學分析評估本發明化合物。
在環境溫度下對ADP-Glo™ (Promega, Madison, WI, USA)試劑進行解凍。藉由將激酶偵測緩衝液與凍乾激酶偵測受質混合來製備激酶偵測試劑。
藉由混合1000µl之1M MgCl
2、500µl之1M Tris-HCL pH 7.4、0.5 mg/ml (25 mg)之BSA及3475 µl之蒸餾H
2O製得500 ml儲備體積之5×反應激酶緩衝液。製得3 ml 2×工作儲備體積之反應激酶緩衝液,其含有100 µM DTT及4 mM MnCl
2之最終濃度。
在冰上對RIPK1酶(Rigel Pharmaceuticals, South San Francisco, CA, USA)之組分進行解凍。在1×激酶反應緩衝液(自2×緩衝液稀釋)中製備經稀釋之RIPK1直至31 ng/孔。在1×激酶反應緩衝液(自2×緩衝液稀釋)中製備166 μM工作儲備ATP分析溶液。
將化合物在DMSO中自250 μM開始以4倍稀釋度連續稀釋,隨後在96孔盤中在2×反應緩衝液中按1:5稀釋。一式兩份地將1.0 μl稀釋化合物添加至384孔盤中。將2 μl經稀釋之活性RIPK1添加至384孔盤(不添加至管柱1),將2×反應緩衝液添加至管柱1。將150 nM之AKT (Anaspec, Fremont, CA, USA)與相等體積之ATP工作儲備液合併且向384孔盤中每孔添加2 μl。最終反應體積為5.0 µl。
快速離心培養盤且在30℃下培育反應物30分鐘。添加5 µl ADP-Glo
TM,終止反應。快速離心培養盤且在室溫下培育反應物40分鐘。隨後添加激酶偵測試劑且在室溫下培育30分鐘。藉由發光(螢光0.1s),使用Wallac Victor2光度計(PerkinElmer, Waltham, MA, USA)測定激酶反應之相對光單位(RLU)。由此實例獲得之IC
50值係由表2提供。表2中之資料確定本發明化合物抑制RIP1K。
表 2 | |
化合物 | RIPK1 ADP-Glo 激酶 (IC 50) |
I-1 | 0.0676 |
I-2 | 6.23 |
I-3 | 0.0582 |
I-4 | 0.0545 |
I-5 | 7.628 |
I-6 | 未測定 |
I-7 | 0.0225 |
I-8 | 0.5213 |
I-9 | 0.0261 |
I-10 | 未測定 |
I-11 | 0.0178 |
I-12 | 6.712 |
I-13 | 0.0081 |
I-14 | 0.0166 |
I-19 | 0.3929 |
I-20 | 1.871 |
I-21 | 0.0567 |
I-22 | 0.0321 |
I-23 | 0.0429 |
I-24 | 0.0272 |
I-25 | 0.5101 |
I-26 | 1.373 |
I-27 | 0.0684 |
I-28 | 0.0679 |
I-29 | 0.0098 |
I-30 | 0.0186 |
I-31 | 0.0158 |
I-32 | 0.0133 |
I-33 | 0.0125 |
I-34 | 0.1386 |
I-35 | 2.077 |
I-36 | 2.803 |
I-37 | 1.144 |
I-38 | 0.0223 |
I-39 | 1.463 |
I-40 | 未測定 |
I-41 | 0.058 |
I-42 | 0.0263 |
I-43 | 0.1098 |
I-44 | 0.9471 |
I-45 | 0.0312 |
I-46 | 4.408 |
I-47 | 0.0873 |
I-48 | 0.0534 |
I-49 | 0.347 |
I-50 | 0.1088 |
I-51 | 0.0492 |
I-52 | 0.0325 |
I-53 | 0.0204 |
I-54 | 0.5823 |
I-55 | 0.089 |
I-56 | 0.0561 |
I-57 | 0.663 |
I-58 | 0.0573 |
I-59 | 0.1182 |
I-60 | 1.289 |
I-61 | 0.0862 |
I-62 | 0.0695 |
I-63 | 0.1335 |
I-64 | 0.1245 |
I-65 | 0.0678 |
I-66 | 13.49 |
I-67 | 11.38 |
I-68 | 0.1178 |
I-69 | 0.0601 |
I-70 | 未測定 |
I-71 | 0.58 |
I-72 | 0.2192 |
I-73 | 0.0924 |
I-74 | 0.054 |
I-75 | 10.57 |
I-76 | 未測定 |
I-77 | 0.1106 |
I-78 | 0.0396 |
I-79 | 0.6523 |
I-80 | 1.874 |
I-81 | 0.5173 |
I-82 | 0.04 |
I-83 | 0.0435 |
I-84 | 0.1185 |
I-85 | 0.1685 |
I-86 | 0.067 |
I-87 | 0.0682 |
I-88 | 0.1119 |
I-89 | 0.1077 |
I-90 | 0.0531 |
I-91 | 未測定 |
I-92 | 0.0282 |
I-93 | 0.0404 |
全細胞分析在此實例中,使U937及L929細胞暴露於本發明化合物,且進行細胞壞死性凋亡分析以評估功能性人類RIP1及鼠類RIP1分析中之化合物活性。
U937及L929細胞係由美國菌種保藏中心(Manassa,VA, USA)獲得。使兩種細胞在完全RPMI 1640培養基(Sigma, ST Louis, MO, USA)中保持對數生長期,該培養基補充有10%胎牛血清(Sigma, ST Louis, MO, USA),在37℃下有5% CO
2。對於壞死性凋亡分析,將L929細胞以10K個細胞/孔接種於Costar 96孔黑色透明底培養盤(Fisher Scientific, Hampton, NH, USA)中之100 μL/孔培養基中持續18小時;在分析當天將U937細胞以50K個細胞/孔塗鋪於含有60 μM zVAD-fmk (Lonza, Basel, Switzerland)之50 μL/孔培養基中。自96孔盤移除L929細胞之培養基且用50 μL/孔含有40 μM zVAD-fmk之新培養基置換。在此實例中評估之本發明之各化合物在DMSO中自2.5 mM開始以4倍稀釋度連續稀釋,且隨後在完全培養基中按1:125稀釋。隨後將50 μL/孔2×化合物添加至盤中之細胞中。將細胞在37℃下在5% CO
2下與化合物一起預培育1小時且之後添加10 μL/孔 11× TNFa (Peprotech, Rocky Hill, NJ, USA),得到2 ng/mL之TNFa最終濃度。在37℃下在5% CO
2下,進行18小時TNFa刺激之後,藉由發光,使用Wallac Victor2光度計(PerkinElmer, Waltham, MA, USA)及根據製造商說明書添加之CellTiter-Glo® Luminescent Cell Viability Reagent Assay (Promega, Madison, WI, USA)測定壞死性凋亡細胞之相對量。來自此實例之結果概述於表3中。此實例確定本文所述之化合物之實施例針對人類RIP1及鼠類RIP1具有出乎意料之有效活性,其實現在疾病之活體內小鼠模型中進行評定。此等結果適用於測定安全且有效之人類用劑量。
表 3 | ||
化合物 | U937 Zvad TNF CTG 恢復 , U937, TNFa+zVAD (IC 50) | L929-CTG- 恢復 , L929, TNFa+zVAD (IC 50) |
I-1 | 0.3756 | 9999 |
I-2 | 40.27 | 9999 |
I-3 | 4.08 | 9999 |
I-4 | 0.2029 | 9999 |
I-5 | 86.64 | 9999 |
I-6 | 884.7 | 9999 |
I-7 | 0.0137 | 12.7 |
I-8 | 4.445 | 9999 |
I-9 | 0.2216 | 9999 |
I-10 | 5015 | 9999 |
I-11 | 0.0343 | 9999 |
I-12 | 17 | 9999 |
I-13 | 0.003 | 3.375 |
I-14 | 0.0066 | 2.337 |
I-19 | 0.9604 | 9999 |
I-20 | 1.565 | |
I-21 | 0.0625 | 159.8 |
I-22 | 0.002 | 2.485 |
I-23 | 0.1009 | 9999 |
I-24 | 0.0144 | 2.143 |
I-25 | 28.6 | 9999 |
I-26 | 0.1762 | 9999 |
I-27 | 0.034 | 5.55 |
I-28 | 0.0165 | 10.73 |
I-29 | 0.0011 | 0.1945 |
I-30 | 0.0679 | 9999 |
I-31 | 0.014 | 5009 |
I-32 | 0.0016 | 0.6741 |
I-33 | 0.0056 | 5.163 |
I-34 | 1.544 | 9999 |
I-35 | 2.681 | 9999 |
I-36 | 0.7144 | 16.11 |
I-37 | 4.067 | 9999 |
I-38 | 0.0439 | 9.786 |
I-39 | 1.377 | 50.88 |
I-40 | 9999 | 9999 |
I-41 | 0.0481 | 9999 |
I-42 | 0.041 | 9999 |
I-43 | 0.2046 | 9999 |
I-44 | 1.665 | 9999 |
I-45 | 0.0364 | 10.46 |
I-46 | 39.4 | 9999 |
I-47 | 0.0257 | 9.496 |
I-48 | 0.0408 | 9999 |
I-49 | 0.7167 | 9999 |
I-50 | 0.2459 | 9999 |
I-51 | 0.1254 | 17.08 |
I-52 | 0.0647 | 20.75 |
I-53 | 0.0462 | 30.7 |
I-54 | 1.245 | 9999 |
I-55 | 0.0206 | 9.496 |
I-56 | 0.0345 | 5.092 |
I-57 | 3.649 | 9999 |
I-58 | 0.0743 | 9999 |
I-59 | 0.8294 | 9999 |
I-60 | 35.76 | 9999 |
I-61 | 0.0181 | 0.1062 |
I-62 | 0.0301 | 10.13 |
I-63 | 0.2895 | 9999 |
I-64 | 0.0077 | 4.059 |
I-65 | 0.0211 | 3.261 |
I-66 | 9999 | 9999 |
I-67 | 9999 | 9999 |
I-68 | 0.0252 | 8.672 |
I-69 | 0.7868 | 9999 |
I-70 | 73.41 | 9999 |
I-71 | 3.483 | 9999 |
I-72 | 0.7081 | 9999 |
I-73 | 0.9028 | 9999 |
I-74 | 0.0898 | 8.624 |
I-75 | 9999 | 9999 |
I-76 | 9999 | 9999 |
I-77 | 0.0096 | 4.085 |
I-78 | 0.0022 | 0.0061 |
I-79 | 16.06 | 9999 |
I-80 | 83.41 | 9999 |
I-81 | 4.245 | 9999 |
I-82 | 0.0084 | 5.292 |
I-83 | 0.0043 | 2.123 |
I-84 | 0.0386 | 8.786 |
I-85 | 0.0309 | 1.353 |
I-86 | 0.0119 | 3.447 |
I-87 | 0.0156 | 9999 |
I-88 | 0.1625 | 9999 |
I-89 | 0.0352 | 7.93 |
I-90 | 0.1698 | 9999 |
I-91 | 9999 | 9999 |
I-92 | 0.0676 | 6 |
I-93 | 0.0371 | 5.168 |
活體內活性在此實例中,使用急性低體溫症小鼠模型分析評估本文所揭示之化合物抑制TNF-α誘發之低溫症的能力。
在第-1天將雌性C57BL/6小鼠隨機分組且進行稱重。在研究當天(第0天),藉由經口管飼向小鼠投與媒劑或測試物。在經口投與測試藥劑之後十五分鐘,向各小鼠投與含有重組人類腫瘤壞死因子α (TNF-a,25.0 µg)及zVAD-FMK (200 µg)之腹膜內(IP)注射液。在零小時(IP注射之前)及每一小時經由直腸探針溫度量測裝置量測體溫。在IP注射TNF-a及zVAD/FMK之後三(3)小時,藉由CO
2窒息使小鼠安樂死且經由心臟穿刺收集血液。收集血清及血漿分別用於測定細胞介素及化合物含量。包括單獨的小鼠組(衛星小鼠)以用於在投與TNFa/zVAD-FMK時測定血漿中之化合物含量。此實例中之活性證實本發明所揭示之化合物之實施例活體內抑制TNF-α信號傳導,且因此可用於治療涉及TNF-α之疾病。
鑒於所揭示之發明之原理可應用於許多可能的實施例,應認識到所說明之實施例僅為本發明之較佳實例且不應視為限制本發明之範疇。而本發明之範疇係由以下申請專利範圍界定。吾人因此主張吾人之本發明全部在此等申請專利範圍之範疇及精神內。
Claims (2)
- 一種化合物,其係選自以下所組成之群組:
I-1 , I-2 , I-3 , I-4 , I-5 , I-6 , I-7 , I-8 , I-9 , I-10 , I-11 , I-12 , I-13 , I-14 , I-19 , I-20 , I-21 , I-22 , I-23 , I-24 , I-25 , I-26 , I-27 , I-28 , I-29 , I-30 , I-31 , I-32 , I-33 , I-34 , I-35 , I-36 , I-37 , I-38 , I-39 , I-40 , I-41 , I-42 , I-43 , I-44 , I-45 , I-46 , I-47 , I-48 , I-49 , I-50 , I-51 , I-52 , I-53 , I-54 , I-55 , I-56 , I-57 , I-58 , I-59 , I-60 , I-61 , I-62 , I-63 , I-64 , I-65 , I-66 , I-67 , I-68 , I-69 , I-70 , I-71 , I-72 , I-73 , I-74 , I-75 , I-76 , I-77 , I-78 , I-79 , I-80 , I-81 , I-82 , I-83 , I-84 , I-85 , I-86 , I-87 , I-88 , I-89 , I-90 , I-91 , I-92 ,及 I-93 。 - 一種醫藥組合物,其包含如請求項1之化合物,且另包含一或多種醫藥上可接受之賦形劑。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063047194P | 2020-07-01 | 2020-07-01 | |
US63/047,194 | 2020-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202408480A TW202408480A (zh) | 2024-03-01 |
TWI840311B true TWI840311B (zh) | 2024-04-21 |
Family
ID=
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201730160A (zh) | 2016-02-05 | 2017-09-01 | 戴納立製藥公司 | 化合物、組合物及方法 |
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201730160A (zh) | 2016-02-05 | 2017-09-01 | 戴納立製藥公司 | 化合物、組合物及方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7187729B2 (ja) | Rip1阻害剤化合物並びにそれを製造及び使用するための方法 | |
JP2022546520A (ja) | Rip1阻害化合物ならびにそれを作製および使用するための方法 | |
JP7493586B2 (ja) | Rip1阻害化合物ならびにそれを作製および使用するための方法 | |
JP7395730B2 (ja) | ヘテロ環式rip1阻害化合物 | |
JP2023520046A (ja) | Rip1k阻害剤 | |
TWI824259B (zh) | Rip1k抑制劑 | |
TWI840311B (zh) | Rip1k抑制劑 | |
US20230310454A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
EA045207B1 (ru) | Соединения, ингибирующие rip1, а также способы их получения и применения |